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A B S T R A C T
Background
Delirium is a common mental disorder, which is distressing and has serious adverse outcomes in hospitalised patients. Prevention of
delirium is desirable from the perspective of patients and carers, and healthcare providers. It is currently unclear, however, whether
interventions for preventing delirium are effective.
Objectives
To assess the effectiveness of interventions for preventing delirium in hospitalised non-Intensive Care Unit (ICU) patients.
Search methods
We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 4 December 2015 for
all randomised studies on preventing delirium. We also searched MEDLINE (Ovid SP), EMBASE (Ovid SP), PsycINFO (Ovid SP),
Central (The Cochrane Library), CINAHL (EBSCOhost), LILACS (BIREME), Web of Science core collection (ISI Web of Science),
ClinicalTrials.gov and the WHO meta register of trials, ICTRP.
Selection criteria
We included randomised controlled trials (RCTs) of single and multi- component non-pharmacological and pharmacological inter-
ventions for preventing delirium in hospitalised non-ICU patients.
Data collection and analysis
Two review authors examined titles and abstracts of citations identiﬁed by the search for eligibility and extracted data independently,
with any disagreements settled by consensus. The primary outcome was incidence of delirium; secondary outcomes included duration
and severity of delirium, institutional care at discharge, quality of life and healthcare costs. We used risk ratios (RRs) as measures of
treatment effect for dichotomous outcomes; and between group mean differences and standard deviations for continuous outcomes.
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Main results
We included 39 trials that recruited 16,082 participants, assessing 22 different interventions or comparisons. Fourteen trials were
placebo-controlled, 15 evaluated a delirium prevention intervention against usual care, and 10 compared two different interventions.
Thirty-two studies were conducted in patients undergoing surgery, the majority in orthopaedic settings. Seven studies were conducted
in general medical or geriatric medicine settings.
We found multi-component interventions reduced the incidence of delirium compared to usual care (RR 0.69, 95% CI 0.59 to 0.81;
seven studies; 1950 participants; moderate-quality evidence). Effect sizes were similar in medical (RR 0.63, 95% CI 0.43 to 0.92; four
studies; 1365 participants) and surgical settings (RR 0.71, 95% CI 0.59 to 0.85; three studies; 585 participants). In the subgroup of
patients with pre-existing dementia, the effect of multi-component interventions remains uncertain (RR 0.90, 95% CI 0.59 to 1.36;
one study, 50 participants; low-quality evidence).
There is no clear evidence that cholinesterase inhibitors are effective in preventing delirium compared to placebo (RR 0.68, 95% CI,
0.17 to 2.62; two studies, 113 participants; very low-quality evidence).
Three trials provide no clear evidence of an effect of antipsychotic medications as a group on the incidence of delirium (RR 0.73, 95%
CI, 0.33 to 1.59; 916 participants; very low-quality evidence). In a pre-planned subgroup analysis there was no evidence for effectiveness
of a typical antipsychotic (haloperidol) (RR 1.05, 95% CI 0.69 to 1.60; two studies; 516 participants, low-quality evidence). However,
delirium incidence was lower (RR 0.36, 95% CI 0.24 to 0.52; one study; 400 participants, moderate-quality evidence) for patients
treated with an atypical antipsychotic (olanzapine) compared to placebo (moderate-quality evidence).
There is no clear evidence that melatonin or melatonin agonists reduce delirium incidence compared to placebo (RR 0.41, 95% CI
0.09 to 1.89; three studies, 529 participants; low-quality evidence).
There is moderate-quality evidence that Bispectral Index (BIS)-guided anaesthesia reduces the incidence of delirium compared to BIS-
blinded anaesthesia or clinical judgement (RR 0.71, 95% CI 0.60 to 0.85; two studies; 2057 participants).
It is not possible to generate robust evidence statements for a range of additional pharmacological and anaesthetic interventions due to
small numbers of trials, of variable methodological quality.
Authors’ conclusions
There is strong evidence supporting multi-component interventions to prevent delirium in hospitalised patients. There is no clear
evidence that cholinesterase inhibitors, antipsychotic medication or melatonin reduce the incidence of delirium. Using the Bispectral
Index to monitor and control depth of anaesthesia reduces the incidence of postoperative delirium. The role of drugs and other
anaesthetic techniques to prevent delirium remains uncertain.
P L A I N L A N G U A G E S U M M A R Y
Interventions to prevent delirium in hospitalised patients, not including those on intensive care units
Review question
We reviewed the evidence for the effectiveness of interventions for preventing delirium in hospitalised patients, not including those on
intensive care units (ICU) (specialised wards for the care of critically ill patients).
Background
Delirium is a common and serious illness for people admitted to hospital. It can be distressing for patients and their families. It also
increases the chances of developing other complications in hospital, being admitted to a care home or dying in hospital. Delirium is a
very expensive condition for health services. Prevention of delirium is therefore desirable for patients, families and health services.
There are many risk factors for developing delirium (e.g. infection, dehydration, certain medications). Therefore, one approach (called
‘multi-component interventions’) to preventing delirium is to target these multiple risk factors. Some medications have effects on the
brain chemicals implicated in developing delirium, and may, therefore, have a role in prevention. There are also a number of other
interventions that target delirium risk factors related to anaesthesia and medical treatment around the time of surgery.
Study characteristics
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This evidence is current to 4 December 2015. We found 39 trials that recruited 16,082 participants testing 22 different multi-
component interventions, medications or anaesthetic interventions, compared to usual care, placebo, or different interventions.
Key findings
We found strong evidence that multi-component interventions can prevent delirium in both medical and surgical settings and less
robust evidence that they reduce the severity of delirium. Evidence about their effect on the duration of delirium is inconclusive.
There is evidence that monitoring the depth of anaesthesia can reduce the occurrence of delirium after general anaesthetic.
We found no clear evidence that a range of medications or other anaesthetic techniques or procedures are effective in preventing
delirium.
Quality of the evidence
There is moderate-quality evidence to indicate that multi-component interventions reduce the incidence of delirium. The evidence
supports implementing multi-component delirium prevention interventions into routine care for patients in hospital.
There is moderate-quality evidence that monitoring depth of general anaesthesia can be used to prevent delirium postoperatively.
The quality of the evidence for a range of medications or other anaesthetic techniques or procedures for preventing delirium is poor
(because of the small number of trials and the variable quality of trial methods), and cannot be used to inform changes to practice.
External funding
None.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M ulti- component delirium prevention intervention compared to usual care for hospitalised non- ICU patients
Intervention: A mult i-component delirium prevent ion intervent ion versus usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
A multi- component
delirium prevention in-
tervention
Incidence of delirium
validated instruments1
209 per 10002 144 per 1000
(123 to 172)
RR 0.69
(0.59 to 0.81)
1950
(7 studies3)
⊕⊕⊕©
moderate4,5,6
Duration of delirium
(days)
The mean durat ion of
delirium in the control
groups ranged f rom
2.1 to 10.2 days
The mean durat ion of
delirium in the interven-
t ion groups was
1.16 days shorter
(2.96 shorter to 0.64
longer)
244
(4 studies)
⊕©©©
very low4,6,7,8,9
Severity of delirium
DRS-R-98 and CAM-S10
The standardised mean
severity of delirium in
the intervent ion groups
was
1.04 standard devia-
tions lower
(1.65 to 0.43 lower)11
67
(2 studies)
⊕⊕©©
low4,12
Length of admission
Days
The mean length of ad-
mission in the control
groups ranged f rom
5 to 38 days
The mean length of ad-
mission in the interven-
t ion groups was
0.01 days longer
(0.48 days shorter to 0.
1920
(6 studies)
⊕⊕⊕©
moderate4,6,7
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51 days longer)
Return to independent
living
682 per 10002 648 per 1000
(580 to 723)
RR 0.95
(0.85 to 1.06)
1116
(4 studies)
⊕⊕⊕©
moderate 4,6,13
Inpatient mortality 81 per 10002 73 per 1000
(45 to 116)
RR 0.90
(0.56 to 1.43)
859
(3 studies)
⊕©©©
very low 6,14,15
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Three validated methods for delirium detect ion used - the CAM, OBS and DRS
2 The assumed risk is the risk in the control group
3 Four studies in medical in pat ients, three studies in surgical pat ients
4 High risk of performance bias due to the lack of blinding of part icipants and personal in all studies (due to the nature of the
intervent ion).
5 Outcomes assessors unblinded 2 studies (one of which carries the largest weight ing (58%) due to high event rate). Risk of
bias otherwise low across studies
6 Higher baseline prevalence of dementia in the control groups of two studies compared to the intervent ion groups causing
risk of bias
7Outcomes assessors unblinded in two studies
8 Minimal important dif f erence (MID) of 1 day assumed. 95%conf idence lim its around the pooled est imate of mean dif ference
includes both ’no dif ference’, and the MID.
9 Downgraded because inconsistent results
10 Delirium Rating Scale-Revised-98 (0 to 46) and Confusion Assessment Method-Severity (0 to 10)
11This is a dif ference in standard deviat ions. A standard deviat ion of > 0.8 represents a large ef fect.
12 Imprecise results - small pooled sample size
13 Outcomes assessors unblinded in one study
14There is some inconsistency of results
15Imprecise results - pooled est imate includes both no ef fect, appreciable benef it and appreciable harm
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B A C K G R O U N D
Description of the condition
Delirium is a disturbance of consciousness and cognition, which
usually has a rapid onset and a ﬂuctuating course. It has been var-
iously termed acute organic brain syndrome, acute organic men-
tal disorder and toxic confusional state. Until the 19th century
delirium was used to describe a disorder of thinking and later de-
scriptions included disturbances of perception, often with over-
active behaviour, or impaired consciousness. The publication of
Diagnostic and Statistical Manual (DSM) III (APA 1987) in 1987
brought these ideas together, combining disturbance of conscious-
ness with impairment of cognition. The core features of delirium
(disturbance in attention, changes in cognition, and acute on-
set and ﬂuctuating course) have now been clariﬁed in the Inter-
national Classiﬁcation of Diseases version 10 (ICD-10) (WHO
1992), DSM-IV (APA 1994), and most recently DSM-V (APA
2013). This consensus has allowed some standardisation of re-
search, and greater comparability between studies, although dif-
ferences remain, such as the requirement for evidence of an un-
derlying cause in DSM-IV and DSM-V, but not in ICD-10.
Delirium is common in hospitalised patients. Ten per cent to 30%
of admissions to a general hospital develop delirium (Levkoff 1991;
Trzepacz 1996) and in general medical inpatients, occurrence rates
ranging from 11% to 42% have been reported (Siddiqi 2006).
Delirium has a prevalence of up to 60% in frail elderly patients
(Francis 1990), and 7% to 9.6% in elderly patients presenting
to emergency departments (Elie 2000; Hustey 2003). Following
coronary artery bypass grafting in the elderly, the incidence has
been reported as 33.6% (Santos 2004), and after bilateral knee re-
placements 41% (Williams-Russo 1992). Following hip fracture,
the overall prevalence is 43% to 61% (Holmes 2000). Cancer also
increases the risk of developing delirium; 18% of those admitted
to an oncology ward, and 26% to 44% of those admitted to hos-
pital or a hospice with a diagnosis of advanced cancer developed
delirium (Centeno 2004; Ljubisavljevic 2003). In patients with
AIDS who are unwell enough to be admitted, incidence of delir-
ium is also high, being reported as 46% (Uldall 1997).
Delirium is serious, with signiﬁcant short- and long-term out-
comes. Mortality is increased (McCusker 2002), functional abili-
ties reduced (Moller 1998), admission to long-term care increased
(Inouye 1998a), and length of stay increased (McCusker 2003a;
Stevens 1998). Impairment of cognitive function can persist for
at least one year (McCusker 2001), as can the symptoms of delir-
ium, especially inattention, disorientation and impaired mem-
ory (McCusker 2003b). Increasingly recognised is the distress an
episode of delirium produces for both sufferers and their carers
(Breitbart 2002).
Research in older people has identiﬁed a range of risk factors for
delirium. The condition clearly has a multi-factorial aetiology, and
these risk factors interact (Inouye 1998b); the more risk factors
that are present, the greater the likelihood that the patient will
develop delirium. Risk factors that have so far been identiﬁed in-
clude: increased age, sensory deprivation (visual or hearing im-
pairment), sleep deprivation, social isolation, physical restraint,
use of bladder catheter, iatrogenic adverse events, poly-pharmacy
(more than three new medications added), use of psychoactive
drugs, co-morbidities, severe illness (especially infection, fracture
or stroke), prior cognitive impairment, temperature abnormality
(fever or hypothermia), dehydration, malnutrition and low serum
albumin (Inouye 1998b; Inouye 1999c; NICE 2010).
Studies in oncology patients have also identiﬁed a range of risk
factors for delirium, for example bone metastases, the presence of
haematological malignancy, advanced age, cognitive impairment,
and low albumin levels (Ljubisavljevic 2003).
The identiﬁcation of such a varied list of aetiological factors sug-
gests several things. First, we may be able to identify patients at
high risk of developing delirium, and by modifying these risk fac-
tors could attempt to prevent it; such prevention strategies could
be targeted to speciﬁc groups of patients.
Second, many of these risk factors can be seen as hospital ’quality
of care’ measures, e.g. malnutrition, dehydration, use of physical
restraints, iatrogenic events. Occurrence of delirium can, there-
fore, be seen as a proxy measure of the quality of inpatient care
(Inouye 1999b; Inouye 2014); and effective interventions to pre-
vent deliriummay be considered integral to quality improvement.
Quality improvement is amajor issue for healthcare, particularly in
services for older people (Institute for Innovation 2006).We know
that healthcare systems and services, internationally, have not kept
pace with demographic transitions, and often fail tomeet the com-
plex needs requiring multidisciplinary care of growing numbers
of older people (Hubbard 2004). General hospitals, in fact, fre-
quently have attributes that unintentionally stimulate or aggravate
delirium (Young 2007). However, addressing this is challenging
and requires wide-ranging changes to systems of care. Focusing on
delirium prevention may help develop the necessary professional
skills, cultural aspects, and service design in such a way as to drive
up quality of care.
Prevention of delirium is clearly desirable for both patients and
carers, and can also reduce health service costs. Healthcare costs
in patients who developed delirium in intensive care units (ICUs)
were 31% higher ($41,836 versus $27,106) (Milbrandt 2004).
A non-randomised study of a multi-component intervention for
delirium also demonstrated overall improved cost-effectiveness (
Rizzo 2001).
Description of the intervention
This review assesses the effectiveness of non-pharmacological and
pharmacological interventions for preventing delirium in hospi-
talised patients, excluding the ICU setting.
A range of non-pharmacological interventions for preventing
delirium in hospitalised patients have been developed. Most have
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taken a multi-factorial approach to delirium prevention, attempt-
ing to prevent several risk factors by protocols, education or sys-
tems redesign, (Cole 2002; Inouye 2000;Milisen 2001), although
some target a single risk factor only. Examples include programmes
of education for ward nursing staff (Rockwood 1999), protocols
targeting speciﬁc risk factors and implemented by a trained in-
terdisciplinary team (Inouye 1999a; Young 2015), and specialist
nursing interventions to educate nursing staff, assess and change
medication, encouragemobilisation and improve the environment
of the patient (Wanich 1992).
Pharmacological interventions are based on an understanding of
the multiple neurotransmitter pathways involved in developing
delirium and substances that might potentially modify these or
modify other important risk factors. These include, for example,
cholinesterase inhibitors, antipsychotics and analgesics. There are
also a number of other interventions that target delirium risk fac-
tors related to surgery and perioperative care, such as varying ap-
proaches to anaesthesia, optimising blood transfusion, and post-
operative pain relief.
How the intervention might work
Delirium has many risk factors and precipitating factors, some
of which may be modiﬁable. Previous work has suggested that a
combination of risk factors may interact to increase vulnerability
to delirium, and models to predict this risk have been developed
and validated (Inouye 1993a). Measures to reduce the number or
severity of these factors may help to prevent delirium and may
attenuate the poor outcomes associated with it.
Single- and multi-component non-pharmacological interventions
target one or more of these risk factors.
Pharmacological interventions either target the important neuro-
transmitter pathways that have been implicated in the complex
pathophysiology of delirium ((e.g. antipsychotics, cholinesterase
inhibitors) or aim to address important risk factors such as sleep
and pain (e.g. melatonin and gabapentinoids).
Various anaesthetic approaches and perioperative procedures also
address potential risk factors for delirium.
Why it is important to do this review
Given that delirium is associatedwith such poor outcomes (Witlox
2010), which do not appear to be modiﬁed with treatment (NICE
2010), interventions to prevent delirium may be particularly im-
portant. Previous reviews (Cole 1999; Milisen 2005) have sug-
gested a role for multi-component delirium prevention interven-
tions, but have not been systematic or have employed less rigorous
selection criteria. A previous Cochrane review of delirium preven-
tion in hospitalised patients published in 2007 found the evidence
was sparse and recommended further research was needed (Siddiqi
2007). It is currently unclear whether interventions for prevention
of delirium are effective.
O B J E C T I V E S
To assess the effectiveness of interventions designed to prevent
delirium in hospitalised non-intensive care unit patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only considered randomised controlled trials for this review.
Types of participants
We included patients aged 16 years or over, admitted to acute
general hospitals and at risk of developing delirium. We excluded
studies conducted in ICU as both the population and interven-
tions in this setting are likely to be very different.We also excluded
community settings e.g. nursing homes. We excluded studies in
mixed settings unless data could be extracted separately for hospi-
talised inpatients.
Types of interventions
We considered all non-pharmacological and pharmacological in-
terventions designed toprevent delirium.Trials including a control
group receiving standard care and trials comparing two types of
intervention were included. Trials of co-ordinated multi-strategy
initiatives to prevent delirium (multi-component interventions)
were included. We deﬁned standard care as the usual care available
on that unit.
Types of outcome measures
We identiﬁed the primary, secondary and adverse outcome mea-
sures that are important for patients, carers and for health and
social care systems.
Primary outcomes
1. Incidence of delirium, using a validated diagnostic method
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Secondary outcomes
1. Duration of delirium
2. Severity of delirium, measured by validated instruments
including the Memorial Delirium Assessment Scale (MDAS)
(Breitbart 1997), Delirium Rating Scale (DRS) (Trzepacz 1988),
and DRS-R-98 (Trzepacz 2001)
3. Length of admission
4. Cognitive status
5. Use of psychotropic medication
6. Behavioural disturbance
7. Activities of daily living
8. Return to independent living
9. Institutional care at discharge
10. Quality of life
11. Carers’ psychological morbidity
12. Staff psychological morbidity
13. Cost of intervention
14. Cost to healthcare services
15. Withdrawal from protocols by patients
Adverse outcomes
1. Adverse events (as deﬁned by study authors)
2. Postoperative complications
3. Falls
4. Pressure ulcers
5. Infections (speciﬁcally wound infections, urinary tract
infections, pneumonia)
6. Cardiac adverse events (speciﬁcally myocardial infarction &
cardiac failure)
7. Mortality
Secondary outcomes were chosen as those likely to be inﬂuenced
by preventing delirium; and adverse outcomes deﬁned as un-
favourable effects that might be associated with the intervention or
comparator, although for some outcomes the distinction between
the two may be arbitrary.
Search methods for identiﬁcation of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s Spe-
cialized Register on 4thDecember 2015. The advanced search was
used to retrieve all randomised studies in which delirium was the
focus.
ALOIS is maintained by the Trials Search Co-ordinator and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy. The studies were
identiﬁed from the following searches.
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others)
3. Quarterly search of The Cochrane Library’s Central Register
of Controlled Trials (CENTRAL)
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ‘Methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
We performed additional searches in many of the sources listed
above to cover the time frame from the last searches performed for
ALOIS, to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1 and results of the searches in Appendix 2.
Searches conducted between October 2008 and December 2015
retrieved a total of 542 results after initial de-duplication and ﬁrst
assessment by the Cochrane Dementia and Cognitive Improve-
ment Group’s Trials Search Co-ordinator.
Searching other resources
We reviewed bibliographies of books and review articles on delir-
ium, and also references from retrieved articles. We contacted ex-
perts in this ﬁeld for further references and to locate unpublished
trials. The Internet was searched using the search engines Google
and Copernic to try to ﬁnd further evidence of unpublished trials
using the same terms as stated above.
We did not apply any time restrictions or language constraints.
Data collection and analysis
Selection of studies
Two review authors independently examined all titles and abstracts
of citations identiﬁed by the search for eligibility, and assessed full
texts of potentially eligible studies for inclusion. All disagreements
were resolved by consensus.
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Data extraction and management
Two review authors used a piloted data extraction form to extract
data on each study independently, and settled any disagreements
by consensus. We created a table of ’Characteristics of included
studies’ using Review Manager 5 (RevMan 2012). Review authors
were not blinded to study authors and institution for study selec-
tion, data extraction or quality assessment. Reports from the same
study were collated under a single study reference.
For delirium incidence and severity, where results were presented
for multiple time points and no summary data were available, we
used the highest recorded number or peak values for the inter-
vention and control arm. This was because we were interested in
interventions that reduced the overall burden of delirium. For ex-
ample, if delirium severity was ascertained on days one, three, and
ﬁve of the hospital stay, then we included only the highest of those
three ascertainments in our analysis of delirium severity.
For severity and duration of delirium, data were included only
from patients with delirium.
To allow use of more of the reported data for syntheses, where
medians and Interquartile ranges (IQR) or ranges were presented
rather than means and standard deviations, we converted values as
follows.We assumed themedian value was equivalent to themean.
We estimated the standard deviation as ’IQR/1.35’ or ’range/4’
(small studies, n < 70) or ’range/6’ (larger studies, n > 70).
Assessment of risk of bias in included studies
Two review authors independently assessed risks of bias for all in-
cluded studies using the criteria described in the Cochrane Hand-
bookfor Systematic Reviews of Interventions (Cochrane Handbook
2011). We assessed included trials for adequacy of sequence gen-
eration, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting and other potential sources of
bias. For each domain, we made a judgement of low risk, high risk
or unclear risk of bias and presented these in a ’Risk of bias’ table
for each study. We settled any disagreements by consensus.
Measures of treatment effect
We used risk ratios (RRs) as measures of treatment effect for di-
chotomous outcomes; and between group mean differences and
standard deviations for continuous outcomes.
Dealing with missing data
Missing data and dropout rates were assessed for each of the in-
cluded studies. We reported the number of participants included
in the ﬁnal analysis as a proportion of all participants in the study.
An available case analysis was performed, including data only on
those whose results were known. Incomplete outcomes assessment
was reported in the ’Risk of bias’ table for each study and discussed
in the main text to enable consideration of the potential impact
of missing data.
Data synthesis
We synthesised dichotomous outcomes for meta-analysis and cal-
culated pooledRRswith 95%conﬁdence intervals (CIs) using ran-
dom-effects methods. We synthesised continuous outcomes and
calculated pooled mean differences, or standardised mean differ-
ences with 95% CIs using random-effects inverse variance meth-
ods.
Subgroup analysis and investigation of heterogeneity
We conducted a pre-planned intervention level subgroup anal-
ysis for multi-component delirium prevention interventions in
surgical and medical settings, and for studies reporting delirium
in the presence of diagnosed dementia. We carried out a further
pre-planned intervention level subgroup analysis to investigate
whether typical and atypical antipsychotic medications were asso-
ciated with varying levels of effectiveness.
Data presentation - ’Summary of ﬁndings’ tables
We used the GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) approach to assess the quality of
the supporting evidence behind each estimate of treatment effect
(Schunemann 2011a; Schunemann 2011b) for selected key inter-
ventions and outcomes. We presented key ﬁndings of the review
including a summary of the amount of data, the magnitude of the
effect size and the overall quality of the evidence, in ’Summary of
ﬁndings’ tables, created using GRADEpro software (GRADEpro
2014).We selected the following interventions: multi-component
delirium prevention interventions; cholinesterase inhibitors; an-
tipsychotics; melatonin and bispectral-index guided-anaesthesia;
and the following outcomes: incidence of delirium, severity of
delirium, duration of delirium, length of admission, return to in-
dependent living and in-hospital mortality, as being most relevant
for clinical practice across a range of hospital settings.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The search results are summarised in a PRISMA diagram (Figure
1). Of the 136 full-text articles retrieved, 40 were considered eli-
gible for inclusion; 69 were excluded (see Excluded studies); and
27 are ongoing (see Ongoing studies). Several articles identiﬁed
as eligible reported outcome data for the same trial. Therefore,
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33 new studies were eligible for inclusion and added to the six
studies included in the original review (Siddiqi 2007), resulting
in 39 included studies (see Included studies). Study authors were
contacted for further information for six of these studies (Ashraf
2015; Bonaventura 2007; de Jonghe 2014;Hatta 2014; Jeffs 2013;
Gauge 2014).However, unpublisheddatawere only used forHatta
2014, for which data for the subgroup of non-ICU study partici-
pants were provided by the authors.
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Figure 1. Study ﬂow diagram
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Included studies
The 39 studies included a total study population of 16,082
randomised participants, and assessed 22 different interven-
tions or comparisons (Abizanda 2011; Aizawa 2002; Al-Aama
2011; Ashraf 2015; Beaussier 2006; Berggren 1987; Bonaventura
2007; Boustani 2012; Chan 2013; de Jonghe 2014; Diaz 2001;
Fukata 2014; Gauge 2014; Gruber-Baldini 2013; Hatta 2014;
Hempenius 2013; Jeffs 2013; Jia 2014; Kalisvaart 2005; Larsen
2010; Leung 2006; Li 2013; Liptzin 2005; Lundstrom 2007;
Lurati 2012; Marcantonio 2001; Marcantonio 2011; Martinez
2012; Mouzopoulos 2009; Munger 2008; Papaioannou 2005;
Pesonen 2011; Radtke 2013; Sampson 2007; Sieber 2010; Stoppe
2013; Urban 2008; Watne 2014; Whitlock 2015).
Study design
Fourteen studies were placebo-controlled trials (Al-Aama 2011;
de Jonghe 2014; Diaz 2001; Hatta 2014; Kalisvaart 2005;
Larsen 2010; Leung 2006; Liptzin 2005; Marcantonio 2011;
Mouzopoulos 2009; Munger 2008; Pesonen 2011; Sampson
2007; Whitlock 2015). Fifteen studies evaluated a delirium pre-
vention intervention against usual care (Abizanda 2011; Aizawa
2002; Ashraf 2015; Bonaventura 2007; Boustani 2012; Fukata
2014; Gauge 2014; Gruber-Baldini 2013; Hempenius 2013; Jeffs
2013; Jia 2014; Lundstrom 2007; Marcantonio 2001; Martinez
2012; Urban 2008). Ten studies compared two different interven-
tions (Beaussier 2006; Berggren 1987; Chan 2013; Li 2013; Lurati
2012; Papaioannou 2005; Radtke 2013; Sieber 2010; Stoppe
2013;Watne 2014).
Sample Size
The sample size of included studies was highly variable, ranging
from 15 to 7507 randomised participants. Eighteen studies ran-
domised less than 100 participants, of which eight randomised
less than 50 (Aizawa 2002; Ashraf 2015; Hatta 2014; Leung 2006;
Marcantonio 2011; Munger 2008; Stoppe 2013; Urban 2008).
Setting
Thirty- two studies were conducted in patients undergoing surgery
or procedural interventions.
Orthopaedic practice was the most common setting (18 studies).
Six of these evaluated interventions in patients undergoing elec-
tive arthroplasty or joint replacement (Kalisvaart 2005; Larsen
2010; Leung 2006; Liptzin 2005; Sampson 2007; Urban 2008);
11 included patients undergoing hip fracture repair Berggren
1987; de Jonghe 2014; Diaz 2001; Gruber-Baldini 2013; Li
2013; Lundstrom 2007; Marcantonio 2001; Marcantonio 2011;
Mouzopoulos 2009; Sieber 2010; Watne 2014), and one study
was conducted in combined elective and emergency orthopaedic
settings (Munger 2008).
Four studies were in patients undergoing cardiac surgery (Gauge
2014; Pesonen 2011; Stoppe 2013; Whitlock 2015); and one
in patients undergoing inpatient cardiac catheterisation (Ashraf
2015).
Two studies were in patients undergoing surgery for cancer
(Hempenius 2013 and Jia 2014), the latter speciﬁcally for colorec-
tal cancer.
Two studies were in patients having general and colorectal surgery
or colorectal surgery alone (Aizawa 2002; Beaussier 2006).
Five studies were in patients undergoing various other elec-
tive surgical procedures (Chan 2013; Fukata 2014; Lurati 2012;
Papaioannou 2005; Radtke 2013). One of these included pa-
tients having abdominal surgery under general anaesthesia or or-
thopaedic surgery under general or spinal anaesthesia (Fukata
2014); and one study was in patients undergoing non-cardiac
surgery under general anaesthesia (Lurati 2012).
Only seven studies (2011 participants) evaluated interventions
in a general medical or geriatric medical hospital environment
(Abizanda 2011; Al-Aama 2011; Bonaventura 2007; Boustani
2012; Hatta 2014; Jeffs 2013; Martinez 2012 ).
Participants
Age
In 29 studies, participants had a mean age in both allocation arms
of more than 70 years. Six studies had a mean age of less than 70
years in one or both groups (Chan 2013; Liptzin 2005; Radtke
2013; Sampson 2007; Stoppe 2013; Whitlock 2015); and two
studies had very low mean age of included participants, Urban
2008 (mean age 53 and 48 years in the intervention and control
groups respectively) and Leung 2006 (overall mean age 59.6 years).
Two studies did not present data on the mean age of participants
(Bonaventura 2007; Papaioannou 2005).
Co-morbidities
Eight studies used the Charlson Index (Charlson 1994) (Boustani
2012; de Jonghe 2014; Hatta 2014; Jeffs 2013; Leung 2006;
Marcantonio 2001; Martinez 2012; Sieber 2010) to compare co-
morbidities between intervention and control groups. One study
(Boustani 2012), reported higher Charlson Index scores in the
usual care group.
Five studies presented the total number of co-morbidities present
for intervention and control groups (Abizanda 2011; Al-Aama
2011; Bonaventura 2007; Diaz 2001; Hempenius 2013).
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Nine studies presented the frequency of a range of speciﬁc co-
morbidities in both the intervention and control groups (Ashraf
2015; Berggren 1987; Chan 2013;Gruber-Baldini 2013; Jia 2014;
Lundstrom 2007; Lurati 2012; Pesonen 2011; Whitlock 2015).
Lundstrom 2007 reported a difference between the intervention
and control arms, with a higher rate of depression in the control
group, and Ashraf 2015 had higher rates of coronary artery dis-
ease in the usual care group and higher rates of depression in the
intervention group.
Seventeen studies did not report co-morbidities at baseline (Aizawa
2002; Beaussier 2006; Fukata 2014; Gauge 2014; Kalisvaart
2005; Larsen 2010; Li 2013; Liptzin 2005; Marcantonio 2011;
Mouzopoulos 2009; Munger 2008; Papaioannou 2005; Radtke
2013; Sampson 2007; Stoppe 2013; Urban 2008; Watne 2014).
Dementia
Eleven of the included studies excluded participants with demen-
tia. This included using dementia diagnosis as an exclusion crite-
ria (Diaz 2001; Jia 2014; Larsen 2010) or based on performance
in cognitive testing (Ashraf 2015; Berggren 1987; Bonaventura
2007; Chan 2013; Li 2013; Papaioannou 2005; Radtke 2013;
Stoppe 2013), most commonly using the Mini-Mental State Ex-
amination (MMSE) score (Folstein 1975).
There were three studies where the proportion of participants with
dementia differed between the intervention and control groups: in
Gruber-Baldini 2013, it was 27.3% in intervention versus 36.1%
in control; in Lundstrom 2007, 27.5% in intervention versus
37.1% in control; and inMarcantonio 2001, 37% in intervention
and 51% in control.
Interventions
Multi-component interventions
Seven studies (2018 participants) evaluated non-pharmacologi-
cal multi-component interventions (Abizanda 2011; Bonaventura
2007; Hempenius 2013; Jeffs 2013; Lundstrom 2007;
Marcantonio 2001; Martinez 2012) in comparison to usual care.
Individual components of eachmulti-component intervention are
summarised in Table 1. The number of components varied be-
tween two (Jeffs 2013) and 13 (Hempenius 2013) (Table 1). Most
included individualised care, an educational component, reorien-
tation, and early mobilisation. Many of the delirium risk factors
targeted with multi-component interventions relate to good basic
care. The nature in which interventions were implemented varied
between the studies: some relied on a protocol-driven approach
(Bonaventura 2007; Jeffs 2013; Marcantonio 2001), whilst others
were more pragmatic in the delivery of the intervention (e.g. the
family delivered the reorientation intervention inMartinez 2012).
Two studieswere based on therapist interventions (Abizanda 2011;
Jeffs 2013), one was multidisciplinary including a Comprehen-
sive Geriatric Assessment (Lundstrom 2007), and two were based
on proactive perioperative input from a geriatrician (Hempenius
2013; Marcantonio 2001).
Pharmacological interventions
Thirteen studies assessed various pharmacological agents.
Although the pathophysiology of delirium remains unclear, acetyl-
choline is the neurotransmitter that has been most implicated
in studies (Koponen 1999; Tune 1999), leading to suggestions
that cholinesterase inhibitors may have a role in delirium manage-
ment. Four studies tested the use of prophylactic cholinesterase
inhibitors (Liptzin 2005; Marcantonio 2011; Munger 2008;
Sampson 2007).
Three studies assessed antipsychotic medication (Fukata 2014;
Kalisvaart 2005; Larsen 2010).
Melatonin is a hormone that has a role in sleep/wake regulation,
and may be responsible for the disruption of the sleep/wake cycle
seen in delirium (Figueroa-Ramos 2009). This has led to sugges-
tions that it could have a role in delirium prevention (Lewis 2004).
Melatonin supplementation has been proposed as a treatment op-
tion for delirium (Bourne 2006), and there is case report evidence
of its usefulness (Hanania 2002). Two studies investigated the use
of melatonin (Al-Aama 2011; de Jonghe 2014 ); and one used a
melatonin agonist (Hatta 2014).
Citicoline (cytidine 5′-diphosphocholine (CDP-choline)), is a
drug that has been implicated in cognitive impairment and mem-
ory, and therefore has been proposed as a treatment in traumatic
brain injury, stroke, vascular dementia, Parkinson’s disease, and
brain aging (Fioravanti 2006a). Citicoline has the function in the
brain of stabilising cell membranes and reducing the presence of
free radicals. In particular, there is some evidence that citicoline
stimulates the release of dopamine neurotransmitters in the brain
(Fioravanti 2005). One study tested citicoline (Diaz 2001).
Diazepam is a long-acting benzodiazepine which is often used as
an anxiolytic and has been used in the cardiac catheterisation set-
ting with good effect (Woodhead 2007). Diphyenhydramine is
an antihistamine medication which can cause sedation and has
been used as an adjunct for individuals undergoing colonoscopy
with good effect (Tu 2006). Evidence regarding premedication and
postoperative delirium is unclear (Fines 2006) with concern that
administering these medications may increase rates of post-proce-
dure or postoperative delirium. One study evaluated the combina-
tion of diazepam and diphenhydramine as premedication before
cardiac catheterisation (Ashraf 2015).
Methylprednisolone is an intravenous steroid preparation with a
wide range of clinical uses. Steroid use has been thought to be ben-
eﬁcial to individuals undergoing cardiopulmonary bypass, with
evidence of reduction in new onset atrial ﬁbrillation, postopera-
tive bleeding and length of stay in the intensive care unit (ICU)
(Whitlock 2008). A subsequent clinical trial failed to show bene-
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ﬁt for the entire population undergoing cardiopulmonary bypass,
but subgroup analysis suggested those at higher risk of adverse
outcomes may beneﬁt (Dieleman 2012). This formed the basis
of the design of Whitlock 2015, evaluating methylprednisolone
for those at high risk undergoing cardiopulmonary bypass, with
incidence of delirium as a safety outcome measure.
Perioperative interventions
Postoperative delirium is a common complication of surgery in
older people (Holmes 2000; Santos 2004; Williams-Russo 1992),
likely to be a consequence of the physiological and biochemical de-
rangement induced by the underlying pathology, surgical trauma
pain and anaesthesia. Perioperative care is, therefore, a potential
focus for interventions to reduce postoperative delirium.
In surgical practice, there has been a move towards a concept
of ‘enhanced recovery’ whereby surgical intervention, anaesthesia
and postoperative care are modiﬁed in such a way as to minimise
the overall impact of surgery, reducing postoperative complica-
tions and expediting recovery (Douglas 2001). Many postopera-
tive complications (e.g. ileus, respiratory depression, chest infec-
tions, and myocardial ischaemia, all of which may predispose to
delirium) could be reduced by the use of regional anaesthesia and
opioid-sparing analgesics (Bonnet 2005).
Eighteen studies tested various interventions addressing modiﬁca-
tions to perioperative practice that might inﬂuence postoperative
delirium. These are subdivided into ﬁve broad approaches; i) those
that reduce opioid utilisation, ii) those that control/reduce depth
of general anaesthesia, iii) those that consider alternative forms
of general anaesthesia, iv) those which avoid general anaesthesia
altogether and v) a miscellaneous group including studies investi-
gating transfusion practice, fast track surgery and a ’delirium-free
protocol’.
i) Opioid-sparing measures:
Techniques to reduce opioid utilisation include the administration
of adjuvant analgesics; addition of intrathecal opioid to general
anaesthesia; and peripheral local anaesthetic blockade. These were
tested in six studies.
Gabapentinoids are commonly used for treatment of epilepsy, anx-
iety, and neuropathic pain, but also have a role as opioid-sparing
adjuncts for postoperative pain relief (Tippana 2007). Leung 2006
tested gabapentin and Pesonen 2011 tested pregabalin.
Ketamine is widely used as an adjuvant analgesic in a variety of
perioperative pain settings (Bell 2006). Urban 2008 investigated
the effect of adding ketamine at induction of anaesthesia as a
postoperative infusion.
Parecoxib sodium is an intravenous analgesic preparation called a
pro-drug of another medication, valdecoxib, which is a selective
cyclo-oxygenase-2 inhibitor (Cheer 2001). The use of non-opioid
adjuvant analgesia is a recognised approach to reduce the need for
opiate medication and thus the associated side effects, particularly
for older adults (Aubrun 2007). One study compared a regimen of
regular intravenous parecoxib to a dose of morphine followed by
administration of saline as postoperative analgesia, with morphine
doses available to either group based on their pain scores.
The use of a ‘single shot spinal’ combined with general anaesthesia
and patient controlled analgesia (PCA) is increasingly used as an
alternative to continuous epidural infusions for intra and postop-
erative analgesia. The premise is that intrathecal opioid, with or
without local anaesthetic adequately replaces an epidural regard-
ing its intended beneﬁts of reduced intraoperative and immediate
postoperative opioid requirements, but without prolonged motor
block or hypotension that would impede immediate postopera-
tive mobilisation. Beaussier 2006 tested using a ’single shot spinal’
with general anaesthesia compared to general anaesthesia alone;
and Mouzopoulos 2009 tested a fascia iliac compartment block
performed every 24 hours from admission to discharge compared
to treatment with paracetamol and intramuscular pethidine for
patients with a fractured neck of femur.
ii) Controlling/reducing the depth of anaesthesia:
Finer titration of depth of anaesthesia could reduce delirium. Bis-
pectral index (BIS), a number derived from analysis of the EEG,
is increasingly used to monitor depth of anaesthesia. A BIS value
of 100 is equivalent to full awareness and a value of 0 represents
no electrical activity.
Sieber 2010 investigated light compared to deep sedation. Light
sedation was represented by a BIS value of 80 and a patient re-
sponsive to vocal commands; and deep sedation by a BIS value of
50 and a patient unresponsive to noxious stimuli (i.e. equivalent
to the effect of a general anaesthetic). Chan 2013 compared BIS-
guided anaesthesia to routine general anaesthesia with propofol.
In the BIS-guided group, the propofol infusion was titrated to
maintain a BIS value of 40 to 60, whereas in the routine group
anaesthesia was titrated according to clinical judgement. Radtke
2013 compared BIS-guided and BIS-blinded groups undergoing
induction and maintenance of general anaesthesia and postoper-
ative analgesia for a range of surgical interventions. Gauge 2014
compared targeted BIS and cerebral oxygenation monitoring for
patients undergoing coronary bypass grafting compared to no BIS
and oxygenation monitoring.
iii) Changing the mode of general anaesthesia:
Two studies explored the effect of mode of general anaesthesia,
one using propofol (Stoppe 2013) and the other xenon (Lurati
2012), compared to sevoﬂurane.
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iv) Avoiding general anaesthesia:
Two studies compared regional anaesthesia with general anaesthe-
sia (Berggren 1987; Papaioannou 2005).
v) Miscellaneous perioperative interventions:
The remaining three studies each tested a different perioperative
intervention.
Intraoperative blood transfusion has been implicated as a risk fac-
tor postoperative delirium (Carson 2011; Robinson 2009), al-
though there are likely to be other aspects of the individual’s con-
dition or care which also inﬂuence the risk of developing delirium
(Edelstein 2004). Gruber-Baldini 2013 tested the use of liberal
versus restrictive blood transfusion thresholds.
Jia 2014 tested fast-track surgery compared to usual care; this ap-
proach as a means of reducing delirium and postoperative cogni-
tive dysfunction has been suggested previously (Krenk 2012). The
fast-track approach tested by Jia 2014 included alterations in the
preoperative preparation, anaesthesia, pain control and postoper-
ative management compared to traditional care. This included:
bowel preparation with oral purgatives rather than enemas, shorter
period of fasting, avoidance of nasogastric tube, epidural rather
than general anaesthesia and earlier removal of urinary catheter
and mobilisation on the ﬁrst postoperative day.
Aizawa 2002 tested a postoperative delirium-free protocol (DFP),
which contained benzodiazepines and pethidine compared to
usual care. They administered intramuscular diazepam at 8 pm
with a continuous infusion of ﬂunitrazepam to maintain sleep and
pethidine for analgesia, given for eight hours for the ﬁrst three
nights after surgery.
Computerised clinical decision support (CCDS)
Computerised clinical decision support software (CCDS) has been
reported as an effective tool in prompting healthcare practitioners
to comply with established protocols and preventive measures (
Dexter 2001). It has also been trialled for improving the care of
patients with delirium superimposed on dementia (Fick 2011).
One study in our review (Boustani 2012), investigated the use of
CCDS in medical inpatients.
Care in geriatric medicine unit versus orthopaedic unit
following hip fracture
Individuals admitted following a fracture are typically placed un-
der the care of an orthopaedic surgeon, pending operative inter-
vention. However, the complex nature of the predominantly older
adult populationwho experience a hip fracture has led to the emer-
gence of orthogeriatric services, where input is also received from
geriatricians. Comprehensive geriatric assessment (CGA) is an ev-
idence-based “multidimensional interdisciplinary diagnostic pro-
cess used to determine the medical, psychological and functional
capabilities of a frail older person to develop a coordinated and
integrated plan for treatment and long-term follow-up” associated
with improved outcomes, particularly when delivered in a dedi-
cated ward (Ellis 2011). Watne 2014 designed their trial around
their local service reconﬁguration where older adults were admit-
ted to their specialist geriatric medicine unit and received CGA
comparing this to the care received in the orthopaedic unit.
Outcomes
Primary outcome
The incidence of delirium was recorded using several validated
instruments, used singly or in combination.
In 15 studies, the Confusion Assessment Method (CAM) (Inouye
1990) alone was used to determine delirium incidence (Abizanda
2011; Ashraf 2015; Beaussier 2006; Boustani 2012; Chan 2013;
Gauge 2014; Jeffs 2013; Leung 2006; Lurati 2012; Marcantonio
2001; Martinez 2012; Munger 2008; Sieber 2010; Urban 2008;
Whitlock 2015). However, Munger 2008 presented data for the
mean CAM score, rather than using the CAM score to deter-
mine delirium presence as a dichotomous outcome. The CAM-
ICU (Ely 2001) was used in two studies (Pesonen 2011; Stoppe
2013), although Pesonen 2011 used it as a continuous measure.
Diagnostic andStatisticalManual (DSM-III andDSM-IV)criteria
alone were used in ﬁve studies (Aizawa 2002; Li 2013; Lundstrom
2007; Papaioannou 2005; Radtke 2013). Jia 2014 used the DRS-
R-98 (Trzepacz 2001) to diagnose incident delirium. Berggren
1987 used the Modiﬁed Organic Brain Syndrome Scale (OBS)
(Gustafson 1985); Fukata 2014 used the NEECHAM confusion
scale (Neelon 1996); and Sampson 2007 used theDelirium Symp-
tom Interview (DSI) (Albert 1992).
Ten studies used multiple instruments for assessing delirium,
some of which included measures to assess delirium severity.
The CAM (Inouye 1990) and Memorial Delirium Assessment
Scale (MDAS) (Breitbart 1997) were used by Al-Aama 2011;
Gruber-Baldini 2013; Marcantonio 2011 andWatne 2014. How-
ever, Marcantonio 2011 only reported aggregated data for re-
peatedCAMassessmentswithin the same participant, which could
not, therefore, be included in analysis of the primary outcome.
Bonaventura 2007 used the CAM and DRS-R-98. DSM III-R or
IVwere used in addition to theCAMbyKalisvaart 2005; to which
Hatta 2014; Larsen 2010 andMouzopoulos 2009 added theDRS-
R-98; while Liptzin 2005 added theDSI. de Jonghe 2014 also used
the Delirium Observation Screening Scale (DOSS) (Schuurmans
2003) in addition to DSM-IV. Hempenius 2013 used the DOSS
which, if positive, resulted in an assessment using DSM-IV criteria
and the DRS-R-98.
Frequency of primary outcome assessment
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Nineteen studies assessed for delirium on a daily basis (Abizanda
2011; de Jonghe 2014; Diaz 2001; Fukata 2014; Hatta 2014;
Hempenius 2013; Jia 2014; Kalisvaart 2005; Larsen 2010;
Leung 2006; Liptzin 2005; Marcantonio 2001; Martinez 2012;
Mouzopoulos 2009; Munger 2008; Papaioannou 2005; Pesonen
2011; Stoppe 2013;Watne 2014 ). Marcantonio 2011 assessed for
delirium daily until discharge and again at two, four and six weeks
after recruitment.
Three studies assessed delirium several times a day: Radtke 2013
and Aizawa 2002 conducted delirium assessments twice daily and
Sampson 2007 assessed three times daily.
Delirium assessments were performed on days one, two, four and
seven following admission by Bonaventura 2007, and on the ﬁrst
and seventh postoperative day by Berggren 1987. Al-Aama 2011
assessed participants every 24 to 48 hours and Jeffs 2013 assessed
every 48hours. Boustani 2012 assessed participants everyweekday.
Urban 2008 assessed for delirium on postoperative day (POD)
one; Lurati 2012 assessed on POD one, two and seven; and Sieber
2010 assessed on POD two and daily thereafter.
At the end of one study (Lundstrom 2007), a retrospective case
notes review was performed by a blinded independent investigator
to identify delirium according to DSM-IV criteria for each post-
operative day until discharge. A single delirium assessment with
the OBS was also performed between the third and ﬁfth postop-
erative day in this study. In Gauge 2014, delirium assessment was
performed on day three +/- one day. Whitlock 2015 assessed only
on postoperative day three, and Li 2013 assessed on postoperative
day three and at one, three and six months. Ashraf 2015 assessed
for delirium four hours post-procedure and on the following day.
In three studies the speciﬁc frequency of delirium assessment was
unclear (Beaussier 2006; Chan 2013; Gruber-Baldini 2013), but
described as ’regularly’, ’throughout study period’ or ’multiple
times’.
Secondary outcomes
Duration of delirium was reported by 12 studies (de Jonghe 2014;
Fukata 2014; Jeffs 2013; Kalisvaart 2005; Larsen 2010; Liptzin
2005; Lundstrom 2007; Marcantonio 2001; Martinez 2012;
Mouzopoulos 2009; Sieber 2010; Watne 2014). Severity of delir-
ium was reported by 11 studies (Al-Aama 2011; de Jonghe 2014;
Gruber-Baldini 2013; Hatta 2014; Hempenius 2013; Jeffs 2013;
Kalisvaart 2005; Larsen 2010; Marcantonio 2011; Mouzopoulos
2009; Watne 2014).
Fourteen studies reported data on cognitive outcomes (Ashraf
2015; Beaussier 2006; Bonaventura 2007; Chan 2013; de
Jonghe 2014; Diaz 2001; Larsen 2010; Li 2013; Munger 2008;
Papaioannou 2005; Pesonen 2011; Radtke 2013; Sieber 2010;
Watne 2014). Mode of cognitive assessment varied: Ashraf 2015;
Bonaventura 2007, Diaz 2001, Larsen 2010; Munger 2008;
Papaioannou 2005 and Sieber 2010 used the Mini Mental State
Examination (MMSE) (Folstein 1975); Beaussier 2006 assessed
the number of days for MMSE to return to preoperative level;
Chan 2013; Li 2013; Radtke 2013 and Watne 2014 assessed
for postoperative cognitive dysfunction; Pesonen 2011 used the
CAM-ICU score on day ﬁve; and de Jonghe 2014 used IQ-
CODE (Jorm 1989) and MMSE (Folstein 1975) assessment at
three months follow-up.
Length of hospital admission was a commonly used outcomemea-
sure, with only 11 of the included studies not reporting on this out-
come (Bonaventura 2007; Diaz 2001; Fukata 2014; Gauge 2014;
Hatta 2014; Larsen 2010; Leung 2006; Lurati 2012;Marcantonio
2011; Mouzopoulos 2009; Urban 2008).
Other secondary outcomes which were reported less frequently
included: activities of daily living (Abizanda 2011; Watne 2014);
behavioural disturbance (Aizawa 2002); activities of daily living
performance (Abizanda 2011; de Jonghe 2014; Watne 2014);
psychotropic medication use (Al-Aama 2011; de Jonghe 2014;
Gruber-Baldini 2013; Pesonen 2011); return to previous residence
or independent living (Hempenius 2013; Jeffs 2013; Lundstrom
2007;Marcantonio 2001); and institutionalisation (Watne 2014).
Adverse Outcomes
Only 15 of the included studies reported data on mortality, ei-
ther in hospital or at follow-up at three or 12 months (Abizanda
2011; Al-Aama 2011; Beaussier 2006; Boustani 2012; Chan 2013;
de Jonghe 2014; Hatta 2014; Lundstrom 2007; Lurati 2012;
Mouzopoulos 2009; Radtke 2013; Sieber 2010; Stoppe 2013;
Watne 2014; Whitlock 2015).
Other adverse outcomes reported include: adverse events (
Abizanda 2011; Hatta 2014; Kalisvaart 2005; Marcantonio 2011;
Sampson 2007); physical morbidity (Berggren 1987; Boustani
2012; Gruber-Baldini 2013; Larsen 2010; Watne 2014); psy-
chological morbidity (Berggren 1987; Chan 2013; Hempenius
2013; Lundstrom 2007); postoperative complications (Chan
2013; Hempenius 2013; Jia 2014; Papaioannou 2005; Sieber
2010; Whitlock 2015); falls (Boustani 2012; Hempenius 2013;
Lundstrom 2007; Martinez 2012; Watne 2014); and pressure ul-
cers (Berggren 1987; Boustani 2012; Lundstrom 2007; Watne
2014).
Exclusion of prevalent delirium at baseline
Failure to exclude delirium at enrolment to the study was a com-
mon problem among included studies. Only 10 studies clearly
excluded or accounted for prevalent cases of delirium at baseline
(Abizanda 2011; Ashraf 2015; Boustani 2012; de Jonghe 2014;
Hatta 2014; Gruber-Baldini 2013; Jeffs 2013; Kalisvaart 2005;
Martinez 2012; Sieber 2010).
Funding sources and declarations of interest
Most of the studies (24 out of 39) were funded via academic or
governmental research institutions or grant funding schemes. Four
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studies were solely industry funded (Boustani 2012; Liptzin 2005;
Munger 2008; Sampson 2007) and two received joint academic
and industry funding (Lurati 2012; Radtke 2013). In nine studies
the funding source was not reported (Aizawa 2002; Ashraf 2015;
Bonaventura 2007; Diaz 2001; Gauge 2014; Jia 2014; Martinez
2012; Mouzopoulos 2009; Sieber 2010).
Eight studies reported there were potential interests to declare
related to their publication (Boustani 2012; Gruber-Baldini 2013;
Hatta 2014; Larsen 2010; Leung 2006; Liptzin 2005; Lurati 2012;
Stoppe 2013), which are listed in the Characteristics of included
studies tables. Fourteen studies did not report on a declaration
of interest (Aizawa 2002; Ashraf 2015; Beaussier 2006; Berggren
1987; Bonaventura 2007;Gauge 2014; Li 2013; Lundstrom2007;
Marcantonio 2001; Munger 2008; Papaioannou 2005; Sampson
2007; Sieber 2010;Urban 2008).
Excluded studies
We excluded 69 studies. Reasons for exclusion are given in
Characteristics of excluded studies. Details of 27 studies identiﬁed
as ongoing are given in Characteristics of ongoing studies.
Risk of bias in included studies
’Risk of bias’ assessments are presented for each study in the ’
Characteristics of included studies’ table and are summarised in the
text below and graphically in Figure 2. Only one study (Whitlock
2015) was assessed as at low risk of bias across all domains.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Only one study (Bonaventura 2007) was assessed as high risk for
selection bias considering both allocation concealment and ran-
dom sequence generation. This was as a consequence of using
the day of admission as the basis for their randomisation, which
cannot be concealed. Nine studies (Aizawa 2002; Ashraf 2015;
Berggren 1987; Gauge 2014; Liptzin 2005;Munger 2008; Radtke
2013; Sieber 2010; Stoppe 2013) were considered as unclear risk
for selection bias on both criteria. This assessment was primarily
made on the grounds of a lack of detail in the published report
around the methods of generating the sequence and allocating
participants to groups.
Blinding
Twenty-three of the included studies (Abizanda 2011; Aizawa
2002; Ashraf 2015; Berggren 1987; Bonaventura 2007; Boustani
2012; Chan 2013; Fukata 2014; Gruber-Baldini 2013; Hatta
2014; Hempenius 2013; Jeffs 2013; Jia 2014; Lundstrom 2007;
Lurati 2012; Marcantonio 2001; Martinez 2012; Mouzopoulos
2009; Papaioannou 2005; Radtke 2013; Stoppe 2013; Urban
2008; Watne 2014) were assessed as high risk for performance
bias as participants and personnel were not blinded to their al-
location, often due to the nature of the intervention precluding
such concealment. However, only six studies (Ashraf 2015; Fukata
2014; Gruber-Baldini 2013; Lundstrom 2007; Martinez 2012;
Watne 2014) were assessed at high risk of both performance and
detection bias due to the assessors being unblinded in addition
to participants and personnel. A further eight studies (Beaussier
2006; Bonaventura 2007; Boustani 2012; Gauge 2014; Jia 2014;
Mouzopoulos 2009; Munger 2008; Papaioannou 2005) were as-
sessed as unclear risk for detection bias due to a lack of reporting.
Incomplete outcome data
Ten studies were assessed as high risk for attrition bias (Al-Aama
2011; Chan 2013; Larsen 2010; Liptzin 2005; Mouzopoulos
2009; Papaioannou 2005; Pesonen 2011; Radtke 2013; Sampson
2007;Urban 2008). This was due to incomplete reporting of losses
or concerns about reasons for exclusion of participants. In partic-
ular, there were concerns about exclusions which may inﬂuence
ascertainment of the primary outcome (delirium incidence) e.g.
participants being too unwell to be assessed or developing post-
operative complications. A further seven studies were considered
at unclear risk for attrition bias (Aizawa 2002; Diaz 2001; Fukata
2014; Gauge 2014; Hempenius 2013; Kalisvaart 2005; Munger
2008. In these cases it was not possible to assess the potential bias
associated with loss of participants due to a lack of detail in study
reports.
Selective reporting
Three studies were assessed as high risk of reporting bias (Beaussier
2006; Berggren 1987; Lurati 2012). In all cases this was due to the
reporting of outcomes not stated in the protocol or themethods for
the study. Twelve studies were considered at low risk of reporting
bias (Abizanda 2011; de Jonghe 2014;Gruber-Baldini 2013;Hatta
2014; Hempenius 2013; Jeffs 2013; Larsen 2010; Marcantonio
2011; Radtke 2013; Stoppe 2013; Watne 2014; Whitlock 2015),
with evidence of published protocols, formal trial registration or
clear statement in relation to reporting contained in the published
text. The remainder were assessed as unclear risk.
Other potential sources of bias
Seven studies were assessed as high risk of bias in this category
(Aizawa 2002; Gruber-Baldini 2013; Li 2013; Lundstrom 2007;
Marcantonio 2001; Papaioannou 2005; Watne 2014).
In Aizawa 2002 no account was taken of how delirium assessment
may have been affected by the sedating effects of the delirium-
free protocol. Similarly in Papaioannou 2005, there were concerns
about unbalanced use of neuraxial analgesia between groups, af-
fecting delirium assessment. Li 2013 administered supplementary
morphine to both groups depending on pain scores, but use of
this is signiﬁcantly unbalanced and this is not accounted-for in
the interpretation of delirium ﬁndings. In Watne 2014, there are
concerns about the integrity of the intervention delivered as the
trial was conducted pragmatically and when beds were not avail-
able in the specialist unit, patients were cared-for in the corridor,
but are counted in the intervention group.
The proportion of included participants with dementia was im-
balanced in three studies (Gruber-Baldini 2013; Lundstrom 2007;
Marcantonio 2001). In all cases there was a lower proportion of
individuals with dementia in the intervention arm than the con-
trol arm. This has the potential to affect rates of incident delirium
as delirium is known to be more common in individuals with de-
mentia (Fong 2015).
Publication of two studies as abstracts (Gauge 2014; Munger
2008) gave insufﬁcient information to allow for other sources of
bias to be assessed, resulting in an assessment of unclear risk.
Effects of interventions
See: Summary of findings for the main comparison A multi-
component delirium prevention intervention compared to usual
care for hospitalised non-ICU patients; Summary of findings 2
Prophylactic cholinesterase inhibitor versus placebo for preventing
delirium in hospitalised non-ICU patients; Summary of findings
3 Prophylactic antipsychotic medications for preventing delirium
in hospitalised non-ICU patients; Summary of findings 4
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Prophylactic melatonin for preventing delirium in hospitalised
non-ICU patients; Summary of findings 5 Bispectral index
(BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical
judgement for preventing delirium in hospitalised non-ICU
patients
1. Multi-component interventions versus usual care
Seven studies investigated the effectiveness of multi-component
interventions for the prevention of delirium (Abizanda 2011;
Bonaventura 2007; Hempenius 2013; Jeffs 2013; Lundstrom
2007; Marcantonio 2001; Martinez 2012). A summary of ﬁnd-
ings for key outcomes is presented in Summary of ﬁndings for the
main comparison.
a. Primary outcome
Available case analysiswas performedon1950of 2018 randomised
participants, using data from all seven studies. Pooled analysis
showed evidence of a reduction in the incidence of delirium for
multi-component interventions compared to usual care (risk ratio
(RR) 0.69, 95% conﬁdence interval (CI) 0.59 to 0.81, I2 = 0%;
1950 participants. We assessed this as moderate-quality evidence
(downgraded due to risk of bias) (Analysis 1.1; Figure 3).
Figure 3. Forest plot of comparison: 1 Multi-component delirium prevention intervention (MCI) versus
usual care, outcome: 1.1 Incident delirium.
b. Secondary outcomes
We pooled data on the duration of delirium from four trials (Jeffs
2013; Lundstrom 2007;Marcantonio 2001;Martinez 2012). The
mean difference between groups was -1.16 days (shorter in the
intervention group) but there was uncertainty about the size and
direction of the effect (mean difference (MD) -1.16, 95% CI -
2.96 to 0.64, I2 = 58%; 244 participants; assessed as very low-
quality evidence due to imprecision, risk of bias and inconsistency)
(Analysis 1.3).
Delirium severity was reported as an outcome in only two multi-
component intervention trials, each of which used different mea-
sures of severity (Hempenius 2013; Jeffs 2013). Compared with
usual care the standardised mean difference (SMD) in delirium
severity was -1.04 (lower with multi-component interventions)
(SMD -1.04, 95% CI -1.65 to -0.43, I2 = 25%; 67 participants;
low-quality evidence due to risk of bias and imprecision) (Analysis
1.4).
We pooled data from six studies, which reported length of hos-
pital admission (Abizanda 2011; Hempenius 2013; Jeffs 2013;
Lundstrom 2007; Marcantonio 2001; Martinez 2012). The mean
length of hospital admission was 0.01 days longer in the interven-
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tion compared to the usual care group (MD 0.01, 95% CI -0.48
to 0.51, I2 = 13%; 1920 participants; moderate-quality evidence
due to risk of bias) (Analysis 1.5).
One study assessed cognition (Bonaventura 2007); there was a
clinically important difference in themeanMMSE score favouring
those receivingmulti-component interventions compared to usual
care (MD 9.10, 95% CI 7.20 to 11.00; 60 participants; very low-
quality evidence due to risk of bias and serious imprecision) (
Analysis 1.6).
Abizanda 2011 reported on the number of participants whose
Barthel Index score (Mahoney 1965) improved by 10 points dur-
ing admission, comparing this between the groups. There was no
evidence of effect of multi-component interventions on improve-
ments in activities of daily living compared to usual care (RR
1.15, 95%CI0.91 to 1.47; 341 participants; low-quality evidence,
downgraded due to risk of bias and imprecision) (Analysis 1.7).
Four studies (Hempenius 2013; Jeffs 2013; Lundstrom 2007;
Marcantonio 2001) reported on return to independent living.
Again, there was no evidence of effect of multi-component inter-
ventions compared to usual care (RR 0.95, 95% CI 0.85 to 1.06,
I2 = 30%; 1116 participants; moderate-quality evidence, down-
graded due to risk of bias) (Analysis 1.8).
Lundstrom 2007 assessed depression with the Geriatric Depres-
sion Scale-15 (GDS-15) (Sheikh 1986), but found no evidence
of any important effect of the intervention on this outcome (MD
0.70, 95% CI -0.44 to 1.84; 149 participants; low-quality evi-
dence, downgraded due to risk of bias and imprecision) (Analysis
1.9).
One study reported no withdrawals from 126 participants (
Marcantonio 2001) (Analysis 1.10).
c. Adverse outcomes
Data on falls were only available from three studies (Hempenius
2013; Lundstrom 2007; Martinez 2012), there was no evidence
of effect from multi-component interventions compared to usual
care (RR 0.57, 95% CI 0.16 to 2.01, I2 = 50%; 746 participants;
very low-quality evidence, downgraded due to risk of bias, serious
imprecision and inconsistency) (Analysis 1.11).
Rates of pressure ulcers were only reported in two studies
(Hempenius 2013; Lundstrom 2007) where there was evidence of
a reduced risk of pressure ulcer formation in those receiving multi-
component interventions compared to usual care (RR 0.48, 95%
CI 0.26 to 0.89, I2 = 0%; 457 participants; low-quality evidence
downgraded, due to risk of bias and imprecision) (Analysis 1.12).
Inpatient mortality was reported in three studies (Abizanda 2011;
Hempenius 2013; Lundstrom 2007), with no evidence of effect of
multi-component interventions on inpatient mortality (RR 0.90,
95%CI 0.56 to 1.43, I2 = 57%; 859 participants; very low-quality
evidence, downgraded due to risk of bias, imprecision and incon-
sistency) (Analysis 1.13).
Lundstrom 2007 also reported on 12-month mortality and found
no evidence of effect of multi-component interventions (RR 0.85,
95% CI 0.46 to 1.56; 199 participants; low-quality evidence due
to risk of bias and imprecision) (Analysis 1.14).
Hempenius 2013 reported on postoperative complications and
there was no evidence of effect of multi-component interven-
tions on cardiovascular adverse events (RR 1.13, 95% CI 0.78 to
1.65; 260 participants; moderate-quality evidence due to impre-
cision) or urinary tract infections (RR 1.20, 95% CI 0.45 to 3.20;
260 participants; low-quality evidence due to serious imprecision)
(Analysis 1.15; Analysis 1.16). Hempenius 2013 also reported on
psychological morbidity, reporting SF-36 scores for mental health
(Ware 1992), dichotomized to having worsened versus improve-
ment/stayed the same and there was no evidence of effect found
(RR 0.88, 95% CI 0.64 to 1.20; 246 participants; moderate-qual-
ity evidence due to imprecision) (Analysis 1.17).
Subgroup analysis by setting
The pre-planned subgroup analysis assessed multi-component
delirium prevention trials in four medical (Abizanda 2011;
Bonaventura 2007; Jeffs 2013; Martinez 2012) and three surgi-
cal (Hempenius 2013; Lundstrom 2007; Marcantonio 2001) set-
tings. There were similar effect sizes in medical (RR 0.63, 95% CI
0.43 to 0.92; 1365 participants) and surgical (RR 0.71, 95% CI
0.59 to 0.85; 585 participants) settings in favour of the interven-
tion reducing incident delirium (moderate-quality evidence due
to risk of bias for both) (Analysis 1.1; Figure 3).
Subgroup analysis by cognitive impairment
Only one trial (Marcantonio 2001) reported incident delirium
in patients with pre-existing dementia. In the intervention group
37% of participants were known to have dementia, compared
to 51% of those in the control group. Delirium incidence was
lower in patients receiving a multi-component intervention in this
subgroup also. However, the results are too imprecise to allow
a conclusion to be drawn (RR 0.90, 95% CI 0.59 to 1.36; 50
participants; low-quality evidence, downgraded due to risk of bias
and imprecision) (Analysis 1.2).
2. Cholinesterase inhibitors versus placebo
Four studies investigated the effect of the cholinesterase in-
hibitor donepezil in the prevention of delirium (Liptzin 2005;
Marcantonio 2011; Munger 2008; Sampson 2007). A ’Summary
of ﬁndings’ table for key outcomes is presented in Summary of
ﬁndings 2.
a. Primary outcome
Data from only two of these four studies (Liptzin 2005; Sampson
2007) could be used to estimate the primary outcome, delirium
incidence, asMarcantonio 2011 reported repeatedCAMmeasures
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within the same individuals, and Munger 2008 reported mean
CAM scores only. There was no evidence of effect of cholinesterase
inhibitors on incident delirium (RR 0.68, 95% CI 0.17 to 2.62, I
2 = 60%; 113 participants; very low-quality evidence due to risk of
bias, serious imprecision and inconsistency) (Analysis 2.1; Figure
4).
Figure 4. Forest plot of comparison: 2 Prophylactic cholinesterase inhibitor versus placebo, outcome: 2.1
Incident delirium.
b. Secondary outcomes
The effect of cholinesterase inhibitors on the duration of delirium
episodes was assessed by Liptzin 2005, but no summary estimate
was calculable due to the limited data available (Analysis 2.2).
The effect of cholinesterase inhibitors on the severity of delirium
episodes was assessed by Marcantonio 2011 who reported no ev-
idence of effect (MD -0.30, 95% CI -4.17 to 3.57; 16 partici-
pants; low-quality evidence, downgraded two levels due to serious
imprecision) (Analysis 2.3).
Pooled data from three studies reporting length of hospital ad-
mission (Liptzin 2005; Munger 2008; Sampson 2007) showed a
mean difference of -0.34 days with cholinesterase inhibitor treat-
ment compared to placebo (MD -0.34, 95% CI -1.54 to 0.86, I
2 = 45%; 128 participants; low-quality evidence downgraded due
to risk of bias and imprecision) (Analysis 2.4).
One study examining the effect of cholinesterase inhibitor on cog-
nition (Munger 2008) found no evidence of effect on MMSE
(Folstein 1975) scores (MD -1.40, 95% CI -4.45 to 1.65; 15 par-
ticipants; very low-quality evidence, downgraded due to risk of
bias and serious imprecision) (Analysis 2.5).
Two studies reported withdrawals from protocol (Liptzin
2005; Marcantonio 2011), ﬁnding no evidence of effect with
cholinesterase inhibitor use compared to placebo (RR 0.95, 95%
CI 0.49 to 1.87, I2 = 0%; 96 participants; low-quality evidence,
downgraded due to risk of bias and imprecision) (Analysis 2.6).
c. Adverse outcomes
Adverse events were reported in two studies in different formats.
Sampson 2007 reported the mean adverse events in each group
and found no evidence of difference in occurrence between groups
(MD 0.13, 95% CI -0.26 to 0.52; 33 participants; low-qual-
ity evidence due to risk of bias and imprecision) (Analysis 2.7).
Marcantonio 2011 reported adverse events as a binary outcome
and found a higher rate of adverse events in the cholinesterase
inhibitor group compared to placebo (RR 6.25, 95% CI 0.35 to
112.52; 16 participants; low-quality evidence downgraded two
levels due to serious imprecision) (Analysis 2.8).
3. Antipsychotics versus placebo
Three studies investigated the effect of antipsychoticmedication in
the prevention of delirium (Fukata 2014; Kalisvaart 2005; Larsen
2010). A ’Summary of ﬁndings’ table for key outcomes is presented
in Summary of ﬁndings 3.
a. Primary outcome
Two large studies evaluated antipsychotic medication versus
placebo in elderly orthopaedic patients and one smaller study
assessed those undergoing abdominal or orthopaedic surgery.
Kalisvaart 2005 assessed oral haloperidol, a ﬁrst generation (typi-
cal) antipsychotic preparation in 430 participants; data were avail-
able for 395 participants for available case analysis. Fukata 2014
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administered prophylactic intravenous haloperidol to 121 patients
frompostoperative days one to three. Larsen 2010 tested oral olan-
zapine, a second generation (atypical) antipsychotic in 495 partic-
ipants, with data for available case analysis for 400.
Pooled analysis of all three studies was inconclusive regarding an
effect of antipsychotic treatment on incident delirium, but there
wasmoderate heterogeneity between the studies (RR0.73, 95%CI
0.33 to 1.59, I2= 90%; 916 participants; very low-quality evidence
due to risk of bias, imprecision and inconsistency) (Analysis 3.1;
Figure 5).
Figure 5. Forest plot of comparison: 3 Prophylactic antipsychotic versus control, outcome: 3.1 Incidence of
delirium.
Subgroup analysis
The pre-planned subgroup analysis assessed the effect of typi-
cal and atypical antipsychotics separately on delirium incidence.
There was no evidence of effect of haloperidol on delirium inci-
dence (RR 1.05, 95% CI 0.69 to 1.60, I2= 43%; two studies; 516
participants; low-quality evidence downgraded due to risk of bias
and inconsistency). However, the risk of incident delirium was
lower with olanzapine than with placebo (RR 0.36, 95% CI 0.24
to 0.52; one study; 400 participants; moderate-quality evidence
due to risk of bias) (Figure 5).
b. Secondary outcomes
All three studies reported duration of delirium episodes. However,
Fukata 2014 present mean duration data without a standard de-
viation so they could not be included in the quantitative analysis.
Between the other two studies there was serious heterogeneity in
duration ﬁndings. Haloperidol showed a large effect size, with a
shorter duration of delirium in the intervention group compared
to control (MD -6.40 days, 95% CI -9.38 to -3.42; one study; 68
participants). Olanzapine showed a longer duration for the inter-
vention group (MD 0.60 days, 95% CI 0.10 to 1.10; one study;
110 participants). The pooled analysis of both showed a mean
difference in delirium duration between intervention and control
groups of -2.74 days (95% CI -9.59 to 4.11, I2 = 95%; 178 partic-
ipants; very low-quality evidence due to serious imprecision and
inconsistency) (Analysis 3.2).
Both Kalisvaart 2005 and Larsen 2010 reported severity of delir-
ium episodes, although there was serious heterogeneity between
studies as before. Haloperidol showed a large effect size, with a
reduction in severity of delirium in the intervention group com-
pared to control (MD -4.00, 95% CI -5.86 to -2.14; 68 partici-
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pants). Olanzapine showed an increased severity for the interven-
tion group (MD 1.90, 95% CI 0.41 to 3.39; 110 participants).
Pooled analysis showed no evidence of effect in delirium severity
with antipsychotic treatment (MD -1.02, 95% CI -6.80 to 4.76,
I2 = 96%; 178 participants; very low-quality evidence due to seri-
ous imprecision and inconsistency) (Analysis 3.3).
Length of admission was only reported in one study (Kalisvaart
2005), which showed amean difference of -5.50 days for haloperi-
dol compared to placebo (95%CI -12.17 to 1.17; 68 participants;
low-quality evidence, downgraded two levels due to serious im-
precision in results (Analysis 3.4).
Cognitive testing, using MMSE (Folstein 1975) was performed
on the ﬁrst day of the delirium episode by Larsen 2010. Those who
received olanzapine had lower MMSE scores (poorer cognitive
function) than those treated with placebo (MD -4.90, 95% CI -
7.42 to -2.38; 110participants; low-quality evidence due to serious
imprecision) (Analysis 3.5).
There was no evidence of effect of treatment allocation on with-
drawal from protocol in pooled analysis including Kalisvaart 2005
& Larsen 2010 (RR 0.92, 95%CI 0.68 to 1.24, I2 = 0%; 925 par-
ticipants; moderate-quality evidence due to risk of bias) (Analysis
3.6).
c. Adverse outcomes
Adverse events were reported by Kalisvaart 2005; there was no
evidence of effect of haloperidol on adverse events (RR 0.39, 95%
CI 0.10 to 1.43; 430 participants; low-quality evidence due to
risk of bias and imprecision) (Analysis 3.7). Larsen 2010 report
data on the occurrence of pneumonia (RR 7.28, 95% CI 0.38 to
140.11; 400 participants), urinary tract infection (RR 0.26, 95%
CI 0.03 to 2.31; 400 participants) and congestive heart failure
(RR 1.04, 95% CI 0.07 to 16.52; 400 participants) and there
was no evidence of effect of olanzapine on the risk of developing
these adverse events (Very low-quality evidence, downgraded due
to risk of bias and serious imprecision) (Analysis 3.8; Analysis 3.9;
Analysis 3.10).
4. Melatonin or melatonin agonists versus placebo
Three studies investigated the effect of melatonin or melatonin
agonists in the prevention of delirium (Al-Aama 2011; de Jonghe
2014; Hatta 2014). Outcome data relevant to this review were
obtained from the authors of Hatta 2014 for 43 participants who
were cared for in acute medical wards rather than ICU. A ’Sum-
mary of ﬁndings’ table for key outcomes is presented in Summary
of ﬁndings 4.
a. Primary outcome
All three studies reported the primary outcome, delirium inci-
dence. The pooled analysis showed no evidence of effect of mela-
tonin on incident delirium (RR 0.41, 95% CI 0.09 to 1.89 I2 =
78%; 529 participants; very low-quality evidence due to risk of
bias, imprecision and inconsistency) (Analysis 4.1; Figure 6).
Figure 6. Forest plot of comparison: 4 Prophylactic melatonin versus placebo, outcome: 4.1 Incident
delirium.
b. Secondary outcomes
Duration of delirium was only reported in one study (de Jonghe
2014). There was no evidence of a difference between melatonin
and placebo groups in deliriumduration (MD0.00, 95%CI -0.57
to 0.57; 104 participants; moderate-quality evidence downgraded
due to imprecision) (Analysis 4.2) .
Severity of delirium was reported in all three studies but each
in a different way. de Jonghe 2014 reported delirium severity
as a binary outcome, severe or not severe (deﬁned as >= 3 mg
haloperidol administered during delirium episode). There was no
evidence of a difference between melatonin and placebo groups
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in the occurrence of severe delirium (RR 0.86, 95% CI 0.58 to
1.27; 104 participants; moderate-quality evidence due to impre-
cision) (Analysis 4.3) Al-Aama 2011 reported delirium severity
using MDAS (Breitbart 1997), however their results include those
with prevalent as well as incident delirium and have not been in-
cluded in the quantitative summary.Hatta 2014 reported delirium
severity using the DRS-R-98 (Trzepacz 2001). There appeared to
be a reduction in delirium severity in those receiving themelatonin
agonist (RR -4.10, 95% CI -19.47 to 11.27; six participants), but
the evidence was of low quality, downgraded two levels due to
serious imprecision (Analysis 4.4).
Length of admission was reported in two studies, and there was
no evidence of difference in admission duration between interven-
tion and control groups (MD 0.09 days, 95% CI -1.20 to 1.39
days, I2 = 0%; 500 participants; moderate-quality evidence due to
imprecision) (Analysis 4.5).
de Jonghe 2014 assessed cognitive impairment using the Charl-
son index (Charlson 1994), IQCODE (Jorm 1989) and MMSE
(Folstein 1975) at three-month follow-up. It appeared that those
in the melatonin group had a lower risk of cognitive impairment,
compared to those receiving placebo (RR 0.86, 95% CI 0.70 to
1.04; 378 participants). However, this evidence was of moder-
ate quality due to imprecision of the result from a single study
(Analysis 4.6).
There was no evidence of difference in performance of activities of
daily living, using the Katz index (Katz 1970), in those receiving
melatonin found by de Jonghe 2014 (MD 0.00, 95%CI -1.20
to 1.20; 369 participants; moderate-quality evidence downgraded
due to imprecision) (Analysis 4.7).
Al-Aama 2011 examined rates of psychotropicmedicationuse, and
reported a high proportion of participants in both melatonin and
control groups were prescribed these drugs (33/61 in melatonin
group and 38/61 in the placebo group). There was no evidence
of a difference in use, however, between groups (RR 0.87, 95%
CI 0.64 to 1.18; 122 participants; moderate-quality evidence due
to imprecision) (Analysis 4.8). de Jonghe 2014 reported use of
anti-psychotic medications and benzodiazepines on a cumulative
basis, looking at mean consumption of each drug class. There
was evidence of reduced use of both anti-psychotic medications
(MD -1.00 mg, 95% CI -1.79 to -0.21 mg; 378 participants;
moderate-quality evidence downgraded as from a single study)
and benzodiazepines (MD -11.60 mg, 95% CI -24.34 to 1.14
mg; 378 participants). However, in the case of benzodiazepine
use the evidence was of low quality, downgraded due to serious
imprecision (Analysis 4.9; Analysis 4.10).
Al-Aama 2011 and Hatta 2014 also compared withdrawals from
the study and found no evidence of a difference betweenmelatonin
and placebo groups (RR 1.00, 95% CI 0.15 to 6.87; 165 partici-
pants; low-quality evidence, due to serious imprecision) (Analysis
4.11).
c. Adverse events
In-hospital mortality was reported in all three studies and mortal-
ity at threemonths only by de Jonghe 2014. There was no evidence
of effect on mortality rates with melatonin compared to placebo at
either time-period: In-hospital mortality (RR 0.84, 95% CI 0.37
to 1.88, I2 = 0%; 543 participants; low-quality evidence due to
imprecision and low event rate) (Analysis 4.12) and three-month
mortality (RR 0.98, 95% CI 0.67 to 1.45; 378 participants; mod-
erate-quality evidence, downgraded due to imprecision) (Analysis
4.13).
Hatta 2014 reported adverse events and there were none reported
in either group.
5. Citicoline versus placebo
One study tested the use of citicoline (Diaz 2001).
a. Primary outcome
The incidence of delirium was lower in the group treated with
citicoline, but the results were too imprecise to allow a conclusion
to be drawn (RR 0.68, 95% CI 0.22 to 2.06; 80 participants;
moderate-quality evidence) (Analysis 5.1).
b. Secondary outcomes
There was no clear evidence of effect on cognitive status with
citicoline treatment using MMSE score (MD -1.47, CI -3.85 to
0.91; 81participants;moderate-quality evidence, downgradeddue
to imprecision) (Analysis 5.2).
c. Adverse outcomes
No data were reported for adverse outcomes.
6. Oral premedication with diazepam and
diphenhydramine versus no premedication
One study of 49 participants undergoing inpatient elective car-
diac catheterisation compared the effect of premedication with
diazepam and diphenhydramine with no premedication (Ashraf
2015).
a. Primary outcome
There were no cases of incident delirium in either group (49 par-
ticipants; low-quality evidence, downgraded due to risk of bias
and evidence from single small study).
b. Secondary outcomes
No data are reported on secondary outcomes.
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c. Adverse outcomes
No data are reported on adverse outcomes.
7. Intravenous (IV) methylprednisolone versus
placebo
One large multicentre study of 7507 participants undergoing car-
diopulmonary bypass procedures who were at high risk of morbid-
ity and mortality compared the effect of intravenous (IV) methyl-
prednisolone versus placebo and incorporated incidence of delir-
ium as a safety outcome (Whitlock 2015).
a. Primary outcome
IV Methylprednisolone has no effect on the incidence of delirium
for patients undergoing high-risk cardiopulmonary bypass proce-
dures (RR 1.02, 95% CI 0.87 to 1.19; 7507 participants; high-
quality evidence) (Analysis 7.1).
b. Secondary outcomes
IV methylprednisolone has no effect on the length of stay for
patients undergoing high-risk cardiopulmonary bypass procedures
(RR 0.00, 95% CI -0.20 to 0.20; 7507 participants; high-quality
evidence) (Analysis 7.2).
c. Adverse outcomes
IV methylprednisolone has no effect on 30-day mortality for pa-
tients undergoing high-risk cardiopulmonary bypass procedures
(RR 0.87, 95% CI 0.70 to 1.07; 7507 participants; high-quality
evidence) (Analysis 7.3).
Evaluating postoperative complications, IV methylprednisolone
appears to increase the risk of myocardial injury compared to
placebo (RR 1.22, 95% CI 1.07 to 1.38; 7507 participants; high-
quality evidence) and has no effect on the risk of respiratory failure
(RR 0.91, 95% CI 0.80 to 1.05; 7507 participants; high-quality
evidence) and infection (RR 0.94, 95% CI 0.84 to 1.06; 7507
participants; high-quality evidence).
8. Gabapentinoids versus placebo
Two studies tested gabapentinoids agents.One assessed gabapentin
in 21 patients (Leung 2006), and the other tested the more potent
preparation, pregabalin, in 70 patients (Pesonen 2011). However,
results for these studies could not be pooled as each measured
different outcomes.
a. Primary outcome
In Leung 2006, the incidence of delirium was lower in the group
treatedwith gabapentin, but the results were too imprecise to allow
a conclusion to be drawn (RR 0.12, 95% CI 0.01 to 1.90; 21
participants; low-quality evidence, downgraded due to risk of bias
and imprecision) (Analysis 8.1).
Pesonen 2011 tested for postoperative delirium using a Finnish
modiﬁed CAM-ICU but reported only median scores, precluding
use of these data in the analysis .
b. Secondary outcomes
Pesonen 2011 reported effect of pregabalin compared to placebo
on length of hospital admission (MD -0.60 days 95% CI -2.12
to 0.92; 60 participants) (Analysis 8.2); cognition (measured with
the CAM-ICU on day ﬁve), (MD 1.00 95% CI -2.76 to 4.76; 60
participants) (Analysis 8.3); and use of psychotropic medication,
(RR 0.53 95% CI 0.21 to 1.38; 60 participants) (Analysis 8.4).
For all three outcomes, results were inconclusive and we judged
the evidence to be low-quality, downgraded due to imprecision
and risk of bias.
Withdrawal from protocol appeared higher in the intervention
group; however the results were too imprecise to allow a conclusion
to be drawn (RR 9.0 95%CI 0.50 to 161.13; 70 participants; very
low-quality evidence downgraded due to risk of bias and serious
imprecision) (Analysis 8.5).
c. Adverse outcomes
No data were reported for adverse outcomes.
9. Ketamine versus placebo
One study (Urban 2008) tested the use of ketamine in 26 patients
undergoing lumbar spinal fusion.
a. Primary outcome
Rates of incident delirium appeared higher among those treated
with ketamine compared to control. However, the results are too
imprecise to allow a conclusion to be drawn (RR 2.00, 95% CI
0.21 to 19.23; 24 participants; very low-quality evidence, down-
graded due to risk of bias and serious imprecision) (Analysis 9.1).
b. Secondary outcomes
There was no evidence of effect of ketamine treatment on with-
drawals from protocol (RR 1.00, 95% CI 0.07 to 14.34; 26 par-
ticipants; very low-quality evidence due to risk of bias and serious
imprecision) (Analysis 9.2).
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c. Adverse outcomes
No data were reported for adverse outcomes.
10. Intravenous (IV) parecoxib sodium analgesia
versus morphine and saline
One study of 80 participants admitted as an emergency for femoral
head replacement surgery compared administration of IV pare-
coxib 12-hourly versus IV morphine (single dose) followed by IV
saline (Li 2013).
a. Primary outcome
The incidence of delirium was lower in those receiving parecoxib
compared to those receiving morphine and saline (RR 0.50, 95%
CI 0.26 to 0.98; 80 participants; low-quality evidence due to in-
directness [as the comparison tests regular analgesia to one dose of
analgesia then placebo], risk of bias and this being a single small
study) (Analysis 10.1).
b. Secondary outcomes
Individuals receiving parecoxib had a shorter length of admission
than those receiving morphine and saline (MD -0.90 days, 95%
CI -1.58 to -0.22 days; 80 participants; low-quality evidence due
to indirectness and results from a single small study) (Analysis
10.2).
Data are presented for rates of postoperative cognitive dysfunction
(POCD) at three days, one week, three months, and six months,
with evidence of a reduction in the risk of POCD at one week (RR
0.38, 95% CI 0.15 to 0.98; 80 participants; low-quality evidence
downgraded due to indirectness, imprecision and results being
from a single small study) (Analysis 10.4).
c. Adverse outcomes
No data were reported for adverse outcomes.
11. Intrathecal morphine and patient controlled
analgesia (PCA) versus saline and PCA
One study (Beaussier 2006) tested the administration of intrathe-
cal morphine preoperatively in addition to postoperative patient-
controlled intravenous morphine for pain control in 59 patients.
Both groups received postoperative PCA, but the intervention
group were given intrathecal morphine, and the control group, a
similar volume of saline preoperatively.
a. Primary outcome
There was no evidence of effect on intrathecal and PCAmorphine
on rates of incident delirium (RR 0.90, 95% CI 0.44 to 1.85; 52
participants; low-quality evidence due to risk of bias and impreci-
sion) (Analysis 11.1).
b. Secondary outcomes
Data were presented on length of admission (MD -0.50 days,
95% CI -1.51 to 0.51; 52 participants) (Analysis 11.2); days for
cognition to return to preoperative level (MD 0.20, 95% CI -
1.03 to 1.43; 52 participants) (Analysis 11.3); and withdrawals
from protocol (RR 0.78, 95% CI 0.19 to 3.17; 59 participants)
(Analysis 11.4) for intrathecal PCA morphine compared to saline
and PCA. For all these outcomes, there was no clear evidence of
effect from the intervention. We judged the evidence to be of low
quality, downgraded due to risk of bias and imprecision.
c. Adverse outcomes
Mortality appeared lower in those in the intrathecal and PCAmor-
phine group, but the results were too imprecise for any conclusions
to be drawn (RR 0.34, 95% CI 0.01 to 8.13; 59 participants; low-
quality evidence, downgraded two levels due to serious impreci-
sion) (Analysis 11.5).
12. Fascia iliaca compartment block (FICB) versus
placebo
One study (Mouzopoulos 2009) with 219 participants tested ad-
ministration of fascia iliaca compartment block (FICB) to manage
pain in hip fracture patients assessed as being at intermediate or
high risk of delirium.
a. Primary outcome
Use of a FICB reduced the risk of incident delirium compared
to placebo (RR 0.45, 95% CI 0.24 to 0.87; 207 participants;
moderate-quality evidence due to risk of bias) (Analysis 12.1).
b. Secondary outcomes
Use of a FICB reduced the severity of delirium episodes (MD -
4.30, 95% CI -6.81 to -1.79; 36 participants) (Analysis 12.2) and
duration of delirium episodes (MD -5.70 days, 95% CI -9.50 to
-1.90; 36 participants) (Analysis 12.3). However, we judged the
evidence to be of very low-quality, downgraded due to risk of bias
and serious imprecision.
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c. Adverse outcomes
There was no evidence of effect of the intervention on risk of
mortality (RR 0.51, 95% CI 0.05 to 5.58; 219 participants; low-
quality evidence downgraded two levels due to serious imprecision
(Analysis 12.4).
13. Light versus deep propofol sedation
One study compared the effect of light and deep propofol sedation
on the prevalence of postoperative delirium in 114 older adult pa-
tients who underwent hip fracture repair under spinal anaesthesia
(Sieber 2010).
a. Primary outcome
The incidence of deliriumwas lower in those receiving light propo-
fol sedation compared to deep propofol sedation (RR 0.48, 95%
CI 0.26 to 0.89; 114 participants; moderate-quality evidence due
to risk of bias) (Analysis 13.1).
b. Secondary outcomes
There was no clear evidence of effect of level of sedation on delir-
ium duration (MD -0.60 days, 95% CI -3.30 to 2.10; 34 partic-
ipants; very low-quality evidence due to risk of bias and serious
imprecision) (Analysis 13.2).
There was no evidence of effect on level of sedation on length
of admission (MD 0.20 days, 95% CI -0.80 to 1.20 days; 114
participants; moderate-quality evidence, downgraded due to risk
of bias) (Analysis 13.3).
Light propofol sedation improved cognitive performance (on day
two postoperatively, assessed using MMSE score (Folstein 1975))
(MD 3.10, 95% CI 0.30 to 5.90; 114 participants; moderate-
quality evidence due to risk of bias) (Analysis 13.4).
c. Adverse outcomes
There was no evidence of effect of level of sedation on inpatient
mortality (RR 0.50, 95% CI 0.05, to 5.36; 114 participants; low-
quality evidence downgraded two levels due to serious impreci-
sion) (Analysis 13.5). There was no evidence of effect of the inter-
vention on the risk of experiencing >=1 postoperative complica-
tion (RR 0.87, 95%CI 0.60 to 1.26; 114 participants; low-quality
evidence due to risk of bias and imprecision) (Analysis 13.6).
14. Bispectral index (BIS)-guided anaesthesia versus
BIS-blinded anaesthesia or clinical judgement
Three studies Chan 2013 (925 participants), Radtke 2013 (1277
participants) and Gauge 2014 (81 participants) investigated the
use of BIS in anaesthesia. Only two of these presented useable data
for inclusion in the review (Chan 2013; Radtke 2013) as insufﬁ-
cient data were reported in Gauge 2014 (conference abstract). A
summary of ﬁndings for key outcomes is presented in Summary
of ﬁndings 5.
a. Primary outcome
BIS-guided anaesthesia was effective in reducing incident delirium
(RR 0.71, 95% CI 0.60 to 0.85, I2 = 0%; 2057 participants;
moderate-quality evidence due to risk of bias) (Analysis 14.1;
Figure 7).
Figure 7. Forest plot of comparison: 11 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia, outcome: 11.1 Incident delirium.
b. Secondary outcomes
BIS-guided anaesthesia resulted in a shorter length of admission
than those receiving BIS-blinded anaesthesia/clinical judgement
(MD -0.94 days, 95% CI -1.45 to -0.43 days, I2 = 0%; 2057
participants; moderate-quality evidence, downgraded due to risk
of bias) (Analysis 14.2).
Use of BIS-guided anaesthesia showed evidence of reducing rates
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of cognitive impairment at seven days (RR 0.87, 95% CI 0.71
to 1.05, I2 = 0%; 1938 participants) (Analysis 14.3) and at three
months (RR 0.71, 95% CI 0.53 to 0.97; 1990 participants) (
Analysis 14.4). However, we considered the evidence to be of low
quality, downgraded due to risk of bias and imprecision.
c. Adverse outcomes
Chan 2013 reported SF-36mental summary scores (Ware 1992) at
follow-up and the BIS-guided group had lower scores, indicating
a poorer assessment of their own mental health (MD -1.90, 95%
CI -3.40 to -0.40; 902 participants; moderate-quality evidence
downgraded as from a single study) (Analysis 14.5).
One study reported mortality at seven days (Chan 2013); there
was no clear evidence of any effect on mortality (RR 1.49, 95%CI
0.42 to 5.25; 921 participants; low-quality evidence, downgraded
two levels due to serious imprecision) (Analysis 14.6).
Two studies reported mortality at three months (Chan 2013;
Radtke 2013); there was no evidence of reduction inmortality (RR
1.10, 95%CI 0.77 to 1.59, I2 = 0%; 1938 participants; moderate-
quality evidence due to imprecision) (Analysis 14.7).
Chan 2013 reported rates of cardiac, respiratory and infectious
adverse events. There was no evidence of a reduction in cardiac
(RR 0.85, 95% CI 0.52 to 1.39; 902 participants) or respiratory
adverse events (RR 0.79, 95% CI 0.59 to 1.07; 902 participants),
but infectious adverse events were lower in the group receiving
BIS-guided anaesthesia (RR 0.72, 95% CI 0.55 to 0.95; 902 par-
ticipants). However, the evidence was deemed of low quality due
to risk of bias and being from a single study.
15. Sevoﬂurane versus propofol anaesthesia
Lurati 2012 compared sevoﬂurane, an inhalational anaesthetic
versus propofol, an intravenous anaesthetic to reduce periopera-
tive myocardial ischaemia in 385 patients undergoing noncardiac
surgery.
a. Primary outcome
There was no evidence of effect on rates of incident delirium with
sevoﬂurane anaesthesia compared to propofol anaesthesia (RR
0.79, 95%CI 0.47 to 1.34; 385 participants; low-quality evidence
downgraded due to risk of bias and imprecision) (Analysis 15.1).
b. Secondary outcomes
No data were reported for secondary outcomes.
c. Adverse outcomes
There was no evidence of a difference in mortality at 12 months
between intervention and control groups (RR 1.19, 95% CI 0.70
to 2.02; 385 participants; low-quality evidence downgraded two
levels due to serious imprecision) (Analysis 15.2).
16. Xenon versus sevoﬂurane anaesthesia
Stoppe 2013 conducted a pilot trial to determine the feasibility
and safety of xenon, a novel anaesthetic gas with neuroprotective
and cardioprotective properties compared with sevoﬂurane a con-
ventional inhalational anaesthetic in 30 patients undergoing elec-
tive coronary artery bypass grafting.
a. Primary outcome
There was no evidence of a difference in incidence of postoperative
delirium between the xenon and sevoﬂurane groups. The highest
incidence of delirium occurred on the second postoperative day
(RR 0.75, 95% 0.20 to 2.79; 30 participants; very low-quality
evidence due to risk of bias and serious imprecision) (Analysis
16.1).
b. Secondary outcomes
Hospital admission appeared to be longer in those treated with
xenon, but the results were too imprecise to allow conclusions
to be drawn (MD 4.00 days, 95% CI -1.72 to 9.72 days; 30
participants; very low-quality evidence, downgraded due to risk
of bias and serious imprecision) (Analysis 16.2).
c. Adverse outcomes
There were no in-hospital deaths amongst study participants
(Analysis 16.3). There was no evidence of effect on adverse events
(RR 0.75, 95% CI 0.34 to 1.64; 30 participants; low-quality ev-
idence downgraded due to risk of bias and imprecision) or the
incidence of sepsis (RR 1.50, 95% CI 0.29 to 7.73; 30 partici-
pants; very low-quality evidence downgraded due to risk of bias
and serious imprecision) (Analysis 16.4; Analysis 16.5).
17. Epidural anaesthesia versus general anaesthesia
Two studies compared epidural versus general anaesthesia (
Berggren 1987; Papaioannou 2005).
a. Primary outcome
We pooled data from both studies for the primary outcome of
incident delirium, but the result was too imprecise to determine an
effect (RR 1.19, 95% CI 0.69 to 2.03, I2 = 0%; 104 participants;
very low-quality evidence downgraded due to risk of bias and
serious imprecision) (Analysis 17.1).
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b. Secondary outcomes
There was no evidence of reduction in admission length, evaluated
as those with a length of stay >10 days versus not (RR 0.59, 95%
CI 0.28 to 1.24; 47 participants) (Analysis 17.2) and cognitive
decline (MD0.15, 95%CI0.02 to 1.06; 47 participants) (Analysis
17.3) from one study (Papaioannou 2005). For both outcomes
the result was inconclusive and we judged the evidence to be low
quality, downgraded due to risk of bias and imprecision.
c. Adverse outcomes
Berggren 1987 examined physical morbidity and found no evi-
dence of reduction in urinary tract infection (MD 1.33, 95% CI
0.57 to 3.09; 57 participants) and psychological morbidity (de-
pression) (RR 1.04; 95% CI 0.23 to 4.71; 57 participants). The
evidence for both outcomes was of low quality downgraded two
levels due to serious imprecision of results) (Analysis 17.4; Analysis
17.5).
There was no evidence for reduction in postoperative compli-
cations using epidural versus general anaesthesia reported by
Papaioannou 2005 (RR 0.92, 95% CI 0.35 to 2.39; 47 partic-
ipants; very low-quality evidence due to risk of bias and serious
imprecision) (Analysis 17.6).
Berggren 1987 investigated the impact on pressure ulcers and re-
ported no evidence of effect of reduction in pressure ulcer forma-
tion between epidural and general anaesthesia groups (RR 0.62,
95%CI 0.16 to 2.36; 57 participants; low-quality evidence down-
graded two levels due to serious imprecision) (Analysis 17.7).
18. Liberal versus restrictive blood transfusion
thresholds
One study Gruber-Baldini 2013 with 139 participants compared
the use of liberal versus restrictive blood transfusion thresholds for
individuals undergoing surgical repair of hip fracture. There was
signiﬁcant overlap in the volume of blood received by participants
in the liberal and restrictive groups.
a. Primary outcome
There was no evidence to support liberal transfusion thresholds
on rates of incident delirium (RR 0.75, 95% CI 0.45 to 1.27;
108 participants; moderate-quality evidence due to risk of bias)
(Analysis 18.1).
b. Secondary outcomes
There was no evidence that liberal transfusion thresholds affected
the severity of delirium (MD -0.10 points, 95% CI -2.99 to 2.79;
38 participants; low-quality evidence due to risk of bias and im-
precision) or length of admission (MD -0.10 days, 95% CI -1.36
to 1.16 days; 138 participants; low-quality evidence downgraded
due to imprecision and risk of bias) (Analysis 18.2; Analysis 18.3).
Use of psychoactive medication appeared balanced between the
liberal and restrictive transfusion groups (RR 0.99, 95% CI 0.87
to 1.12; 138 participants; low-quality evidence downgraded due
to risk of bias and as results from a single small study) (Analysis
18.4).
c. Adverse outcomes
Data were reported on the occurrence of post-randomisation ad-
verse events, speciﬁcally infections and congestive heart failure.
There was no evidence that liberal transfusions reduced the risk of
infections (RR 1.09, 95% CI 0.23 to 5.22; 138 participants; very
low-quality evidence downgraded due to risk of bias and serious
imprecision) or congestive heart failure (RR 0.55, 95% CI 0.05 to
5.88; 138 participants; very low-quality evidence downgraded due
to risk of bias and serious imprecision) (Analysis 18.5; Analysis
18.6).
19. Fast-track surgery versus usual care
One study Jia 2014 with 240 participants evaluated the effects of
fast-track surgery for older adults with colorectal cancer compared
to usual care.
a. Primary outcome
Evidence from this study supports fast-track surgery as an inter-
vention to reduce incident delirium (RR 0.26, 95% CI 0.09 to
0.77; 233 participants; low-quality evidence, downgraded due to
imprecision of results and risk of bias) (Analysis 19.1).
b. Secondary outcomes
There is evidence to support fast-track surgery in reducing length
of admission (MD -4.20 days, 95% CI -4.60 to -3.80 days; 233
participants; high-quality evidence) (Analysis 19.2).
c. Adverse outcomes
The study reports on the occurrence of urinary tract infection and
heart failure. It appeared that fast-track surgery reduced the rate
of urinary tract infection (RR 0.38, 95% CI 0.14 to 1.04), but
this was low-quality evidence as the result was too imprecise to
draw a conclusion and therewas risk of bias in outcome assessment
(Analysis 19.3). There is evidence to support fast-track surgery
reducing the occurrence of heart failure compared to usual care
(RR 0.31, 95% CI 0.10 to 0.91; 233 participants; low-quality
evidence downgradeddue to risk of bias and imprecision) (Analysis
19.4)
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20. Postoperative delirium-free protocol (DFP) versus
usual care
One small study Aizawa 2002 with 42 participants evaluated a
’delirium-free protocol’ which was comprised of overnight infu-
sions of diazepam, ﬂunitrazepam and pethidine to older postop-
erative surgical patients.
a. Primary outcome
DFP use was associated with a lower rate of incident delirium,
but the result was imprecise (RR 0.14, 95% CI 0.02 to 1.06; 40
participants; low-quality evidence downgraded due to risk of bias
and imprecision) (Analysis 20.1).
b. Secondary outcomes
There was no evidence of effect of theDFP on length of admission
(MD -4.30 days, 95% CI -12.51 to 3.91 days; 40 participants;
very low-quality evidence, downgraded due to risk of bias and
serious imprecision) (Analysis 20.2).
There was no evidence of effect of the DFP on the risk of be-
havioural disturbance (RR 0.20, 95% CI 0.03 to 1.56; 40 partic-
ipants; low-quality evidence, downgraded due to risk of bias and
imprecision) (Analysis 20.3).
c. Adverse outcomes
No data were reported for adverse outcomes.
21. Computerised clinical decision support system
(CCDSS) versus usual care
One study Boustani 2012 assessed the use of a computerised clini-
cal decision support system (CCDSS) on the management of 427
older adults with cognitive impairment compared to usual care.
a. Primary outcome
There was no evidence of the effect of CCDSS in reducing inci-
dent delirium (RR 1.08, 95% CI 0.82 to 1.43; 424 participants;
moderate-quality evidence due to risk of bias) (Analysis 21.1).
b. Secondary outcomes
There was no evidence of reduction in the length of admission
(MD 0.90 days, 95% CI -0.35 to 2.15 days; 424 participants;
low-quality evidence, downgraded due to serious imprecision) (
Analysis 21.2).
c. Adverse outcomes
There was no evidence of a change in rates of mortality within 30
days of discharge (RR1.04, 95%CI 0.49 to 2.23; 424 participants;
low-quality evidence downgraded due to serious imprecision) (
Analysis 21.3).
There was no evidence of effect on rates of falls (RR 0.93, 95%
CI 0.39 to 2.19; 424 participants) or pressure ulcers (RR 1.09,
95% CI 0.64 to 1.84; 424 participants) with use of the CCDSS
with moderate-quality evidence downgraded due to imprecision.
(Analysis 21.4; Analysis 21.5)
22. Geriatric unit care versus orthopaedic unit care
One trial of 329 older adults following hip fracture compared care
in a specialist geriatric unit and comprehensive geriatric assessment
to care in their orthopaedic unit (Watne 2014).
a. Primary outcome
There was no evidence that care in the geriatric unit reduced the
incidence of delirium compared to care in the orthopaedic unit
(RR 0.98, 95% CI 0.79 to 1.22; 329 participants; low-quality
evidence downgradeddue to risk of bias and imprecision) (Analysis
22.1).
b. Secondary outcomes
There was no evidence that care in the geriatric unit reduced the
duration (MD -1.00 days, 95% CI -2.04 to 0.04 days; 163 partic-
ipants) (Analysis 22.2) or severity of delirium episodes (MD 1.50
points, 95% CI -1.00 to 4.00 points; 163 participants) (Analysis
22.3) compared to the orthopaedic unit, low-quality evidence for
both outcomes, downgraded due to risk of bias and imprecision.
Care in the geriatric unit increased length of hospital admission by
a mean of three days (RR 3.00, 95% CI 1.94 to 4.06 days; mod-
erate-quality evidence downgraded due to risk of bias) compared
to the orthopaedic unit (Analysis 22.4).
Outcome assessments at four and 12 months were conducted
blinded to original allocation, unlike those conducted while in
hospital.
There was no evidence that care in the geriatric unit affected cog-
nitive function (using a composite score) at four months follow-
up (MD 1.80 points, 95% CI -5.92 to 9.52 points; 228 partici-
pants; low-quality evidence downgraded two levels due to serious
imprecision) (Analysis 22.5). Care in the geriatric unit appeared
to increase the rate of incident dementia at 12 months (RR 2.26,
95% CI 0.60 to 8.49; 193 participants) (Analysis 22.6), however,
the evidence was deemed to be of low quality and was downgraded
two levels due to serious imprecision.
There was no evidence that activities of daily living (measured by
Barthel Index (Mahoney 1965)) were affected by allocation to the
geriatric unit or the orthopaedic unit (MD 1.00, 95% CI -0.70 to
31Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.70; moderate-quality evidence downgraded due to imprecision)
(Analysis 22.7).
There was no evidence that care in the geriatric unit affected risk
of Institutionalisation at four (RR 1.06, 95% CI 0.58 to 1.91;
242 participants; moderate-quality evidence downgraded due to
imprecision) (Analysis 22.8) and 12 months (RR 0.86, 95% CI
0.47 to 1.59; 193 participants; moderate-quality evidence down-
graded due to imprecision) (Analysis 22.9).
c. Adverse outcomes
There was no evidence that care in the geriatric unit improved
the rate of in-hospital mortality (RR 0.56, 95% CI 0.21 to 1.47;
329 participants; moderate-quality evidence downgraded due to
imprecision) compared to the orthopaedic unit (Analysis 22.10).
Evaluating other adverse outcomes there was no evidence that care
in the geriatric unit reduced the rate of falls (RR 1.30, 95% CI
0.61 to 2.77; 329 participants) (Analysis 22.11); pressure ulcer
formation (RR 0.38, 95% CI 0.10 to 1.41; 329 participants) (
Analysis 22.12); other medical adverse events (RR 0.96, 95% CI
0.76 to 1.23; 329 participants) (Analysis 22.13); or postoperative
complications (RR 0.68, 95% CI 0.20 to 2.36; 329 participants)
(Analysis 22.14) with low-quality evidence for each comparison,
downgraded due to risk of bias and imprecision.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Prophylactic cholinesterase inhibitor versus placebo for preventing delirium in hospitalised non- ICU patients
Intervention: Prophylact ic cholinesterase inhibitor versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Prophylac-
tic cholinesterase in-
hibitors
Incidence of delirium
DSM-IV criteria, DSI,
CAM,
218 per 10001 148 per 1000
(37 to 572)
RR 0.68
(0.17 to 2.62)
113
(2 studies)
⊕©©©
very low2,3,4
Duration of delirium -
not measured
N/ A N/ A N/ A N/ A
Severity of delirium
MDAS
The mean severity of
delirium in the control
groups was
1.3 points
The mean severity of
delirium in the interven-
t ion groups was
0.30 points lower
(4.17 lower to 3.57
higher)
16
(1 study)
⊕⊕©©
low5
Length of admission
Days
The mean length of ad-
mission ranged across
control groups f rom
4-12.1 days
The mean length of ad-
mission in the interven-
t ion groups was
0.34 days shorter
(1.54 shorter to 0.86
longer)
128
(3 studies)
⊕⊕©©
low6,7
Return to independent
living - not measured
N/ A N/ A N/ A N/ A
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Inpatient mortality - not
measured
N/ A N/ A N/ A N/ A
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risk is the risk in the control group
2 Both studies are at high risk of attrit ion bias and have incomplete outcome data.
3 Downgraded because inconsistent results
4 Estimate of ef fect includes ’no benef it ’ and both appreciable benef it and appreciable harm.
5 Estimate of ef fect includes both ’no ef fect ’ and minimally important dif f erence, downgraded two levels due to serious
imprecision
6 Risk of bias unclear in all domains in one study (abstract only available). Remaining two studies have incomplete outcome
report ing and are at risk of attrit ion bias
7 Downgraded due to imprecision in result
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Prophylactic antipsychotic medications for preventing delirium in hospitalised non- ICU patients
Intervention: Prophylact ic ant ipsychot ic medicat ions versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Prophylactic antipsy-
chotic medications
Incidence of delirium
CAM/ NEECHAM
Follow-up range: 0-8
postoperat ive days
300 per 10001 165 per 1000
(69 to 390)
RR 0.55
(0.23 to 1.3)
916
(3 studies)
⊕©©©
very low2,3,4
Duration of delirium
Days
Follow-up: 3-8 postop-
erat ive days
The mean durat ion of
delirium in the control
groups ranged f rom
2.2 to 5.4 days
The mean durat ion of
delirium in the interven-
t ion groups was
2.74 days shorter
(9.59 shorter to 4.11
longer)
178
(2 studies)
⊕©©©
very low2,5
Severity of delirium
DRS. Scale f rom: 0 to
46.
Follow-up: 3-8 postop-
erat ive days
The mean severity of
delirium in the control
groups ranged f rom
14.4 to 16.4 points
The mean severity of
delirium in the interven-
t ion groups was
1.02 points lower
(6.8 lower to 4.76
higher)
178
(2 studies)
⊕©©©
very low2,5
Length of admission
Days
The mean length of ad-
mission in the control
group was
17.1 days
The mean length of ad-
mission in the interven-
t ion groups was
5.5 days shorter
(12.17 shorter to 1.17
longer)
68
(1 study)
⊕⊕©©
low5
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Return to independent
living - not measured
N/ A N/ A N/ A N/ A
Inpatient mortality - not
measured
N/ A N/ A N/ A N/ A
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risk is the risk in the control group
2Downgraded because inconsistent results
3 Downgraded because of imprecision in results
4 Downgraded due to risk of bias
5 Downgraded two levels because very imprecise results
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Prophylactic melatonin for preventing delirium in hospitalised non- ICU patients
Intervention: Prophylact ic melatonin versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Prophylactic melatonin
Incidence of delirium
CAM/ DSM IV/ DRS-R-9s
Follow-up: every 24 to
48 hours unt il dis-
charge or 8 days
242 per 10001 128 per 1000
(22 to 788)
RR 0.53
(0.09 to 3.25)
529
(3 studies)
⊕©©©
very low2,3,4
Duration of delirium
Days
Follow-up: every 24 to
48 hours unt il dis-
charge
The mean durat ion of
delirium in the control
group was
2 days
The mean durat ion of
delirium in the interven-
t ion groups was
0 days longer
(0.57 shorter to 0.57
longer)
104
(1 study)
⊕⊕⊕©
moderate3
Severity of delirium
(binary severe vs. not
severe)
Number of pat ients re-
quiring greater than
3mg of haloperidol
Follow-up: daily unt il
discharge
531 per 1000 457 per 1000
(308 to 674)
RR 0.86
(0.58 to 1.27)
104
(1 study)
⊕⊕⊕©
moderate3
3
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Severity of delirium
DRS-R-98 score
The mean severity of
delirium in the control
group was
6.3 points
The mean severity of
delirium in the inter-
vent ion group was 4.1
points lower
(19.47 points lower to
11.27 points higher)
6
(1 study)
⊕⊕©©
low5
Length of admission
Days
The mean length of ad-
mission in the control
groups ranged f rom
11 to 18.5 days
The mean length of ad-
mission in the interven-
t ion groups was
0.09 days longer
(1.2 shorter to 1.39
longer)
500
(2 studies)
⊕⊕⊕©
moderate3
Return to independent
living - not measured
N/ A N/ A N/ A N/ A
In-hospital mortality
Mortality
Follow-up: every 24 to
48 hours unt il dis-
charge or 8 days
47 per 10001 39 per 1000
(17 to 88)
RR 0.84
(0.37 to 1.88)
543
(3 studies)
⊕⊕©©
low6
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risk is the risk in the control group
2 Downgraded because inconsistent results
3 Downgraded because imprecise results
4 Downgraded due to risk of bias3
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5 Downgraded because imprecise results and very small number of events
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/ clinical judgement for preventing delirium in hospitalised non- ICU patients
Intervention: Bispectral index (BIS)-guided anaesthesia
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
BIS-blinded/ clinical
judgement
BIS-guided
Incidence of delirium
CAM, DSM-IV
Follow-up: daily af ter
surgery unt il discharge;
twice daily f rom post-
operat ive day 1 to 7
226 per 10001 160 per 1000
(135 to 192)
RR 0.71
(0.60 to 0.85)
2057
(2 studies)
⊕⊕⊕©
moderate2
Duration of delirium -
not measured
N/ A N/ A N/ A N/ A
Severity of delirium -
not measured
N/ A N/ A N/ A N/ A
Length of admission
Days
The mean length of ad-
mission in the control
groups ranged f rom
7 to 15.7 days
The mean length of ad-
mission in the interven-
t ion group was 0.94
days shorter (0.43 days
shorter to 1.45 days
shorter)
- 2057
(2 studies)
⊕⊕⊕©
moderate2
Return to independent
living - not measured
N/ A N/ A N/ A N/ A
In-hospital mortality -
not measured
N/ A N/ A N/ A N/ A
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The assumed risk is the risk in the control group (BIS-blinded/ clinical judgement)
2 Downgraded due to risk of bias
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D I S C U S S I O N
Summary of main results
Evidence for the effectiveness of most interventions for preventing
delirium remains uncertain, with the exception of multi-compo-
nent interventions.
Multi-component interventions
There is moderate-quality evidence from seven randomised con-
trolled trials that multi-component interventions reduce delirium
incidence, with an overall reduction in the risk of delirium by
about 30% compared with usual care. Moreover, they appear to
have similar effect sizes in medical and surgical study populations.
Despite the higher risk of delirium in patients with dementia,
only one trial reported data on the incidence of delirium in this
subgroup (for 50 participants); and in this study, dementia preva-
lence was unbalanced between intervention and control groups
(Marcantonio 2001). The effectiveness of these interventions in
patients with dementia remains uncertain.
Effects on delirium duration, length of hospital admission, insti-
tutionalisation and severity of delirium are also uncertain. There
is no clear evidence of effect on mortality (either inpatient, or at
12 months); 12-month mortality was only reported in one trial
(Lundstrom 2007). Clinically important differences are reported
for cognition (in one study; 60 participants, Bonaventura 2007)
and pressure ulcers (two studies; 457 participants, Hempenius
2013; Lundstrom 2007), all in a direction favouring multi-com-
ponent interventions, although there is uncertainty in these results
due to imprecision.
Pharmacological interventions
Cholinesterase inhibitors
We foundno clear evidence of beneﬁt for a cholinesterase inhibitor,
donepezil, in preventing delirium in an elective orthopaedic pop-
ulation without cognitive impairment. The available evidence was
judged to be very low-quality due to imprecision and considerable
inconsistency.
Antipsychotic medication
Overall, there is no clear evidence for effectiveness of antipsychotic
medications as a group in delirium prevention, although there is
uncertainty in this result because of imprecision and inconsistency.
The pre-planned subgroup analysis indicates that an atypical an-
tipsychotic drug (olanzapine) may reduce incidence of delirium,
with a potentially large effect size, but there is no clear evidence
supporting effectiveness of the typical antipsychotic, haloperidol.
However, it is possible that in one study of haloperidol, optimisa-
tion of non-pharmacological delirium prevention in both the in-
tervention and control arms precluded detection of any additional
beneﬁt from medication. In the other study, haloperidol was ad-
ministered on the ﬁrst postoperative day for three days and this
may have been too late for any preventive beneﬁts, although this
study was also at high risk of bias due its unblinded nature.
The impact on severity and duration of delirium also differed be-
tween two studies of haloperidol and olanzapine, but paradox-
ically, favoured the intervention group for haloperidol, and the
control group for olanzapine. There is no clear evidence for effect
of antipsychotic medication on length of hospital admission.
Melatonin
There is no clear evidence to support effectiveness of melatonin
or melatonin agonists in delirium prevention. However, there is
considerable heterogeneity in results, which may have been a re-
sult of differing study populations and different dosages. Al-Aama
2011 reported a clinically important effect size in reducing delir-
ium incidence inmedical inpatients using 0.5 mgmelatonin daily,
(low-quality evidence because of incomplete follow-up); whilst de
Jonghe 2014 reported no effect using melatonin 3 mg daily in hip
fracture patients undergoing acute surgery. Ramelteon, a mela-
tonin agonist, has previously been proposed as a safer treatment for
insomnia (Miyamoto 2009), but we found no evidence of beneﬁt
in delirium prevention in one trial.
Other pharmacological interventions
We found no evidence to support effectiveness of citicoline in
reducing delirium incidence.
Methylprednisolone had no effect on delirium incidence.
In one small trial of premedication using diazepam and diphen-
hydramine for elective inpatient cardiac catheterisation there were
no cases of delirium in either group; thus the evidence that choice
of premedication affects delirium incidence remains inconclusive.
Perioperative interventions
Opioid-sparing measures
The evidence about the effect of gabapentin, ketamine or intrathe-
cal and patient controlled analgesia (PCA) morphine for delirium
prevention is inconclusive.
There was evidence that intravenous (IV) parecoxib reduced the
incidence of delirium compared tomorphine and saline. However,
the evidence was of low quality, from a single study and affected
by potential confounding related to the administration of supple-
mentary morphine.
There is evidence that fascia iliaca compartment block (FICB)
to manage pain in hip fracture patients is effective in reducing
incidence of delirium. Lower-quality evidence also suggested that
it could reduce the severity and length of delirium episodes.
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Reducing/controlling the depth of anaesthesia
Reduction in depth of general anaesthesia or controlling the depth
is effective in preventing delirium. Both use of light propofol seda-
tion compared to deep, and Bispectral index (BIS)-guided anaes-
thesia compared to BIS-blinded anaesthesia/clinical judgement
were effective approaches.
Changing the mode of anaesthesia
There is no evidence of difference in effect on delirium incidence
of using propofol or xenon compared to sevoﬂurane anaesthesia.
Avoiding general anaesthesia
The evidence for effectiveness of epidural anaesthesia compared
to general anaesthesia in delirium prevention is uncertain.
Miscellaneous perioperative interventions
There was no evidence fromone study that liberal versus restrictive
blood transfusion was effective in preventing delirium.
One study of fast-track surgery in elderly cancer patients suggested
that it reduces the incidence of delirium and length of hospital
admission.
One study which used a ’delirium-free protocol’ for older adults
undergoing open laparotomy is likely to have resulted in sedation
of participants and failed to demonstrate any evidence of beneﬁt
on delirium incidence.
Computerised clinical decision support system (CCDSS)
One study using a computerised clinical decision support system
conducted in general and geriatric medical patients did not result
in improvement in delirium incidence.
Geriatric unit care versus orthopaedic unit
There was no evidence that care in the geriatric medicine unit re-
duced the incidence duration or severity of delirium or other cog-
nitive and functional outcomes. However, geriatric unit care in-
creased length of hospital stay compared to care in the orthopaedic
unit.
Overall completeness and applicability of
evidence
Although 39 trials were identiﬁed for inclusion in this review, the
body of evidence for delirium prevention in hospitalised non-ICU
patients remains limited, except for multi-component interven-
tions (seven trials). Most other interventions were only investi-
gated in one or two small trials, with considerable heterogeneity
in the interventions, outcomes, populations and settings studied,
precluding meta-analyses. Only one study (of a multi-component
intervention in surgical patients) presented results for people with
dementia, an important subgroup to study in delirium prevention.
The effectiveness of delirium interventions might be expected to
differ given the higher prevalence of delirium and poorer outcomes
in dementia.
For multi-component interventions, it is likely that the included
trials and meta-analyses were underpowered to detect mortality
and institutionalisation (both relatively rare outcomes), and this
may explain the lack of observed impact on these endpoints, de-
spite the reduction in incident delirium.
Although there was evidence suggesting FICB, controlling depth
of anaesthesia and fast-track surgery could reduce postoperative
delirium incidence, it is important to note that in clinical prac-
tice, there will be a range of considerations apart from effective-
ness in delirium prevention (including co-morbidities, falls risk,
and rehabilitation requirements) guiding choice of approaches to
surgery and anaesthesia. Recommendations regarding surgery and
anaesthetic practice cannot, therefore, be made based on the evi-
dence from this review alone.
Most studies included delirium incidence as an outcome, and both
cognition and length of hospital admission were also frequently
reported. However, other important outcomes including delirium
duration and severity, mortality, institutionalisation, activities of
daily living (ADL) performance, and adverse outcomes were not
commonly reported. No studies investigated the impact on qual-
ity of life, carers’ psychological morbidity, staff psychological mor-
bidity, or costs. Future studies need to address these gaps in the
interventions, settings and outcomes studied.
Failure to exclude prevalent delirium at enrolment was a common
limitation of themajority of included studies (29/39). This has the
potential to reduce precision in the results as interventions cannot
prevent cases of delirium already present in recruited participants.
Quality of the evidence
We used GRADEpro software (GRADEpro 2014) to inform the
generation of evidence quality statements for ﬁve comparisons: i)
multi-component interventions versus usual care; ii) cholinesterase
inhibitors versus placebo; iii) antipsychotic medication versus
placebo; iv) melatonin versus placebo and v) BIS-guided versus
BIS-blinded anaesthesia/clinical judgement. Full tabulations for
each outcome are available in: Summary of ﬁndings for the main
comparison, Summary of ﬁndings 2, Summary of ﬁndings 3,
Summary of ﬁndings 4 and Summary of ﬁndings 5.
On the basis of seven randomised controlled trials (RCTs) (four
in medical patients and three in surgical patients) n = 1950 par-
ticipants, there is moderate-quality evidence that multi-compo-
nent delirium prevention interventions can reduce rates of inci-
dent delirium; this is consistent across the included trials. Evidence
has been downgraded due to the possibility of performance bias
(the nature of the intervention precludes blinding of participants
and those delivering intervention). Outcome assessors were un-
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blinded to the intervention in two studies, including the study
with the largest weighting and highest event rate. Furthermore,
there is a risk of other bias in two of the included studies due to an
imbalance between the intervention and control groups in respect
to the prevalence of pre-existing dementia.
Heterogeneity in the multi-component interventions studied
makes it difﬁcult to ascertain whether speciﬁc components of the
interventions are particularly effective in the prevention of delir-
ium.
There is moderate-quality evidence that multi-component inter-
ventions have no effect on length of hospital stay (six studies, n
= 1920 participants) and moderate-quality evidence of no effect
on the likelihood of return to independent living (four studies, n
= 1116). There is considerable uncertainty regarding the effect of
multi-component interventions on the duration of delirium due
to unblinded outcome assessment in two studies, imbalance in the
prevalence of dementia in two studies and imprecise results.
On the basis of two RCTs (n = 113 participants), there is consider-
able uncertainty regarding the effect of prophylactic cholinesterase
inhibitors on reducing delirium incidence due to very low-quality
evidence. Both of these studies have missing outcome data; evi-
dence was downgraded due to imprecision and inconsistency in
the results. There is low-quality evidence for the effect of prophy-
lactic cholinesterase inhibitors on the outcome of delirium sever-
ity (one study; n = 16 participants) and length of admission (two
studies; n = 128 participants). Evidence was downgraded due to
serious imprecision of the delirium severity results and for impre-
cision and risk of bias in length of admission.
On the basis of three RCTs (n = 916 participants), there is con-
siderable uncertainty regarding the effect of antipsychotic medi-
cations on the incidence of delirium due to low-quality evidence
that has been downgraded because of risk of bias, inconsistency
and imprecise results. There is very low-quality evidence on the
effect of antipsychotic medications on the severity (two studies,
n = 178 participants) and duration of delirium (two studies, n
= 178 participants), and low-quality evidence on length of stay
because of inconsistent and very imprecise results (one study, n =
68 participants).
On the basis of three RCTs (n = 529 participants), there is consid-
erable uncertainty regarding the effect of prophylactic melatonin/
melatonin agonists on the incidence of delirium due to very low-
quality evidence that has been downgraded because of risk of bias,
imprecise and inconsistent results. There is moderate-quality ev-
idence that melatonin does not affect the duration of delirium,
downgraded as the results are from a single study (n = 104). There
is uncertainty regarding the effect ofmelatonin on severity of delir-
ium due to moderate-quality evidence from one study using a
binary outcome (n = 104) and low-quality evidence from a sec-
ond study downgraded due to serious imprecision (n = 6). There
is moderate-quality evidence that melatonin does not reduce the
length of stay (two studies; 500 participants); results were down-
graded for inconsistency. There is uncertainty regarding the effect
of melatonin on in-hospital mortality due to low-quality evidence
from three studies that was downgraded because of imprecise re-
sults and a very small number of events (n = 543 participants).
On the basis of two RCTs (n = 2057 participants), there is mod-
erate-quality evidence that BIS-guided anaesthesia reduces the in-
cidence of delirium compared to BIS-blinded anaesthesia/clinical
judgement. The evidence was downgraded due to the risk of bias
associated with participants and personnel being unblinded and
incomplete outcome assessment. There was also an unclear risk of
selection bias in Radtke 2013. There is also moderate-quality ev-
idence that BIS-guided anaesthesia resulted in a shorter length of
hospital admission compared to BIS-blinded anaesthesia/clinical
judgement (two studies, n = 2057 participants), also downgraded
due to risk of bias.
Potential biases in the review process
This reviewhas followedCochrane procedures and there were only
a small number of amendments to the review process, which are
outlined in Differences between protocol and review.
Agreements and disagreements with other
studies or reviews
The previous version of this review (Siddiqi 2007) only included
six studies, none of which assessed the same intervention. The
review highlighted the potential role for multi-component inter-
vention (a Geriatric Consultation Service) and the use of atypical
antipsychotic medication, but identiﬁed the need for a larger body
of evidence before drawing conclusions or practice recommenda-
tions. The evidence base for multi-component interventions for
the prevention of incident delirium in hospitalised non-ICU pa-
tients has expanded considerably since the previous version, and
the evidence summarised in this update supports the use of multi-
component interventions. However, we found a continuing lack
of evidence to support the use of antipsychotic medication as a
group in the prevention of delirium.
Our principal review ﬁnding of the positive role of multi-compo-
nent interventions to prevent delirium is consistent with the wider
published literature (Abraha 2015). The multi-component inter-
vention programme known as the Hospital Elder Life Program
(HELP) for Prevention of Delirium has demonstrated effective
reductions in the incidence of delirium in non-randomised trials
(Inouye 1999a; Inouye 2000). Hshieh 2015 published a meta-
analysis of intervention studies using multi-component non-phar-
macological interventions and, although identifying similar issues
with heterogeneity limiting reporting, found evidence to support
reductions in delirium incidence and falls. Two recent system-
atic reviews have reached similar conclusions to those of this re-
view. Martinez 2015 identiﬁed that multi-component interven-
tions were effective in reducing incident delirium and accidental
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falls for hospitalised adults. Zhang 2013 speciﬁcally reviewed the
role of interventions to prevent postoperative delirium and identi-
ﬁed thatmulti-component interventions were beneﬁcial, although
the review also identiﬁed positive beneﬁts from sedation and an-
tipsychotic medications not replicated by our ﬁndings.
Multi-component interventions for delirium prevention are now
also recognised and recommended in practice guidelines. The UK
National Institute for Health and Care Excellence (NICE) guide-
lines for delirium were published in 2010 (NICE 2010). These
identiﬁed multi-component interventions as having a critical role
in identifying and addressing modiﬁable, clinical risk factors for
delirium prevention. Multi-component assessment and interven-
tion is recommended within 24 hours of admission for those at
risk; the intervention should be personalised to the needs of the in-
dividual and delivered by a multidisciplinary team (NICE 2010).
Cost savings are identiﬁed to be anticipated, although we found
no data on this in our review.
The lack of impact of multi-component interventions on mor-
tality and institutionalisation, despite a reduction in delirium is
a surprising ﬁnding. Falls and institutionalisation are thought to
be associated with frailty and may represent complications of the
frailty syndrome (Clegg 2013; Eeles 2012; Fried 2001). Death and
institutionalisation as endpoints may, therefore, represent non-
modiﬁable manifestations of frailty, and be relatively insensitive
to a reduction in incident delirium, although a recent study has
questioned the association of delirium with frailty (Joosten 2014).
Reporting baseline frailty in future trials (measured with a vali-
dated frailty assessment instrument) would help to clarify this re-
lationship.
Our ﬁndings for cholinesterase inhibitors are consistent with pre-
vious related studies. A large trial of another cholinesterase in-
hibitor, rivastigmine, for treatment of delirium in intensive care
patients was halted in 2010 following safety concerns and no evi-
dence of effectiveness (Sheldon 2010; van Eijk 2010).
Findings for antipsychotics are also consistent with a recent pub-
lished review (Fok 2015).
The heterogeneity of our results for melatonin has also been re-
ported by Chen and colleagues (Chen 2015). They conducted a
subgroup analysis, and concluded that melatonin was effective in
preventing delirium in medical, but not surgical patients.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence base for multi-component interventions to prevent
delirium in patients admitted to medical and surgical wards is
strong and supports the adoption of systems of care that incorpo-
rate multi-component interventions to prevent delirium in hospi-
tals as part of routine care.
Implications for research
Further “proof of concept” randomised controlled trials investi-
gating the effectiveness of multi-component interventions to pre-
vent delirium in hospitalised non-ICU patients are unwarranted
(and unethical, as an effective treatment is denied to the control
group). The focus of future research should be trials of implemen-
tation and to identify the key ’active’ components to improve our
understanding of the determinants for successful and efﬁcient de-
ployment of multi-component interventions. Such trials should
consider cluster randomisation (to minimise performance bias);
incorporate more discriminatory baseline descriptors (to better ac-
count for delirium, frailty, and dementia interactions); and have at
least a medium-term follow-up period (to assess the personal and
system-level impact of delirium prevention). Preliminary evidence
for the content of multi-component interventions suggests that
they should include as a minimum: staff education; individualised
care (sometimes referred to as person-centred care); re-orientation
at frequent intervals; and early mobilisation, but this needs fur-
ther investigation. These areas are familiar aspects of care but are
currently poorly and unreliably delivered.
Monitoring the depth of anaesthesia through awareness of the Bis-
pectral index (BIS) and the ability to control the level of anaesthe-
sia reduced the incidence of postoperative delirium. However, the
optimal level for depth of anaesthesia has not been established in
the included studies and this remains an area for further research.
The role of drugs and other anaesthetic techniques (to reduce post-
operative delirium) in the prevention of delirium remains uncer-
tain with negative or conﬂicting ﬁndings. New research is justiﬁed,
particularly regarding the role of typical and atypical antipsychotics
and melatonin (including different settings, variations in physio-
logical melatonin levels and different doses), but should account
for developments in the understanding of the neuropathophysi-
ology of delirium. In the case of atypical antipsychotics, the asso-
ciation between antipsychotics and increased mortality amongst
older people with cognitive impairment may limit their usefulness
as a prophylactic measure in this population (Huybrechts 2012).
Furthermore, given the current evidence base supporting the use
of multi-component interventions, future trials of pharmacolog-
ical agents for delirium prevention should optimise multi-com-
ponent non-pharmacological delirium prevention in intervention
and control arms to look for any additional beneﬁt obtained from
medication. The evidence does not support cholinesterase in-
hibitors for delirium prevention as a priority for further investiga-
tion.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abizanda 2011
Methods Design: Randomised controlled trial of a short-term occupational therapy intervention
in an acute geriatric unit
Date of study: November 2002 to June 2003
Power calculation: Yes
Frequency of outcomes assessment: Daily during hospitalisation
Inclusion criteria: All patients aged 65 and over consecutively admitted to the acute
geriatric unit with an acute medical illness or exacerbation of existing chronic condition
Exclusion criteria: None reported
Participants Number in study: 400
Country: Spain
Setting: One acute geriatric unit
Age: Mean age 83.7 years (SD 6.1) in intervention group, 83.3 years (SD 6.5) in control
group
Sex: 43.4% male in intervention group, 43.1% male in control group
Co-morbidity: Number of previous chronic conditions 3.8 in intervention group, 3.5
in control group
Dementia: 35.3% in intervention group, 31.4% in control group
Interventions Intervention: Occupational therapy intervention (OTI) schedule consisted of a daily 45-
minute session with patient and relative/caregiver Monday-Friday for the duration of
admission. Activities were carried out according to needs and day of admission. Ther-
apeutic plan included: cognitive stimulation; instruction on preventing complications
including immobility, confusion, falls, urinary incontinence, pressure sores; retraining
in ADL; assessment of technical aids for home
Control: All participants received medical treatment, nursing care, physical therapy and
social assistance
Outcomes 1. Incident delirium, measured using CAM
2. Length of admission
3. Activities of daily living (ADL), measured using Barthel index
4. In-hospital mortality
5. Adverse events
Notes Funding source: Institute of Health Sciences, Junta de Comunidades de Castilla-La
Mancha
Declarations of interest: “All authors declare that there is not any personal, ﬁnancial or
potential conﬂict of interest, and therefore have nothing to declare.”
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
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Abizanda 2011 (Continued)
Allocation concealment (selection bias) Low risk Assignment to randomised group by a geri-
atrician who did not participate in the clin-
ical management of participants
Random sequence generation (selection
bias)
Low risk Computerised randomisation system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The geriatricians caring for the patients and
providing their routine care were blinded
to allocated group. Participants were not
blinded due to the nature of the interven-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor and the individual per-
forming data analysis were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number withmissing data are balanced be-
tween groups and there do not appear to
be any systematic differences between the
groups
Selective reporting (reporting bias) Low risk No changes were made to trial outcomes
after the trial was initiated
Other bias Low risk No evidence of other bias
Aizawa 2002
Methods Design: Randomised controlled trial of a delirium-free protocol administered postoper-
atively in a general and colorectal surgery unit
Date of study: November 1996 to March 1999
Power calculation: No
Frequency of outcomes assessment: Twice daily screening interview after surgery for 7
consecutive days
Inclusion criteria: Consecutive patients over 70 and under 86 years who underwent re-
section of gastric or colorectal cancer under general anaesthesia in one hospital depart-
ment
Exclusion criteria: Liver cirrhosis or dysfunction; renal dysfunction; respiratory distur-
bance; other poor risk factors; mental disorder; visual impairment; extended resection
of other organs or emergency surgery
Participants Number in study: n = 42 randomised, outcomes reported for n = 40
Country: Japan
Setting: General surgery inpatients
Age: Mean age 75.9 (SD 4.5) for intervention group; mean age 76.2 (SD 4.1) for control
group
Sex: 26 males and 14 females (15/20 males in intervention and 11/20 in control group)
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Aizawa 2002 (Continued)
Co-morbidity: Not reported
Ilness severity: APACHE score 8.3 (SD 1.4) for intervention and 7.6 (SD 1.7) in control
group
Dementia: Not known
Interventions Intervention: Delirium-free protocol (DFP): Post surgery, Diazepam 0.1 mg/kg IM at
20.00, Flunitrazepam 0.04 mg/kg IV and Pethidine 1 mg/kg IV infusions 20.00-04.00
for 3 nights
Control: Treatment as usual. No placebo
Outcomes 1. Incident delirium in 7 postoperative days by psychiatrist using DSM-IV criteria
2. Behavioural disturbance in 7 postoperative days
3. Length of admission
Notes Funding source: Not reported
Declarations of interest: Not reported
Delirium not excluded at enrolment
Intervention used likely to sedate and therefore interfere with assessments for delirium
Very speciﬁc patient group
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Randomisation method unclear thus allo-
cation is unclear
Random sequence generation (selection
bias)
Unclear risk Stated random assignment but method not
described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk All participants and personnel unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment made by psychiatrist
unaware of original allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Two dropouts but not clear from which
group and no data presented for these
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias High risk The issue of how delirium was assessed in
patients who might be sedated by the DFP
is not addressed
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Al-Aama 2011
Methods Design: Randomised controlled trial of melatonin for 14 days or until discharge in a
medical unit in a tertiary care hospital
Date of study: October 2007 to February 2008
Power calculation: No
Frequency of outcomes assessment: Every 24 to 48 hours during admission
Inclusion criteria: admissions of 65 years and older to through the emergency department
to Internal Medicine inpatient services
Exclusion criteria: Expected stay or life expectancy <48 hours; unable to communicate
in English; unable to take oral medications; had an intracranial bleed or seizures; INR
<1 or >4 while on warfarin; known allergy to the study compounds
Participants Number in study: 145
Country: Canada
Setting: Internal Medicine inpatient services in a tertiary care hospital
Age mean (SD): Intervention: 84.3 (5.9), Control 84.6 (6.2); P = 0.8
Sex: Male Intervention 46%, Control 39%; P= 0.58
Co-morbidity: mean number(SD) Intervention 5.3 (2.3), 5.2 (1.9); P = 0.48
Dementia: Intervention 18%, Control 23%; P = 1.0
Interventions Intervention: Melatonin tablets half of 1 mg, rapid dissolving, daily for 14 days or until
discharge
Control: Lactose tablets 100 mg halved, similar in appearance
Outcomes 1. Incident delirium measured using CAM
2. Delirium severity, measured using MDAS but included prevalent cases
3. Length of admission
4. Use of psychotropic medication
5. Withdrawal from protocol
6. Mortality
Notes Funding source: Divison of Geriatric Medicine, University of Western Ontario
Declarations of interest: “None of the authors or study teammembers has had any conﬂict
of interest or any afﬁliation or relation with any melatonin producing organization”
Delirium not excluded at enrolment, but data available for prevalent delirium
Four participants not randomised- unclear why
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Pharmacy kept randomisation code
Random sequence generation (selection
bias)
Low risk Patients were assigned using computer-
generated blocked-randomisation (block
size: 4)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and clinicians blinded. In case
of emergency, an independent physician
could request unmasking of the treatment
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Al-Aama 2011 (Continued)
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All the assessments were carried out by re-
search assistants and clinicians blinded to
group assignment. The investigators did
not become aware of treatment allocation
until several months after study completion
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals and missing data for 11 in
intervention group, 12 in control group.
Reasons for missing data not separated by
group, therefore difﬁcult to tell whether
reasons could be due to side effect of study
medication, or more delirium episodes in
one group
The results are presented as available case
analysis rather than intention-to-treat. The
authors present a sensitivity analysis to con-
sider worst case ﬁgures for delirium inci-
dence that all those missing from the inter-
vention group have delirium and that none
of those in the control group had delirium
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
Ashraf 2015
Methods Design: Randomised controlled trial of oral premedication with diazepam and diphen-
hydramine versus no premedication in older people undergoing cardiac catheterisation
Date of study: Not reported
Power calculation: Yes
Frequency of outcomes assessment: 4 hours post-procedure and 1-day post-procedure
for inpatients
Inclusion criteria: Aged > 70 years; elective cardiac catheterisation
Exclusion criteria: MMSE <20; pre-existing delirium on CAM; allergy to diphenhy-
dramine, diazepam or midazolam
Participants Number in study: 93 (53% inpatients; demographic data for entire sample)
Country: USA
Setting: Cardiac catheterisation facility within a single site medical centre
Age: Mean age 78 years (SD 4.8) in intervention group; 77 years (SD 3.5) in control
group
Sex: Males 25 (53%) in intervention; 28 (61%) in control
Co-morbidity: Data reported on rates of hypertension, diabetes, hyperlipidaemia, coro-
nary artery disease, anxiety, depression, delirium, COPD and atrial ﬁbrillation. Imbal-
ance on CAD 34% vs 52% and depression 13% vs 4%
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Ashraf 2015 (Continued)
Dementia: Baseline MMSE comparable between groups. Excluded if MMSE < 20
Interventions Intervention: Oral premedication with diazepam 5 mg and diphenhydramine 25 mg
Control: No premedication prior to procedure
Outcomes 1. Incident delirium using CAM
2. Cognitive function using MMSE (data not fully reported in paper)
3. Length of stay (data not fully reported in paper)
Notes Funding source: Not reported
Declaration of interest: Not reported
Delirium excluded at enrolment.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Method not described
Random sequence generation (selection
bias)
Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo given to the control group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk States ‘the catheterization laboratory staff
and nursing staff that took care of patients
after the procedure and majority of the op-
erators were unaware of the randomisation’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete reporting of all included partic-
ipants
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
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Beaussier 2006
Methods Design: Randomised controlled trial of intrathecal morphine versus patient-controlled
intravenous morphine for postoperative analgesia and recovery after major colorectal
surgery
Date of study: July 2001 to December 2003
Power calculation: Yes
Frequency of outcomes assessment: Not reported
Inclusion criteria: Cancer of left colon or rectum with surgical indication for resection
in patients over 70 years with normal preoperative functional status
Exclusion criteria: ASA III/IV, BMI > 30, IBD, contraindications to intrathecal mor-
phine, preoperative mental dysfunction, chronic pain, preoperative opioid consumption,
psychiatric disorders, inability to use PCA
Participants Number in study: 59
Country: France
Setting: One surgical department
Age: Mean age 78 years (SD 5 years) in intervention group, 77 years (SD 5 years) in
control group
Sex: 58% male in intervention group, 46% male in control group
Co-morbidity: Not reported
Dementia: Mean preoperative MMSE 27 (SD 2) in intervention group, 28 (SD 2) in
control group
Interventions Intervention: Preoperatively, a dose of 300 mcg of morphine was injected via the L4/L5
interspace. Postoperatively, patients had IV PCA
Control: Preoperatively, a 3 mL dose of saline was injected into the subcutaneous space
between L4/L5. Postoperatively, patients had PCA
Postoperative management was identical for all patients.
Outcomes 1. Incident delirium, measured using CAM
2. Cognitive status, deﬁned as number of days forMMSE to return to preoperative value
3. Length of admission
4. Mortality
5. Withdrawal from protocol
Notes Funding Source: Institutional grant from the Assistance Publique-Hopitaux de Paris
Declarations of interest: Not reported
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A physician independent from the study
group opened a sealed letter that assigned
the group of allocation according to the
rank of inclusion
Random sequence generation (selection
bias)
Low risk Computer-generated random number list
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Beaussier 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded as already under gen-
eral anaesthesia. Personnel providing care
for the patient blinded to their assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind RCT but no statement of
outcome assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/59 patients not included in ﬁnal analysis
although reasons for exclusion reported
Selective reporting (reporting bias) High risk Reported outcomes which were not pre-
speciﬁed in the methods
Other bias Low risk No evidence of other bias
Berggren 1987
Methods Design: Randomised trial of epidural and general anaesthesia in patients operated on for
fracture neck of femur
Date of study: March 1983 to November 1984
Power calculation: No
Frequency of outcomes assessment: First and seventh day postoperatively
Inclusion criteria: All fully lucid, consenting patients admitted to an orthopaedic unit
for fracture neck of femur
Exclusion criteria: Score more than 6/36 on 12 item disorientation sub-scale of Organic
Brain Syndrome (OBS) assessed within 3 hours of admission
Participants Number in study: 57
Country: Sweden
Setting: Orthopaedic ward of one university hospital
Age mean years (SD): Epidural 78(8), General 77(7)
Sex M:F: Epidural 4/24, General 7/22
Co-morbidity: No signiﬁcant differences between groups (Chi2 test) for ischaemic heart
disease, hypertension, diabetes mellitus, cerebrovascular disease, respiratory disease, de-
pression, parkinsonism or sensory impairment
Dementia: Not mentioned speciﬁcally but would in effect be excluded by exclusion
criteria
Interventions Intervention: Epidural anaesthesia
Comparison: Halothane anaesthesia
Outcomes 1. Incident delirium measured using a modiﬁed version of the Organic Brain Syndrome
Scale on postoperative days 1 and 7
2. Length of admission (data not fully reported)
3. Physical morbidity (stroke, urinary tract infection)
4. Psychological morbidity (depression)
5. Pressure ulcers
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Berggren 1987 (Continued)
Notes Funding source: Swedish Medical Council; King Gustav V Birthday Foundation; Umea
University Research Foundation
Declarations of interest: Not reported
Delirium not excluded at enrolment
No data presented for length of admission but reported as no difference between the two
groups
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Allocation concealment method not de-
scribed
Random sequence generation (selection
bias)
Unclear risk Method for random sequence generation
not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors did not know allocation of par-
ticipants at time of testing for delirium
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in outcome re-
porting
Selective reporting (reporting bias) High risk Reported outcomes which were not pre-
speciﬁed in the methods
Other bias Low risk No evidence of other bias
Bonaventura 2007
Methods Design: Randomised controlled trial of a multi-component intervention, the Interven-
tion to Prevent Delirium (IPD) in older patients admitted to medical and geriatric wards
Date of study: 2005 to 2006
Power calculation: No
Frequency of outcomes assessment: Days 1, 2, 4 and 7 of admission
Inclusion criteria: Age > or = to 65 years admitted to medical and geriatric wards in one
hospital
Exclusion criteria: MMSE score < or =25, at least 1 relative not present, transfer out of
ward, pre-existing dementia, blindness, deafness, aphasia or unable to understand Italian
Participants Number in study: 60
Country: Italy
Setting: Medical and geriatric wards
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Bonaventura 2007 (Continued)
Age: Not given
Sex M:F: Intervention 12/18, Control 12/18
Co-morbidity: comparable P = 0.77
Dementia: Excluded
Interventions Intervention: Intervention to Prevent Delirium (IPD), a series of structured and stan-
dardised welfare actions based on existing guidelines, including support in the following
areas: cognitive re-orientation, sensory and environmental, mobilisation, hydration, and
’socio-emotional’
Control: Usual care, not described further
Outcomes 1. Incident delirium measured using CAM & DRS-R-98 on days 1, 2, 4, 7 of hospital
stay
2. Cogntive status using MMSE
3. Functional performance using Barthel Index
Notes Funding source: Not reported
Declarations of interest: Not reported
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Odd and even days of admission used so
concealment unlikely
Random sequence generation (selection
bias)
High risk Sequence generated using day of admission
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants andpersonnel not blinded, not
possible given nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessment blinding not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in the
analysis
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
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Boustani 2012
Methods Design: Randomised controlled trial of a clinical decision support system to improve the
care of hospitalised older adults with cognitive impairment
Date of study: July 2006 to March 2008
Power calculation: No
Frequency of outcomes assessment: Every weekday during hospital admission
Inclusion criteria: At least 65 years of age, hospitalised on a medical ward, English-
speaking, and cognitive impairment at the time of hospital admission.
Exclusion criteria: Patients were excluded if they had previously been enrolled in the
study, were aphasic, or unresponsive at the time of screening
Participants Number in study: 427
Country: USA
Setting: Medical wards of Wishard Memorial University Hospital
Age: Mean age 76.8 years (SD 7.9 years) in intervention group, 77.6 years (SD 8.3 years)
in control group
Sex: 39.7% male in intervention group, 28.9% male in control group
Co-morbidity: Mean Charlson comorbidity index 1.8 (SD 1.8) in intervention group,
2.4 (SD 2.1) in control group
Dementia: Not reported
Interventions Intervention: Electronically delivered clinical decision support system (CDSS)
(1) Each time a physician enters an order for a patient randomised to the intervention
arm, the physician received non-interruptive alerts of the presence of CI, Foley catheter,
physical restraints, anticholinergic drugs, or the need for ACE services;
(2) If the physician orders a urinary catheter, s/he will receive interruptive alerts to
recommending discontinuing the catheter;
(3) If the physician orders physical restraints, s/he will receive interruptive alerts recom-
mending substituting physical restraints with the use of a professional sitter or low dose
trazodone;
(4) If the physician orders any of the 18 inappropriate anticholinergics, s/he will receive
interruptive alerts recommending stopping the drug, suggesting an alternative, or rec-
ommending dose modiﬁcation
(5) The physician was required to make a decision to accept, reject, or modify any of the
interruptive alerts
Control: Patients randomised into usual care did not receive CDSS
Outcomes 1. Incident delirium, measured using CAM
2. Mortality
3. Length of hospital stay
4. Falls
5. Pressure ulcers
Notes Funding source: NIA Paul B. Beeson K23 Career Development Award
Declarations of interest: “Dr Boustani has work supported by grants from the NIA and
AHRQ. He is also a member of the Pﬁzer speakers’ bureau. Dr Buckley has provided
expert testimony for local law ﬁrms. Mr Perkins owns stock in several pharmaceutical
ﬁrms”
Delirium assessed but not excluded at enrolment
Risk of bias
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Boustani 2012 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Central process following computer gener-
ation
Random sequence generation (selection
bias)
Low risk A computer-generated process was em-
ployed for sequence generation in a 1:1 ra-
tio
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind personnel treating the
patients in the CDSS group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of research assistants conducting
outcome assessments not known
Incomplete outcome data (attrition bias)
All outcomes
Low risk 427 enrolled into trial, outcome data avail-
able for 424with no account given formiss-
ing participants or which group they were
assigned to. However, small as proportion
of total sample
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
Chan 2013
Methods Design: Prospective randomised double-blinded parallel group study assessing BIS-
guided anaesthesia in elective surgical patients
Date of study: January 2007-December 2009
Power calculation: Not for delirium as delirium was a secondary outcome. Study under-
powered given delirium rate of 20%
Frequency of outcomes assessment: mornings after surgery, 1 week, 3 months
Inclusion criteria: > 60yrs old; scheduled for elective major surgery anticipated to last >
2 hours or longer which has an anticipated hospital stay of at least 4 days
Exclusion criteria: unavailable/unable to co-operate with interviews; illiteracy; hearing/
visual impairment; major psychosis; CNS diseases; suspected dementia/MMSE 23 or
less
Participants Number in study: 921
Country: Hong-Kong
Setting: General hospital
Age: Mean age of 68.1 (SD 8.2) in intervention group 67.6 (SD 8.3) in control group
Sex: 62.2% of intervention group and 60.4% of control group were male
Co-morbidity: no signiﬁcant differences in pre-existing medical conditions (cardiovas-
cular, respiratory, endocrine or other) between intervention and control groups
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Chan 2013 (Continued)
Dementia: Excluded is MMSE 23 or less
Interventions Intervention: BIS-guided anaesthesia - anaesthetic dosage adjusted tomaintain BIS value
between 40-60 from commencement of anaesthesia to the end of surgery; alarm sounded
when out of range
Control: Routine care, anaesthetic drug administration was titrated according to clinical
judgment. BIS monitoring was continued in this group, but the BIS number, its trend,
and the EEG waveform were omitted from the display, speciﬁcally designed for this trial
Outcomes 1. Incident delirium, measured using CAM
2. Length of admission
3. Cognitive status (postoperative cognitive dysfunction) at 1 week and 3 months
4. Mortality at 1 week and 3 months
5. Postoperative complications
6. Psychological morbidity, measured using Short-Form-36 Mental Score
Notes Funding source: ResearchGrants Council of Hong Kong andHealth andHealth Services
Research Fund
Declarations of interest: “The authors have no conﬂicts of interest to disclose”
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk No evidence that allocations know
Random sequence generation (selection
bias)
Low risk Computer-generated random assignment
accessed via intranet
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients, surgeons and all research staff were
blinded but, concern re: anaesthetists and
theatre team in view of alarm system for
intervention group only
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome data available for n = 783 at one
week and n = 835 at 3 months but n = 921
were randomised. Reasons for exclusion re-
ported: n = 80 were excluded in the inter-
vention group and n = 58 in the control
group at one week; n = 32 were excluded
in the intervention group and n = 25 in the
control group at three months
In n = 97 cases participants were not as-
sessed at one week due to being ’unﬁt
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Chan 2013 (Continued)
for testing’, compared with n = 5 at three
months
Selective reporting (reporting bias) Unclear risk Limited protocol available on Centre for
Clinical Trials online registry
Other bias Low risk No evidence of other bias
de Jonghe 2014
Methods Design: Multi-centre randomised controlled trial
Date of study: November 2008-May 2012
Power calculation: performed, study adequately powered
Frequency of outcomes assessment: Daily following inclusion until discharge; 3-month
follow-up
Inclusion criteria: Patients 65 years and older admitted for surgical treatment of hip
fractures; enrolment within 24 hours of admission; individual willing to participate;
medically able to receive study medication according to the protocol for the duration of
the study
Exclusion criteria: Delirium at enrolment; patients transferred from another hospital; if
postoperative admission to the ICU or coronary care unit was anticipated; inability to
speak or understand Dutch; concomitant use of melatonin
Participants Number in study: 452
Country: The Netherlands
Setting: Teaching hospitals
Age: Mean age 84.1 (SD 8.0) in intervention group, 83.4 (SD 7.5) in control group
Sex: 53 (28.5%) male in intervention group, 62 (32.3%) of control group
Co-morbidity: Median Charlson Index 1.0 (IQR: 0.8-2.0) in intervention group, 1.0
(IQR: 1.0-2.0) in control group
Dementia: Median MMSE 23 (IQR: 12-28.8) in intervention group with 104 (55.9%)
described as having cognitive impairment.MedianMMSE23 (IQR: 9.5-28.0) in control
group with 106 (55.2%) described as having cognitive impairment
Interventions Intervention: 3 mg of melatonin
Control: Placebo
Outcomes 1. Incident delirium during the ﬁrst eight days after initiation of the study medication
using DSM-IV and DOSS
2. Duration of delirium
3. ’Severe’ delirium (deﬁned as percentage of patients who received a total of ≥3mg
haloperidol)
4. Length of admission
5. Use of psychotropic medications (reported as total dose rather than frequency of
administration)
6. Cognitive outcomes at 3 months, using Charlson Index, IQCODE and MMSE
7. Functional outcomes at 3 months, using Katz ADL Index
8. In-hospital mortality
9. Mortality at 3 months
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Notes Funding source:DutchNational Programof Innovative Care for vulnerable older persons
(a program operated by ZonMw, a Dutch institute that funds health research)
Declarations of interest: None declared
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation blinded, randomisation list
maintained by the trial pharmacist
Random sequence generation (selection
bias)
Unclear risk Randomisation was stratiﬁed by study cen-
tre, with ﬁxed blocks of 10 patients within
each stratum
Before the start of the study, an indepen-
dent statistician generated a randomisation
schedule and the trial pharmacist main-
tained the randomisation list
Not described method of sequence genera-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators, other staff members and pa-
tients remained blinded until after the last
patient had completed the study and the
follow-up and data analyses had been com-
pleted
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above, blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 452 were randomised of which 70 did not
complete the study, generally balanced be-
tween the groups although rates of preva-
lent delirium different between groups.
Complete reporting of reasons for with-
drawals and missing data
Selective reporting (reporting bias) Low risk Outcome data presented as per pre-pub-
lished protocol
Other bias Low risk No evidence of other bias
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Diaz 2001
Methods Design: Randomised controlled study of citicoline in hip fracture surgery patients
Date of study: Study dates not reported
Power calculation: Yes, indicates 88 patients needed, but results for 81 given
Frequency of outcomes assessment: Immediately and on days 1, 2 and 3 postoperatively
Inclusion criteria: 70 years or over, admitted with hip fracture
Exclusion criteria: Organic brain disorder, major cerebrovascular disease, anaesthetic risk
ASA IV
Participants Number in study: 81
Country: Chile
Setting: Multi-centre orthopaedic or trauma departments
Age mean years (SD): Citicoline 79.5 (6.6), Control 80.0 (5.9) P = 0.9
Sex M:F: Citicoline 4/31, Control 10/36; P = 0.2
Co-morbidity: Speciﬁc conditions not described. Present in 28/35 in intervention group
and 39/46 in control group
Dementia: Excluded
Interventions Intervention: Citicoline 400 mg orally 8 hourly, given between 24 hrs before and 4 days
after surgery (n = 35).
Control: Placebo matched for colour, consistency and ﬂavour (n = 46)
If anticholinergics and benzodiazepines were being used they were stopped, and anaemia
and haemodynamic variables corrected in both groups
Outcomes 1. Incident delirium immediately, day 1, day 2 and day 3 postoperatively using MMSE,
AMT, CAM
2. Cognitive status, using MMSE
Notes Funding source: Not reported
Declarations of interest: Not reported
Delirium excluded at enrolment using MMSE, AMT, CAM
Study underpowered, as incidence of delirium much lower than the 20% used in power
calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Carried out and codes kept by hospital
pharmacy independently of researchers
Random sequence generation (selection
bias)
Low risk ’Lottery drawing’ independently of re-
searchers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matched placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blind to allocation
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Diaz 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Sample size reported but unclear howmany
randomised
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
Fukata 2014
Methods Design: Randomised open-label trial of postoperative low dose intravenous haloperidol
in older patients undergoing abdominal, orthopaedic or other surgery
Date of study: January 2007 - December 2012
Power calculation: Yes
Frequency of outcomes assessment: Daily from postoperative day 0 to day 7
Inclusion criteria: 75 years or older; elective abdominal surgery under general anaesthesia
or elective orthopaedic surgery under general or spinal anaesthesia andwho could consent
to participate
Exclusion criteria: Emergency surgery; preoperative NEECHAM score < 20; periodic
dosing with newly added or switched antipsychotics, antidepressants, hypnotics or anti-
Parkinson agents within 2 weeks prior to surgery; previous treatment with haloperidol
for delirium after surgery before the initiation of postoperative preventive haloperidol
administration
Participants Number in study: 121
Country: Japan
Setting: General and orthopaedic surgery units in ﬁve co-operative hospitals
Age: Mean age 80.5 years (SD 0.5) in intervention group versus 80.2 (SD 0.5) for
controls
Sex: Males: Intervention 32/59; Control: 32/62
Co-morbidity: Abdominal surgery in 52 intervention and 55 controls; orthopaedic
surgery in 5 intervention and 4 control; and other surgery in 2 intervention and 3 control
patients; No differences in urinary incontinence, past history of excitement/hyperkine-
sia; or use of oral psychotropics
Dementia: Not speciﬁcally assessed. MMSE score (mean (SD) in intervention = 23.3
(0.7) and 23.0 (0.7) in control patients
Interventions Intervention: 2.5 mg/day of intravenous haloperidol dissolved in 100 mL of saline for
ﬁrst 3 days after surgery. Administered by infusion at 6 pm
Control: Usual care
Outcomes 1. Delirium incidence using NEECHAM
2. Delirium incidence stratiﬁed by low MMSE score (data not fully reported in paper)
3. Delirium severity using NEECHAM (data not fully reported in paper)
4. Delirium duration (data not fully reported in paper)
5. Adverse events (data not fully reported in paper)
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Fukata 2014 (Continued)
Notes Funding source: Research Grant for Longevity Sciences (17C-3, 21-13) from the Min-
istry of Health, Labour and Welfare and The Research Funding for Longevity Sciences
(23-28) from the National Center for Geriatrics and Gerontology (NCGG), Japan
Declaration of interest: The authors declare ’no conﬂicts of interest’
Delirium not fully excluded at enrolment - excluded if NEECHAM < 20 but this may
not exclude all delirium
Haloperidol given one day postoperatively rather than preoperatively or immediately
postoperatively as in other studies, and prevalent delirium not excluded
Inclusion criteria only mention abdominal and orthopaedic surgery but results presented
for 5 patients who underwent ‘other’ including vascular surgery
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Method not described
Random sequence generation (selection
bias)
Low risk Computer-generated allocation, adjusted
for age, gender and department
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel unblinded to al-
location; control group did not receive any
IV medication/placebo
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study; delirium assessment un-
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported on 119/121 patients. 2 pa-
tients in control group received haloperi-
dol for delirium on day of surgery, there-
fore withdrawn
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other bias
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Gauge 2014
Methods Design: Randomised controlled trial of optimisation of intraoperative depth of anaes-
thesia and cerebral oxygenation
Date of study: Study dates not reported
Power calculation: Yes - powered as pilot study
Frequency of outcomes assessment: Assessed at 3 +/- 1 days following surgery
Inclusion criteria: Aged over 64 years, undergoing coronary artery bypass graft surgery
Exclusion criteria: Not reported
Participants Number in study: 81
Country: Not reported
Setting: Not reported
Age: Mean age 71.9 years (whole sample)
Sex: 86% male (whole sample)
Co-morbidity: Not reported
Dementia: Baseline MMSE ranged from 24 to 30 for whole sample
Interventions Intervention: Intraoperative monitoring of depth of anaesthesia using bispectral index
and cerebral oxygenation monitoring
Control: Surgery performed blinded to bispectral index and cerebral oxygenation mon-
itoring
Outcomes 1. Incidence of postoperative delirium using CAM
Notes Funding source: Not reported
Declarations of interest: Not reported
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk No information provided - abstract only
Random sequence generation (selection
bias)
Unclear risk No information provided - abstract only
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided - abstract only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided - abstract only
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided - abstract only
Selective reporting (reporting bias) Unclear risk No information provided - abstract only
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Gauge 2014 (Continued)
Other bias Unclear risk No information provided - abstract only
Gruber-Baldini 2013
Methods Design: Randomised controlled trial of liberal blood transfusion thresholds compared
to restrictive transfusion practice for hip fracture patients
Date of study: April 2008-February 2009
Power calculation: Yes
Frequency of outcomes assessment: multiple times within 5 days after randomisation or
up to hospital discharge (if hospital stay was shorter)
Inclusion criteria: aged 50 and older; undergoing surgical repair of hip fracture; Hb
< 10 g/dL within 3 days after surgery; clinical evidence of cardiovascular disease or
cardiovascular disease risk factors
Exclusion criteria: non-English speaking; unable to walk unaided before fracture; de-
clined blood transfusions; multiple traumas; pathological hip fracture; clinical acute my-
ocardial infarction within 30 days pre-randomisation; previous participants in the trial;
symptoms associated with anaemia; actively bleeding at time of potential randomisation
Participants Number in study: 139
Country: USA and Canada
Setting: 13 hospitals
Age: Mean age 82.4 (SD 7.4) in intervention group compared to 80.6 (SD 10.4) in
control group
Sex: 81.8% of intervention group were female compared to 47% of control group
Co-morbidity: numbers and percentages of common co-morbidities reported in paper
(stroke/TIA, chronic lung disease, cancer, diabetes, atrial ﬁbrillation, Parkinson’s disease,
hearing problems, visual problems and alcohol abuse or withdrawal)
Dementia: 27.3%of intervention group had dementia compared to 36.1%of the control
group
Interventions Intervention (aka liberal treatment): One unit of packed red blood cells and as much
blood as needed to maintain a haemoglobin concentration >10 g/dL
Control (aka restrictive treatment): only transfused if symptoms of anaemia developed
or at the study physicians discretion or if Hb < 8 g/dL
Outcomes 1. Incident delirium, using CAM
2. Delirium severity, using MDAS
3. Length of admission
4. Psychoactive medication use
5. Physical morbidity (post-randomisation adverse events)
Notes Funding source: Research grant from National Heart Lung and Blood Institute
Declarations of interest: “Dr Magaziner received support from Amgen, Eli Lilly, Glaxo
SmithKline, Merck, Novartis and Sanoﬁ Aventis to conduct research through his in-
stitution, provide academic consultation, or serve on an advisory board. Dr Roffey re-
ports working as a consultant for Palladian Health. Dr Cardson reports receiving grant
support to his institution from Amgen. Dr Marcantionio is a recipient of a Mid-Career
Investigator Award in Patient-Oriented Research from the National Institute on Aging”
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Delirium assessed at baseline but not excluded
>1/3 of the restrictive group received transfusion
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk No evidence to suggest allocations revealed
Random sequence generation (selection
bias)
Low risk Automated central telephone randomisa-
tion system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Research staff unblinded to treatment sta-
tus except at one site
Incomplete outcome data (attrition bias)
All outcomes
Low risk 139 randomised, outcome assessment data
available for 138
Selective reporting (reporting bias) Low risk Data reported for all participants included
in the study
Other bias High risk Imbalance in dementia prevalence between
intervention and control groups (27.3% in
intervention versus 36.1% in control)
Hatta 2014
Methods Design: Randomised controlled trial of ramelteon, a melatonin agonist
Date of study: September 2011 to October 2012
Power calculation: Yes
Frequency of outcomes assessment: Daily for up to seven days
Inclusion criteria: aged 65-89; newly admitted for serious medical problems; able to take
oral medications
Exclusion criteria: expected stay or life expectancy less than 48 hours; severe liver dys-
function; Lewy body disease; delirium at time of admission; patients taking ﬂuvoxamine;
those with mood disorders; drug or alcohol withdrawal
Participants Number in study: 43 were admitted to acute medical wards (67 in total study cohort,
24 admitted to ICU)
Country: Japan
Setting: Acute medical wards in four university hospitals and one general hospital
Age: Mean age 78.2 (SD 6.6) in the ramelteon group and 78.3 (SD 6.8) in the placebo
group
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Hatta 2014 (Continued)
Sex: 48% of the intervention group were male compared with 32% of the placebo group
Comorbidity: Charlson Index mean 3.2 (SD 2.4) in intervention group compared with
2.6 (SD 2.2) in placebo group
Dementia: Clinical Dementia Rating mean score 0.5 (SD 0.7) in the intervention group
compared with 0.6 (SD 0.9) in the placebo group
Interventions Intervention: Ramelteon tablet 8 mg daily at 9 pm until development of delirium or up
to seven days
Control: Lactose powder 330 mg daily at 9 pm until development of delirium or up to
seven days
Outcomes 1. Incidence of delirium using DRS-R-98, cut-off 14.5
2. Severity of delirium using DRS-R-98
3. Withdrawal from protocol
4. Adverse events
5. Inpatient mortality
Notes Funding source: Japan Society for the Promotion of Science (Grant-in-Aid for Scientiﬁc
Research)
Declarationof interest: Authors declare receivinghonoraria from&serving as consultants
for Eli Lilly, Janssen,GlaxoSmithKline, Shionogi;Merck Sharp&Dohme;Otsuka; Pﬁzer;
Mochida; Tsumura; Dainippon-Sumitomo; Daiichi-Sankyo; Eisai, and Ono
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation concealed using envelope
method
Random sequence generation (selection
bias)
Low risk Random number table, sealed opaque en-
velope
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not blinded, nurses adminis-
tering medication not blinded; although
other personnel blinded. Placebo not sim-
ilar to active tablet
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Low risk Reporting of outcomes as identiﬁed in the
protocol published on the UMIN-CTR
registry 00005591
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Other bias Low risk No evidence of other bias
Hempenius 2013
Methods Design: multi-centre, randomised controlled trial
Date of study: June 2007-June 2010
Power calculation: Yes but study underpowered
Frequency of outcomes assessment: days 1-10 postoperatively, 3 times per day
Inclusion criteria: over 65 yrs; due to undergo elective surgery for a solid tumour, deemed
to be frail (using Groningen Frailty Indicator >3)
Exclusion criteria: unable to complete protocol; unable to complete follow-up; unable
to complete questionnaire
Participants Number in study: 297
Country: The Netherlands
Setting: 3 hospitals (1 university medical centre, 1 teaching hospital and 1 community
hospital)
Age: Mean age 77.45 (SD 6.72) in intervention group; 77.63 (SD 7.69) in usual care
group
Sex: 62.2% of intervention group were female compared with 65.8% of usual care group
Co-morbidity: stratiﬁed into < or equal to 2 co-morbidities (39.6% of intervention
group 40.4% of usual care group) or >2 co-morbidities (60.4% in intervention group
59.6% of usual care group)
Dementia: MMSE performed at baseline; mean score 26.6 in intervention group vs. 26.
33 in usual care group (P = 0.49)
Interventions Intervention: Multi-component intervention focused on best supportive care and the
prevention of delirium. Preoperative geriatric team assessment with daily monitoring
during hospital stay, supported by the use of standardised checklists
Usual care: only had access to geriatric care if treating physician requested referral
Outcomes 1. Incident delirium, using DOSS - if > 3 then had specialist assessment using DSM-IV.
Assessments performed up to 10 days postoperatively
2. Delirium severity, using DRS-R-98
3. Length of admission
4. Mortality
5. Return to independent living
6. Postoperative complications
7. Quality of life using Short-Form-36
8. Falls
Notes Funding source: Netherlands Organisation for Health Research and Development
Declarations of interest: “The authors declared that no competing interests exist”
Delirium not excluded at enrolment
No record of how many in usual care group received geriatrician input
Risk of bias
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Hempenius 2013 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Central allocation system
Random sequence generation (selection
bias)
Low risk Interactive voice response telephone system
for randomisation provided by university
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and research nurses unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Delirium assessment blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 297 participants randomised, outcome as-
sessments available for 260 (n = 127 in
intervention group and n = 133 in con-
trol group) - no information provided, de-
scribed as ’lost to follow-up’
Selective reporting (reporting bias) Low risk Outcomes reported as per original protocol
Other bias Low risk No evidence of other bias
Jeffs 2013
Methods Design: Randomised controlled trial
Date of study: May 2005-December 2007
Power calculation: yes - incorporating incident delirium and absolute risk reduction of
6%
Frequency of outcomes assessment: every 48 hours
Inclusion criteria: aged 65 years or older; admitted to a medical unit in the study area;
in hospital < 48 hours
Exclusion criteria: severe dysphasia rendering communication impossible; death expected
within 24 hours; isolation for infection control; documented contraindication to mobil-
isation; admission to the Stroke Unit or to critical care; planned admission of < 48 hours;
major psychiatric diagnosis; previous inclusion in the study; delirium documented in
the admission notes; transfer from another hospital
Participants Number in study: 649
Country: Australia
Setting: Acute medical wards, secondary referral centre
Age: Mean age of 79.6 (SD 7.5) in intervention group, 79.1 (7.9) in control group
Sex: 45% of intervention group were male, compared to 50% of control group
Co-morbidity: Charlson index of 2 (1-3) in both groups at baseline
Dementia:MMSE recorded at baseline in both groups: 25 (20-28) in intervention group
vs. 26 (19-28) in control group
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Jeffs 2013 (Continued)
Interventions Intervention: Participants randomised to the intervention arm received a graded physical
activity and orientation programme twice daily, which was delivered in addition to usual
care. A certiﬁed Allied Health Assistant, trained in administering exercise programmes,
delivered the intervention after initial assessment of the participant by a physiotherapist.
The programme started on the same day as the participant was randomised. Commen-
surate with ability, participants were prescribed one of four exercise programmes: bed,
seated, standing or rails. All programmes were customised to the participant’s ability and
were reviewed daily. Exercise programmes were modiﬁed to ensure suitable progression
for those participants who made signiﬁcant gains
The orientation programme comprised formal and informal elements. The formal el-
ement of the programme comprised a series of seven questions aimed at assessing and
improving orientation (day, month, year, date, ward, bed number and name of primary
nurse). The participant was asked the questions in sequence and prompted with the cor-
rect answer if they were not able to give a correct response. The informal element of the
programme related to engaging in the exercise programme and in the social interaction
with the Allied Health Assistant and/or Physiotherapist
Control: Usual care included 24-hour nursing care, daily medical assessment and allied
health referral by medical, nursing or other staff. Allied health input was provided on
referral only, but daily ward meetings were held to review patient progress and facilitate
referrals. Patients with signiﬁcant functional, cognitive or social issues could be referred to
the Aged Care medical consultation service that performed a daily round and could offer
advice regarding the recognition, investigation and management of geriatric syndromes
including delirium
Outcomes 1. Incidence of delirium, using CAM
2. Duration of delirium
3. Severity of delirium, using CAM
4. Length of stay
5. Return to previous residence
Notes Funding source: HCF Health and Medical Research Foundation
Declarations of interest: “No competing interests”
Very low rates of delirium in both arms. Authors suggest may be due to 48 hourly
assessments or not selecting those at high risk
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Sealed opaque envelopes for allocation
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not clear,
just states ’randomisation was achieved us-
ing sealed opaque envelopes’
Blinding of participants and personnel
(performance bias)
High risk Participants not informedof allocation, but
unable to fully blind due to nature of in-
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Jeffs 2013 (Continued)
All outcomes tervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk n = 17 in intervention and n = 18 in con-
trol did not receive the intervention, but
were assessed on an intention-to-treat anal-
ysis basis
Selective reporting (reporting bias) Low risk Trial protocol retrospectively registered
with Australian New Zealand Clinical Tri-
als Registry ACTRN 012605000044628;
outcomes reported in accordance with pro-
tocol
Other bias Low risk No evidence of other bias
Jia 2014
Methods Design: Randomised controlled trial of fast-track surgery for colorectal cancer compared
to usual care
Date of study: 2008-2011
Power calculation: No
Frequency of outcomes assessment: Day of admission and then daily from postoperative
days 1 to 5
Inclusion criteria: patients aged 70 years and over with colorectal cancers admitted to
the Fourth Hospital of Hebei Medical Univerity for open curative resection.
Exclusion criteria: history of dementia; Parkinson’s disease; alcohol intake of > or equal
to 250 g/day; long-term use of sleeping pills or anxiolytics; those who received anaes-
thesia within the past 30 days. Enrolled patients who were given intraoperative blood
transfusions or were admitted to the ICU were excluded from analysis
Participants Number in study: 240
Country: China
Setting: University hospital
Age: Mean age of 75.6 (SD 4.2) in intervention group; 74.8 (SD 4) in control group
Sex: 65% of intervention group were male, compared to 60% of the control group
Co-morbidity: Hypertension and diabetes were recorded at baseline, no signiﬁcant dif-
ferences between the groups (P = 0.275 and 0.511 respectively)
Dementia: those with diagnosed dementia were excluded from the study
Interventions Fast-track surgery group: Bowel preparation with oral purgatives instead of a mechanical
enema; thoracic epidural anaesthesia and postoperative analgesic maintenance via the
epidural catheter maintained for 48h; no nasogastric tube insertion; no drainage tube
placement with the exception of the low rectal anastomosis; water was allowed from
6 hours post operation, liquid diet in the morning and semi-liquid diet at noon and
evening of the ﬁrst and second postoperative day (POD) with regular diet on POD 3;
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Jia 2014 (Continued)
early urine catheter withdrawal; early out-of-bed mobilisation
Traditional therapy group: usual preoperative and postoperative care
Outcomes 1. Incidence of delirium, using DRS-R-98
2. Length of admission
3. Postoperative complications
Notes Funding source: Not reported
Declarations of interest: “No conﬂicts of interest”
Delirium not clearly excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Allocation method not clearly described
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded due
to nature of intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if psychiatrist performing outcome
assessment was blinded to allocation or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk n = 240 participants were randomised, out-
come assessment available for n = 233.
Three in intervention group and four in
the control group did not receive their allo-
cated intervention and were excluded from
outcome assessment data - these individu-
als did not meet study inclusion criteria
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
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Kalisvaart 2005
Methods Design: Randomised controlled study of haloperidol prophylaxis in patients undergoing
hip surgery
Date of study: August 2000 to August 2002
Power calculation: Yes
Frequency of outcomes assessment: Daily Delirium Rating Scale Revised 98 (DRS-R-
98), MMSE, Digit span by trained assessors
Inclusion criteria: Patients aged 70 years or over admitted for acute or elective hip surgery,
who were at intermediate or high risk of delirium postoperatively
Exclusion criteria: Prevalent delirium, haloperidol allergy, prolonged QTc interval, use
of cholinesterase inhibitors or levodopa, parkinsonism, epilepsy, inability to participate
in interviews, delay in surgery more than 72 hrs from admission
Participants Number in study: 430
Country: The Netherlands
Setting: 2 surgical and 3 orthopaedic wards in 1 teaching hospital
Age mean (SD): Intervention 78.76.0), Control 79.66.3); P = 0.15
Sex M:F: Intervention 19.9%, Control 21.1%
Co-morbidity: Not reported
Ilness severity: APACHE scores mean (SD) Intervention 13.4 (3.2), Control 13.3 (3.1)
Dementia: Not reported
Interventions Intervention: Haloperidol 0.5 mg orally three times daily on admission until 3 days
postoperatively
Control: Placebo tablets identical in appearance
Proactive geriatric consultation offered to all patients in both groups
If delirium occurred, patients treated with haloperidol or lorazepam (or both) 3 times
daily in increasing doses depending on symptoms
Outcomes 1. Incident delirium postoperatively using DSM-IV and CAM
2. Delirium severity
3. Duration of delirium
4. Length of admission
5. Withdrawal from protocol
6. Adverse events
Notes Funding source: Medical Center Alkmaar
Declarations of interest: “Financial disclosure: none”
Delirium at enrolment excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Randomisationby hospital pharmacy inde-
pendent of researchers. Codes held in sealed
envelopes
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code
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Kalisvaart 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matched placebos used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Members of the research team not involved
in the clinical care of patients performed all
baseline and outcome assessments
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete outcomes data available for n =
395, missing data for n = 35 (24 in control,
11 in intervention)
192/212 in intervention and 190/218 in
control treated according to protocol. Out-
come data available reported as intention-
to-treat by study authors
More lost to follow-up in placebo group
than intervention group and lack of infor-
mation about those who were lost
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
Larsen 2010
Methods Design: Randomised controlled trial of olanzapine to prevent postoperative delirium in
elderly joint replacement patients
Date of study: 2005 to 2007
Power calculation: Yes
Frequency of outcomes assessment: Daily from postoperative day 1 to postoperative day
8
Inclusion criteria: All patients aged 65 years and over, patients aged less than 65 years
with a history of delirium, impending joint-replacement surgery, ability to speak English,
and ability to provide informed consent
Exclusion criteria: Diagnosis of dementia, active alcohol use (>10 drinks per week), a
history of alcohol dependence or abuse, allergy to olanzapine, and current use of an
antipsychotic medication
Participants Number in study: 495
Country: USA
Setting: Orthopaedic wards
Age: Mean age 73.4 years (SD 6.1 years) in intervention group, 74.0 years (SD 6.2 years)
in control group
Sex: 48% female in intervention group, 60% female in control group
Co-morbidity: Not reported
Dementia: Patients with dementia were excluded
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Larsen 2010 (Continued)
Interventions Intervention: First dose of olanzapine 5 mg (orally disintegrating tablet (ODT)) admin-
istered immediately before surgery in the pre-anaesthesia care unit by nursing staff. Sec-
ond dose of olanzapine 5 mg administered in the post-anaesthesia care unit by nursing
staff blind to the intervention arm
Control: Oral dispersible tablet placebo of similar appearance to the olanzapine tablet
Outcomes 1. Incident delirium, measured using CAM/DSM-III-R
2. Severity of delirium, measured using DRS-R-98
3. Duration of delirium
4. Withdrawal from protocol
5. Cognition using MMSE
6. Adverse events
Notes Funding source: New England Baptist Hospital Research Department
Declarations of interest: “Theodore A Stern, has been a consultant to and is on the
speaker’s bureau of Eli Lilly and Company, and has been a consultant to and shareholder
of WiFiMed, the company that designed the Tablet PC data-management software. No
other authors reported conﬂicts of interest”
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Randomisation sequence held in pharmacy
department. Randomisation carried out by
pharmacy department
Random sequence generation (selection
bias)
Low risk Statisticianprovidedpharmacywith a com-
puter-generated random-number table
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Hospital pharmacy prepackaged the study
drug and placebo in identical packages and
blinded investigators and participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessments conducted by re-
search assistants and nurses and veriﬁed by
a clinical psychologist. All were blind to al-
location group
Incomplete outcome data (attrition bias)
All outcomes
High risk 95 dropouts not included in ﬁnal analysis
(n = 47 in intervention, n = 48 in control)
. Reasons stated but imbalance between
groupswith loss due to anxiety, surgery can-
celled and family pressure as signiﬁcant fac-
tors. High rate of delirium (40% in placebo
group vs 14.3% in intervention group),
concern that some of the exclusions may
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Larsen 2010 (Continued)
inﬂuence outcome assessment
Selective reporting (reporting bias) Low risk Study protocol registered on ClinicalTrials.
gov NCT000699946; outcomes reported
in accordance with protocol
Other bias Low risk No evidence of other bias
Leung 2006
Methods Design: Pilot randomised controlled trial of gabapentin to decrease postoperative delir-
ium in older patients
Date of study: 2005
Power calculation: No
Frequency of outcomes assessment: Daily from postoperative day 1 to postoperative day
3
Inclusion criteria: Consecutive patients who were > 45 years of age, undergoing surgery
involving the spine, requiring general anaesthesia, and expected to remain in the hospital
postoperatively for > 72 hours.
Exclusion criteria: Patients who could not complete the delirium testing, already taking
preoperative gabapentin, or with sensitivity to gabapentin
Participants Number in study: 21
Country: USA
Setting: Elective spinal surgery
Age: Mean age 59.6 years
Sex: 48% female
Co-morbidity: Charlson co-morbidity index 1.2 (SD 1.9) in intervention group, 0.5
(SD 1.0) in control group
Dementia: Not reported
Interventions Intervention: Gabapentin 900 mg administered by mouth 1 to 2 hours before surgery
and anaesthesia. 900 mg dose continued daily for the ﬁrst 3 postoperative days
Control: Placebo as control. Unclear whether matching placebo used
Outcomes 1. Incident delirium, measured using CAM
Notes Funding source: National Institute of Aging, National Institute of Health
Declarations of interest: “Dr Rowbotham consults for, and owns stock in, a company
developing an analogue of gabapentin, an investigational agent”
Pilot trial
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
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Leung 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Random number list given to the research
pharmacist who prepared and delivered
the designated drug to each study patient
according to the randomised allocation.
However, not clear how the random num-
ber list allocation was concealed from the
pharmacist by the co-investigator who cre-
ated it
Random sequence generation (selection
bias)
Low risk Computerised random number list gener-
ated by co-investigator
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled so participants and per-
sonnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained interviewer blinded to the study
drug assignment measured the occurrence
of delirium
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for in analysis
Selective reporting (reporting bias) Unclear risk Insufﬁcient information presented tomake
judgment
Other bias Low risk No evidence of other bias
Li 2013
Methods Design: Randomised controlled trial of intravenous parecoxib sodium analgesia for those
undergoing femoral head replacement
Date of study: January 2011 - May 2012
Power calculation: Unclear
Frequency of outcomes assessment: 3 days, 1 month, 3 months & 6 months
Inclusion criteria: age >70 years old; weight < 90 kg; diagnosed with femoral neck
fracture caused by trauma and required for analgesia; anaesthetic risk ASA II or III;
achieved satisfactory intraoperative anaesthesia outcome; sedation only by intravenous
midazolam; maintain normal blood pressure and heart rate by ephedrine and atropine.
Exclusion criteria: the score of MMSE < 23; have a history of psychosis or neurological
disorder; severe peptic ulcer; long-term use of antipsychotics or sedative medication; a
history of alcohol abuse; a history of allergic to non-steroid anti-inﬂammatory drug;
intraoperative blood transfusion; unable to accomplish preoperative cognitive function
test due to communication disorders and poor educational background
Participants Number in study: 80
Country: China
Setting: Recruited from the Emergency Department
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Li 2013 (Continued)
Age: Mean 76.6 (SD 2.6)
Sex: Male sex 29 (36%)
Co-morbidity: Not described
Dementia: Excluded those with lowMMSE (< 23) and also those who could not perform
pre-op cognitive function tests (due to communication disorders and poor educational
background)
Interventions Intervention: Intravenous parecoxib sodium (non-steroidal anti-inﬂammatory medica-
tion). Dosage based by weight. Given 12 hourly over 3 days (total of 6 injections). Given
up to 2 mg IV morphine if pain score elevated despite intervention
Control: Intravenous morphine 2 mg or 4 mg at ﬁrst injection, thereafter given 5 injec-
tions of 2 mL of saline every 12 hours over 3 days (total of 6 injections). Could also be
given up to 2 mg IV morphine if pain score elevated
Outcomes 1. Incident delirium using DSM-IV
2. Length of admission
3. Postoperative cognitive dysfunction using APA criteria (3 days, 1 week, 3 months, 6
months)
Notes Funding source: Science and Technology Development Project of Qingdao Science and
Technology Bureau
Declaration of interest: Not reported
Unclear if delirium excluded at enrolment.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Group assignment ’managed by one spe-
ciﬁc staff ’ but not clear if allocation con-
cealment maintained
Random sequence generation (selection
bias)
Low risk Random number tables used to generate
randomisation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, personnel administeringmed-
ications and monitoring patient were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Paper states study was double-blind, out-
come assessment procedure not described
in translation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Paper reports complete follow-up
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
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Li 2013 (Continued)
Other bias High risk Potential confounding for unbalanced use
of additional morphine doses between
group; 7.9 mg in parecoxib group vs. 31.3
mg in morphine and saline group
Liptzin 2005
Methods Design: Randomised controlled trial of donepezil in patients undergoing elective arthro-
plasty of the knee or hip
Date of study: May 2000 to April 2003
Power calculation: Yes but used a higher estimate of delirium incidence than found in
study
Frequency of outcomes assessment: Daily pre- and postoperatively, and postoperative
daily medical records review; delirium presence determined from this information at day
7 and 14 postoperatively
Inclusion criteria: Patients over 50 years, able to give informed consent, admitted for
elective knee or hip arthroplasty
Exclusion criteria: Gastro-oesophageal reﬂux disease, sick sinus syndrome, already using
donepezil or intolerant to it, non-English speaking
Participants Number in study: 90
Country: USA
Setting: Orthopaedic department in a medical academic centre
Age mean(SD) years: Intervention 67.2 (8.7), Control 69.4 (8.9); P = 0.03
Sex M:F: Intervention 43%, Control 35%; P = 0.17
Co-morbidity: Not reported
Dementia: Not reported
Interventions Intervention: Donepezil 5 mg once daily for 14 days before and after surgery, doubled
to 10 mg if developed any symptoms of delirium
Control: Placebo identical in appearance
Outcomes 1. Incident postoperative delirium, using DSM-IV criteria from DSI and CAM
2. Duration of delirium (data not fully reported in paper)
3. Length of admission
4. Withdrawal from protocol
Notes Funding source: Pﬁzer Corporation
Declarations of interest: “This study was supported by an unrestricted research grant
from Pﬁzer Corporation. Dr Liptzin has also been a consultant or speaker for Pﬁzer,
Novartis, Janssen, Forest Labs, and Bristol Myers Squibb”
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
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Liptzin 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Information on concealment not provided
Random sequence generation (selection
bias)
Unclear risk Randomisation by research pharmacist,
method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules of active drug and
placebo used so participants and personnel
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment by research assistant
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Incomplete follow-up. Intention-to-treat
analysis not conducted. Number of drop-
outs similar in both groups but sufﬁciently
high to potentially affect results
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other bias
Lundstrom 2007
Methods Design: Randomised controlled trial of multi-component delirium prevention interven-
tion for older hip fracture patients
Date of study: May 2000 to December 2002
Power calculation: Yes
Frequency of outcomes assessment: All patients tested once between day 3 and day 5
postoperatively using organic brain scale,MMSEand geriatric depression scale. Delirium
diagnosed retrospectively after the study had ﬁnished by specialist in geriatric medicine
blind to allocation group on the basis of the nursing assessments by applying the DSM-
IV criteria
Inclusion criteria: Patients aged 70 years and older consecutively admitted to the or-
thopaedic department in Umea hospital, Sweden.
Exclusion criteria: Age under 70, severe rheumatoid arthritis, severe hip osteoarthritis,
severe renal failure, pathological fracture and patients who were bedridden before the
fracture
Participants Number in study: 199
Country: Sweden
Setting: Orthopaedic hip fracture patients
Age: Mean age 82 years
Sex: 74% female
Co-morbidity: No baseline between group differences in cardiovascular disease, respira-
tory disease, hypertension or diabetes. More patients in control group with depression
(46% v 32%, P = 0.03)
Dementia: 27.5 % in intervention group, 37.1% in control group
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Lundstrom 2007 (Continued)
Interventions Intervention: Multi-disciplinary team providing comprehensive geriatric assessment,
management and rehabilitation on a geriatric ward. Intervention comprising: staff educa-
tion; teamwork; individual care planning; delirium prevention detection and treatment;
prevention and treatment of complications; bowel/bladder function; sleep; decubitus ul-
cer prevention/treatment; pain management; oxygenation; body temperature measure-
ment; nutrition; rehabilitation; secondary prevention of falls/fractures and osteoporosis
prophylaxis
Control: Usual care on orthopaedic ward.
Outcomes 1. Incident delirium, diagnosed retrospectively using DSM-IV based on nursing notes
(for the duration of the inpatient stay) and OBS (measured once between the 3rd and
5th postoperative day)
2. Duration of delirium, diagnosed retrospectively using DSM-IV based on nursing
notes and OBS
3. Length of admission
4. Cognitive status, measured using MMSE
5. Falls
6. New pressure ulcers
7. Psychological morbidity (Depression)
8. Mortality - inpatient and at 12 months
Notes Funding source: Swedish Research Council & Vardal Foundation
Declarations of interest: Not reported
Prevalent delirium not excluded at enrolment (21.8% intervention group, 30.9% control
group) and patients with prevalent delirium appear to have been included in outcome
data
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Sealed opaque envelopes to conceal alloca-
tion
Random sequence generation (selection
bias)
Unclear risk No information given on how randomisa-
tion sequence generated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk All staff aware of allocation group, patients
potentially aware due to nature of interven-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Staff recording outcomemeasurements not
blind to study arm. Blinded specialist made
diagnosis of delirium retrospectively based
on staff measurements and medical/ nurs-
ing records
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Lundstrom 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients included in the
analysis
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias High risk Imbalance in dementia prevalence between
intervention and control groups (27.5% in
intervention versus 37.1% in control)
Lurati 2012
Methods Design: Randomised controlled trial
Date of study: February 2006-October 2010
Power calculation: Yes
Frequency of outcomes assessment: postoperative days 1, 2 and 7 or on the day of hospital
discharge, whichever occurred ﬁrst
Inclusion criteria: patients scheduled for surgery under general anaesthesia were eligible
if they either had proven coronary artery disease (CAD) and were scheduled for major
surgery or had 2 or more risk factors for CAD and were scheduled for major vascular
surgery
Exclusion criteria: Current medication with sulphonylurea derivatives or theophylline
unless stopped 2 or more days before surgery; current congestive heart failure; current
unstable angina pectoris; preoperative haemodynamic instability, deﬁned as the use of
vasopressors; hepatic disease deﬁned as alanine aminotransferase and/or aspartate amino-
transferase values >100 U/L; renal insufﬁciency, deﬁned as creatinine clearance < 30 mL/
min; emergent surgery; severe chronic obstructive pulmonary disease, deﬁned as forced
expiratory volume in the ﬁrst second of expiration < 1L; prior enrolment in the study;
concurrent enrolment in another RCT; pregnancy; absence of written informed consent
Participants Number in study: 385
Country: Switzerland
Setting: Tertiary referral hospital and two secondary care hospitals
Age: Mean age 78 (SD 8) in sevoﬂurane group; 73 (SD 8) in propofol group
Sex: 75% of sevoﬂurane group were male compared with 77.6% of propofol group
Co-morbidity: Numbers with history of CAD, TIA/Stroke, CHF and diabetes reported
for both groups
Dementia: not reported
Interventions In both groups anaesthesia induction was with etomidate. The protocol did not regulate
dosage for the induction or maintenance of anaesthesia or any other aspects of intraop-
erative management
Sevoﬂurane: Anaesthesia maintained using sevoﬂurane
Propofol: Anaesthesia maintained using propofol
Outcomes 1. Incidence of delirium using CAM
2. Mortality at 12 months
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Lurati 2012 (Continued)
Notes Funding source: University Hospital Basel; Roche Diagnostics; Abbot AG
Declarations of interest: “RocheDiagnostics Switzerland provided in-kind support (assay
kits). Abbott AG Switzerland provided some ﬁnancial support for the conduction of the
study. No other potential conﬂicts of interest are to be disclosed for any of the authors.”
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Numbered, sealed opaque envelopes to
conceal allocation
Random sequence generation (selection
bias)
Low risk Computer-generated random allocation
sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants blinded to allocation, anaes-
thesiologists not blinded as able to work-
out allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. Seventeen patients
randomised in error, but reasons reported
and excluded from analysis
Selective reporting (reporting bias) High risk Protocol for Trial of the Effect of Anesthet-
ics on Morbidity and Mortality (TEAM-
Project) NCT00286585 but no informa-
tion about reporting of delirium outcomes
in original protocol
Other bias Low risk No evidence of other bias
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Marcantonio 2001
Methods Design: Randomised controlled trial of proactive geriatric consultation in patients with
hip fracture
Date of study: Study dates not reported
Power calculation: Yes. Study adequately powered for bivariate analyses but not for the
multivariate or stratiﬁed analyses.
Frequency of outcomes assessment: Daily interviews from enrolment to discharge to
complete MMSE, DSI, CAM, MDAS
Inclusion criteria: All patients aged 65 years and older, admitted for primary surgical
repair of hip fracture, who were at intermediate or high risk of delirium (presence of 1
or more delirium risk factors)
Exclusion criteria: Metatstatic cancer or comorbid illness reducing life expectancy to less
than 6 months; Unable to obtain consent (or proxy assent) within 24 hrs of surgery, or
48 hrs of admission
Participants Number in study: 126
Country: USA
Setting: One academic centre orthopaedic department
Age mean (SD): Intervention 78 (8), Control 80 (8); P = 0.39
Sex M:F: Intervention 21%, Control 22%; P = 0.9
Co-morbidity: Charlson Index > 4 Intervention 39%, Control 33%; P = 0.49
Dementia: Intervention 37%, Control 51%; P = 0.13. However, dementia assessment
only reported for 90% of participants
Interventions Intervention: Proactive consultation by Consultant Geriatrician, with daily visits starting
preoperatively or within 24 hrs post operatively for duration of admission. Protocol based
targeted recommendations over and above what was already being done by team, limited
to 5 at initial visit and 3 at follow-up visits.
Controls: Usual care, consisting of management by orthopaedic team and consultation
by internal medicine or geriatrics on reactive rather than proactive basis
Outcomes 1. Delirium incidence- total cumulative during admission, using CAM (performed daily
throughout inpatient stay)
2. Delirium incidence in dementia subgroup
3. Delirium duration
4. Length of admission
5. Return to independent living
6. Withdrawals from protocol
Notes Funding source: Older Americans Independence Center; Charles Farnworth Trust;
Declarations of interest: Not reported
Delirium examined but not reported at intake, making interpretation of results for
primary outcome of cumulative delirium incidence difﬁcult
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Sealed envelopes prepared with allocation
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Marcantonio 2001 (Continued)
Random sequence generation (selection
bias)
Low risk Random number table used to generate se-
quence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nature of intervention precluded blinding
of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent researchers conducted delir-
ium assessments and timed not to coin-
cide with Geriatrician consultation. States
blinding successfully maintained
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias High risk Imbalance in dementia prevalence between
intervention and control groups (37% in
intervention and 51% in control)
Marcantonio 2011
Methods Design: Pilot randomised controlled trial of donepezil for delirium after hip fracture
Date of study: January 2007 - August 2008
Power calculation: No
Frequency of outcomes assessment: Daily during hospital stay and at weeks 2, 4 and 6
Inclusion criteria: Admitted to the orthopaedic service for surgical repair of hip fracture
and: age 70 and older, English speaking, residence within 40 mile radius of medical
centre, life expectancy 6 months or greater, not currently taking cholinesterase inhibitor
therapy
Exclusion criteria: Pathological fracture due to metastatic cancer, advanced dementia,
little potential for functional recovery
Participants Number in study: 16
Country: USA
Setting: Orthopaedic hip fracture patients
Age: Mean age 88.0 years (SD 5.2) in intervention group; 87.0 (3.7) in control group
Sex: 71% female in intervention group; 44% female in control group
Co-morbidity: Not reported
Dementia: 43 % in intervention group, 44% in control group
Interventions Intervention: 5 mg dose of donepezil initiated on the day before or within 24 hours of
surgery and continued for a total of 30 days
Control: Matching placebo.
All participants received perioperative co-management from a geriatric team on or-
thogeriatric ward
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Marcantonio 2011 (Continued)
Outcomes 1. Incident delirium,measured using CAMbut not included inmeta-analysis as reported
as cumulative measures within individuals
2. Delirium severity, measured using MDAS
3. Withdrawal from trial
4. Adverse events
Notes Funding Source: National Institute of Aging
Declarations of interest: “The authors have no ﬁnancial or any other kind of personal
conﬂicts with this paper”
Delirium not excluded at enrolment
Only 16 participants in pilot trial
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate allocation concealment likely:
on-site pharmacy prepared and dispensed
active medication and placebo; study team
masked to treatment assignment
Random sequence generation (selection
bias)
Unclear risk Permuted block randomisation used but
method of sequence generation not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded to allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Delirium assessment conducted by trained
research interviewer blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis performed, all
randomised participants included in the
analysis
Selective reporting (reporting bias) Low risk Protocol for Supporting the Health of
Adults Undergoing Orthopedic Surgery
During the Recovery Period (SHARP)
NCT00586196; reporting in accordance
with protocol
Other bias Low risk No evidence of other bias
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Martinez 2012
Methods Design: Randomised controlled trial of a multi-component delirium prevention inter-
vention provided by family members
Date of study: September 2009-June 2010
Power calculation: Yes
Frequency of outcomes assessment: Daily during hospital stay
Inclusion criteria: All patients at risk for delirium (> 70 years, cognitive impairment
(MMSE < 24 prior to admission) alcoholism or metabolic imbalance at admission)
Exclusion criteria: Delirium at admission, no family support, admitted to ward other
than general medicine, those in a room with more than two beds
Participants Number in study: 287
Country: Chile
Setting: Internal medicine ward of acute hospital
Age: Mean age 78.1 years (SD 6.3) in intervention group; 78.3 years (6.1) in control
group
Sex: 42% female in intervention group; 33% female in control group
Co-morbidity: Median Charlson comorbidity index (CCI) 2 (interquartile range, IQR,
1-4) in intervention group, median CCI 2 (IQR 1-3) in control group
Dementia: 9% in intervention group, 8% in control group
Interventions Intervention: Multi-component non-pharmacological intervention provided by family
members, including education regarding confusional syndromes; provision of a clock and
calendar; avoidance of sensory deprivation (glasses, denture and hearing aids available as
needed); presence of familiar objects in the room; re-orientation of patient provided by
family members; extended visiting times (5 hours daily)
Control: Usual care from the attending physician
Outcomes 1. Incident delirium, measured using CAM performed daily, throughout admission
2. Duration of delirium
3. Length of admission
4. Falls
Notes Funding source: Not reported
Declarations of interest: “No conﬂicts of interest declared”
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Randomisation performed by a statistician
who was not involved in data collection
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel unblinded due
to the nature of the intervention
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Martinez 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-1 treat analysis performed,
5% loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other forms of bias
Mouzopoulos 2009
Methods Design: Randomised placebo-controlled trial of fascia iliaca compartment block (FICB)
prophylaxis for hip fracture patients at risk for delirium
Date of study: July 2004-March 2008
Power calculation: No
Frequency of outcomes assessment: Daily during hospitalisation
Inclusion criteria: Men and women aged 70 years and older admitted for hip fracture
surgery
Exclusion criteria: Delirium at admission, metastatic hip cancer, history of bupivacaine
allergy, use of cholinesterase inhibitors, severe coagulopathy, Parkinsonism, epilepsy, lev-
odopa treatment, delay of surgery of more than 72 hours after admission, and inability to
participate in interviews (profound dementia, respiratory isolation, intubation, aphasia,
coma or terminal illness)
Participants Number in study: 219
Country: Greece
Setting: Orthopaedic ward
Age: Mean age 72.7 years
Sex: 74% female
Co-morbidity: Not reported
Dementia: Not reported
Interventions Intervention: Fascia iliaca compartment block (FICB) using a 0.25 mg dose of 0.3 mL/
kg bupivacaine at admission and repeated daily until either delirium developed or hip
fracture surgery was performed. 24 hours after surgery, the same dose of FICB was
administered and repeated every 24 hours until either delirium occurred or discharge
Control: Matching placebo using water for injection following same regimen
Outcomes 1. Incident delirium measured using DSM-IV/CAM
2. Delirium severity, measured using DRS-R-98
3. Duration of delirium
4. Mortality
Notes Funding source: Not reported
Declarations of interest: “The authors declare that they have no conﬂict of interest related
to the publication of this manuscript”
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Mouzopoulos 2009 (Continued)
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation concealed by central allocation
method
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single (participant) blinding. Orthopaedic
surgeons performing the local anaesthetic
injection do not appear to be blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed outcome assess-
ments and if blinded or not
Incomplete outcome data (attrition bias)
All outcomes
High risk Nine patients not included in outcome as-
sessment and lack of information about
those lost to follow-up
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other forms of bias
Munger 2008
Methods Design: Randomised controlled trial of donepezil in preventing delirium and postoper-
ative cognitive decline following orthopaedic surgery
Date of study: Study dates not reported
Power calculation: Not reported
Frequency of outcomes assessment: Recorded on four occasions, but unclear when
Inclusion criteria: Aged 65 years and over, no prior donepezil use and scheduled for hip
fracture repair or elective hip or knee replacement surgery.
Exclusion criteria: Not stated
Participants Number in study: 15
Country: USA
Setting: Orthopaedic surgery
Age: Mean age 74.1 years
Sex: 66% female
Co-morbidity: Not reported
Dementia: Not reported
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Munger 2008 (Continued)
Interventions Elective patients: donepezil 5 mg starting 7 days prior to surgery and tapering off during
the third week following surgery
Hip fracture patients: donepezil 5 mg starting on the day of surgery ending 5 days
postoperatively
Control: placebo
Outcomes 1) Incident delirium, but reported using mean CAM rather than dichotomous data
2) Length of admission
3) Cognitive status using MMSE
Notes Funding source: Clarian Values Fund, Pﬁzer Inc
Declarations of interest: Not reported
Pilot study, 15 participants. Mean CAM reported as opposed to numbers of people with
delirium so limitations regarding interpretation of data. Although MMSE measured
daily, frequency of CAM, MDAS not reported. Four time points were reported in the
results table but not stated when these were
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk No information provided - abstract data
only
Random sequence generation (selection
bias)
Unclear risk No information provided - abstract data
only
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided - abstract data
only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided - abstract data
only
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided - abstract data
only
Selective reporting (reporting bias) Unclear risk No information provided - abstract data
only
Other bias Unclear risk No information provided - abstract data
only
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Papaioannou 2005
Methods Design: Randomised trial of regional and general anaesthesia in elective surgery patients
Date of study: Study dates not reported
Power calculation: Yes
Frequency of outcomes assessment: daily for ﬁrst three postoperative days
Inclusion criteria: Patients aged 60 years or over
scheduled for elective surgery that could be performed under regional or general anaes-
thesia and who had agreed to be randomly allocated to receive either type of anaesthesia
Exclusion criteria: Illiteracy, severe auditory or visual disturbances, central nervous system
disorders, alcohol or drug dependence, treatment with tranquillisers or antidepressants,
Parkinson’s disease, and preoperative MMSE score less than 23 (indicative of dementia)
Participants Number in study: 50
Country: Greece
Setting: Unclear
Age 60-69/70 and over: Regional 14/5, General 15/13
Sex M/F: Regional 12/7, General 18/10
Co-morbidity: Not reported
ASA score: ASA I-II/II-IV: Regional 16/3, General 27/1
Dementia: Excluded
Interventions Intervention: Regional anaesthesia (epidural or spinal)
Control: General anaesthesia via propofol infusion or inhaled anaesthetic
Both given to achieve a Ramsay sedation score of≤2. Benzodiazepines not administered
for premedication or intraoperative sedation
Outcomes 1. Incident delirium using DSM-III criteria with informant history from attending
relatives and nurses. Unclear whether patients interviewed
2. Length of admission
3. Cognitive status using MMSE
4. Postoperative complications
Notes Funding source: European Commission BIOMED2 program BMH4-98-3335 and
Greek Ministry of Health
Declarations of interest: Not reported
Deliriumdiagnosed using informant history from attending relatives and nurses. Unclear
whether patients interviewed
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation concealed by central
Random sequence generation (selection
bias)
Low risk Computer programme used
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Papaioannou 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to nature of interven-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment is unclear,
“incidence of delirium was evaluated by
asking the attending nurses and relatives for
features fulﬁlling the DSM III criteria”
Incomplete outcome data (attrition bias)
All outcomes
High risk 50 patients randomised, 4 randomised to
intervention crossed-over to general anaes-
thesia. Delirium incidence results pre-
sented are per protocol, intention-to-treat
not reported in original paper
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias High risk Potential confounding from unbalanced
neuraxial analgesia use 18 in regional anaes-
thesia, 3 in general anaesthesia group
Pesonen 2011
Methods Design: Randomised controlled trial of pregabalin as an opioid-sparing agent in elderly
patients after cardiac surgery
Date of study: April 2008-September 2009
Power calculation: Yes
Frequency of outcomes assessment: Preoperatively and on postoperative days 1-5
Inclusion criteria: Aged 75 years and over and undergoing primary elective coronary
artery bypass grafting with cardiopulmonary bypass (CPB) or single valve repair or
replacement with CPB
Exclusion criteria: Left ventricular ejection fraction < 30%, acute renal failure or chronic
kidney disease (creatinine > 150 micromol/L), liver disease, congestive cardiac failure,
type I diabetes mellitus, neurological disease other than transient ischaemic attack, pre-
operative infections, BMI > 35, psychiatric disease or alcohol abuse, chronic pain syn-
drome and recent use of gabapentinoids
Participants Number in study: 70
Country: Finland
Setting: Cardiac surgery patients at University teaching hospital
Age: Median age 79.5 years (IQR 75-89) in intervention group, 79.6 years (IQR 75-91)
in control group
Sex: 40% female in intervention group, 54% female in control group
Co-morbidity: No baseline between-group differences in TIA, hypertension, diabetes or
COPD
Dementia: Not reported
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Pesonen 2011 (Continued)
Interventions Intervention: Patients were premedicated orally 1 hour before surgery with lorazepam
(0.02-0.03 mg/kg) and the study drug, pregabalin 150 mg (Lyrica 75 mg capsule, Pﬁzer
GmbH, Freiburg, Germany) or placebo. Beginning on the ﬁrst postoperative morning,
patients received 75 mg pregabalin or placebo twice daily until the ﬁfth postoperative
day
Control: Patients received matching placebo
Outcomes 1. Delirium, measured using CAM-ICU (continuous score) - not included in meta-
analysis
2. Length of admission
3. Cognition, mean CAM-ICU score on day 5
4. Psychotropic medication use
5. Withdrawal from protocol
Notes Funding source:HelsinkiUniversityHospital Research Fund and Finska Lakaresallskapet
(Finnish Medical Association)
Declarations of interest: “No conﬂicts of interest declared”
Continuous score ofCAM-ICUreported as opposed todeliriumpresent/absent so unable
to use data in outcome table
Continuous delirium score slightly higher on postoperative day 1 in intervention group
(median 24 versus 21, P = 0.04), but no differences on days 2, 3, 4 or 5
Delirium not excluded at admission
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Pharmacy conducted randomisation
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical placebo used
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/70 patients randomised excluded from
analysis; 6 from intervention, and 4 from
control group
Selective reporting (reporting bias) Unclear risk Insufﬁecient information to assess
Other bias Low risk No evidence of other bias
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Radtke 2013
Methods Design: parallel group randomised controlled trial
Date of study: March 2009-May 2010
Power calculation: Yes but stopped early so study underpowered
Frequency of outcomes assessment: days 1-7 postoperatively and at 3 months
Inclusion criteria: aged 60 years or older; planned for elective surgery lasting at least 60
minutes
Exclusion criteria: MMSE < 24; history of neurologic deﬁcits; participation in pharma-
ceutical study; not planned for general anaesthesia; did not speak language of authors;
unable to provide written consent
Participants Number in study: 1277
Country: Berlin
Setting: Two campuses of university hospital
Age: Mean age 69.7 (SD 6.3) in intervention group, 70.1 (SD 6.5) in control group
Sex: 44.7% of intervention group were female with 47.6% in the control group
Co-morbidity: Not reported
Dementia: Excluded based on MMSE
Interventions Intervention: BIS data were allowed to be included in the management of anaesthesia
Control: Anaesthesia was provided with blinded BIS monitoring; unblinding of moni-
toring was allowed if it was deemed necessary for the patient’s beneﬁt
Outcomes 1. Incident delirium, using DSM-IV
2. Mortality, at 3 months
3. Length of admission
4. Cognitive status (Postoperative cognitive dysfunction)
Notes Funding source: Charite-Universitatsmedizin Berlin and Aspect Medical Systems (now
Covidien)
Declarations of interest: “None declared”
Delirium not excluded at enrolment
Stopped early due to lack of funding
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Method for allocation concealment unclear
Random sequence generation (selection
bias)
Unclear risk Not clearly described - “patients were con-
secutively recruited and after stratiﬁcation
electronically randomised into two study
groups”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Allocation of anaesthetist dependent on
whether for intervention or control so
blinding not possible and unblinding of
group in ~10% of cases
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Radtke 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment performed by trained
medical personnel under Psychiatrist su-
pervision, blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk n = 1277 participants randomised, out-
come assessment available for n = 1155. n =
45 in intervention group and n = 39 in con-
trol group did not receive their allocated
intervention and were excluded from the
analysis
Of n = 593 assigned to intervention n = 18
were lost to follow-up (n = 575 analysed).
Of n = 600 assigned to control n = 20 were
lost to follow-up (n = 580 analysed)
9.6% of randomised participants do not
have outcome data
Selective reporting (reporting bias) Low risk ISRCTN registration with protocol, out-
comes reported in accordance with proto-
col
Other bias Low risk No evidence of other bias
Sampson 2007
Methods Design: Randomised double-blind controlled trial of donepezil in patients undergoing
elective total hip replacement surgery
Date of study: October 2003 to January 2004
Power calculation: No
Frequency of outcomes assessment: Three times daily for duration of treatment + 1 day
after
Inclusion criteria: All consenting patients undergoing elective hip replacement and at-
tending pre-admission assessment clinic
Exclusion criteria:MMSE less than26, sensory impairment, hypersensitivity to donepezil
or piperidine derivatives, or contraindications to donepezil
Participants Number in study: 50
Country: UK
Setting: One orthopaedic department in teaching hospital
Age mean (SD) Intervention 69.7 (8.4), Placebo 65.1 (11.1) P = 0.1
Sex % male: Intervention 57.9, Placebo 42.9 P = 0.39
Co-morbidity: Not reported
Dementia: Not assessed, MMSE < 26 excluded
Interventions Intervention: Donepezil 5 mg starting postoperatively on returning to orthopaedic ward,
every 24 hours for 3 days
Control: Identical placebo
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Sampson 2007 (Continued)
Outcomes 1. Incident delirium measured using Delirium Symptom Interview
2. Length of hospital admission
3. Adverse events
Notes Funding source: Unrestricted educational grant from Pﬁzer Esai, UK
Declarations of interest: Not reported
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation concealment managed centrally
by pharmacy
Random sequence generation (selection
bias)
Unclear risk Block randomisation method but sequence
generation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matched placebo used so participants and
personnel blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors not aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk 50 participants randomised, outcome as-
sessment available for 33 (n = 19 in inter-
vention group, n = 14 in control group)
. Surgery cancelled for 7 participants, 10
withdrew consent
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other bias
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Sieber 2010
Methods Design: Randomised controlled trial of light sedation during spinal anaesthesia for re-
ducing postoperative delirium in elderly hip fracture patients
Date of study: April 2005-October 2008
Power calculation: Yes
Frequency of outcomes assessment: Daily from second postoperative day
Inclusion criteria: Aged 65 years and over undergoing hip fracture repair with spinal
anaesthesia and propofol sedation
Exclusion criteria: Contraindications to spinal anaesthesia, prior hip surgery, mental or
language barriers that would preclude data collection, severe heart failure, severe COPD
Participants Number in study: 114
Country: USA
Setting: Hip fracture patients
Age: Mean age 81.2 years (SD 7.6) in intervention group, 81.8 years (SD 6.7) in control
group
Sex: 70% female in intervention group, 75% female in control group
Co-morbidity: Mean Charlson comorbidity index score 1.6 (1.2) in intervention group,
1.4 (1.4) in control group
Dementia: 37% in intervention group, 33% in control group
Interventions Intervention: Sedation was provided during surgery by a propofol infusion targeted to a
bispectral index (BIS) of 80 or higher in the light sedation group
Control: Sedation was provided during surgery by a propofol infusion targeted to a
bispectral index (BIS) of approximately 50 in the deep sedation group
In general, these targets render the light sedation group responsive to voice and the heavy
sedation group unresponsive to noxious stimuli
Outcomes 1. Incident delirium, measured using CAM
2. Duration of delirium
3. Length of admission
4. Mortality (in hospital, at 1-year and overall)
5. Cognition using MMSE on postoperative day 2
6. Postoperative complications (Patients with >=1 complications)
Notes Funding source: Not reported
Declarations of interest: Not reported
Light sedation group received signiﬁcantly more midazolam (5.5 mg/kg vs 1.3 mg/kg, P
= 0.02). Mean BIS in light sedation group 85.7 (11.3) vs 49.9 (13.5) control P < 0.001
Exclusion of patients with MMSE<15 limits generalisability of ﬁndings
Delirium excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Method of concealing allocation not clearly
described
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Sieber 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of generating sequence not clearly
described: “randomised block design with
random length blocks.....incorporated a
stratiﬁcation scheme for age and cognitive
impairment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study teammembers, patient and physi-
cian blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Deliriumassessments conducted by trained
research nurse blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis performed. No
withdrawals.
Selective reporting (reporting bias) Unclear risk Protocol for the study approved by John
Hopkins Medicine Institutional Review
Board but this is not publicly available
Other bias Low risk No evidence of other bias
Stoppe 2013
Methods Design: Randomised controlled trial
Date of study: Study dates not reported
Power calculation: Yes
Frequency of outcomes assessment: daily postoperatively
Inclusion criteria: undergoing elective isolated coronary artery bypass grafting (CABG)
with the use of cardiopulmonary by-pass (CPB); age > 50 years; ASA physical status II-IV;
preserved cardiac function (left ventricular ejection fraction > 50%) and EuroSCORE <
or equal to 8
Exclusion criteria: cardiac, respiratory, liver or renal failure; acute coronary syndrome
within 24 hours before surgery; haemodynamic instability; emergency operations; lack
of informed consent; severe neurological dysfunction; depression; a geriatric depression
score (GDS) > 5; MMSE <24; patients with a predisposition to malignant hyperther-
mia and/or hypersensitivity to the study drugs; women with childbearing potential or
pregnancy
Participants Number in study: 30
Country: Germany
Setting: Cardiac surgery inpatients
Age: Mean age 66 (48-81) in xenon group; 68 (51-79) in sevoﬂurane group
Sex: 80% of both groups were male
Co-morbidity: not reported at baseline
Dementia: MMSE< 24 were excluded
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Stoppe 2013 (Continued)
Interventions Both groups received induction of anaesthesia with propofol and sufentanil. Muscle
relaxation was obtained with rocuronium. Anaesthetic depth was adjusted by titration of
end-expiratory xenonor sevoﬂurane concentrations according to changes in physiological
parameters and BIS values. During CPB, patients received a propofol infusion instead
of xenon or sevoﬂurane
Xenon: Maintenance of anaesthesia was achieved by continuous infusion of sufentanil
and xenon (end-expiratory concentrations of 45-50 vol%)
Sevoﬂurane: Maintenance of anaesthesia was achieved by continuous infusion of sufen-
tanil and sevoﬂurane (end-expiratory concentrations of 1-1.4 vol%)
Outcomes 1. Incidence of delirium, using CAM-ICU
2. Mortality
3. Length of stay
4. Adverse events
Notes Funding source: Deutsche Forschungsgemeinschaft (DFG) grants
Declarations of interest: “MC and RR received lecture and consultant fees from Air
Liquide Sante International, a company interested in developing clinical applications for
medical gases, including xenon”
Delirium not clearly excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Method not described
Random sequence generation (selection
bias)
Unclear risk Method not described, states patients “ran-
domly assigned to receive....”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and staff not clearly blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessments conducted
by trained study scientists blinded to allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients were included in
the analysis
Selective reporting (reporting bias) Low risk Protocol registered on ClinicalTrials.gov
and trial reported in accordance with pub-
lished protocol
Other bias Low risk No evidence of other bias
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Urban 2008
Methods Design: Randomised controlled trial of ketamine as an adjunct to postoperative pain
management after spinal fusion
Date of study: Study dates not reported
Power calculation: Yes
Frequency of outcomes assessment: Postoperative day 1
Inclusion criteria: Patients scheduled for elective lumbar spinal fusions who were taking
opioids on a daily basis
Exclusion criteria: Any patients who remained at a pain numerical rating scale of 10 after
2 hours
Participants Number in study: 26
Country: USA
Setting: Patients scheduled for elective lumbar spinal fusions
Age: Mean age 53 years (SD 12) in intervention group, 48 years (SD 9) in control group
Sex: Not reported
Co-morbidity: Not reported
Dementia: Not reported
Interventions Intervention: Patients in the ketamine group received 0.2 mg/kg on induction of general
anaesthesia and then 2 mcg/kg/hr until discharge from the post-anaesthesia care unit
Control: All patients received a general anaesthetic with midazolam 5 mg, 70% nitrous
oxide, 0.4% isoﬂurane, fentanyl at 1-2 mcg/kg/hr and propofol at 70-100 mg/hr. Spinal
morphine (10 mcg/kg) was administered at instrumentation
Outcomes 1) Incident delirium, measured using CAM on postoperative day 1
Notes Funding source: Department of Anesthesia, Hospital for Special Surgery, New York
Declarations of interest: Not reported
Delirium not excluded at enrolment
Study author conclusion: use of ketamine as an adjunct to postoperative pain manage-
ment in opioid tolerant patients after spinal fusion reduced postoperative pain. There
was no effect on delirium
Small trial (n = 24). Only reported delirium on postoperative day 1
Concern about the integrity of the intervention 3 in control failed their initial pain
management and were converted to IV ketamine
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Random sequence generation (selection
bias)
Low risk Computer generated randomisation se-
quence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients blinded but the physicians and
nurses were cognitive of the groups
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Urban 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors (physical therapists)
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis performed as
there was cross-over between intervention
and control groups
However, two patients excluded after ran-
domised so no outcome assessment data in-
cluded
Any patients who remained at a numeri-
cal rating scale of 10 after 2 hours were ex-
cluded
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to assess
Other bias Low risk No evidence of other bias
Watne 2014
Methods Design: Randomised controlled trial comparing care in an acute geriatric ward or stan-
dard orthopaedic ward following hip fracture
Date of study: September 2009 - January 2012
Power calculation: Yes but powered for primary outcome of cognitive function not
delirium
Frequency of outcomes assessment: Daily using CAM preoperatively and until the ﬁfth
postoperative day or for patients with delirium until discharge
Inclusion criteria: All acute admissions to Oslo University Hospital with a hip fracture
Exclusion criteria: Hip fracture due to high energy trauma (deﬁned as a fall from higher
than one metre) or if they were moribund on admission
Participants Number in study: 332 randomised; 329 included in analyses
Country: Norway
Setting: University hospital
Age: Mean age 84 years (range: 55 to 99) for intervention group and 85 years (range: 46
to 101)
Sex: Male sex 42 (26%) for intervention group; 38 (23%) for controls
Co-morbidity: Not reported
Dementia: 49% in both intervention and control groups diagnosis by expert evaluation
Interventions Intervention: Acute geriatric ward - 20 bed ward mainly admitting patients suffering
from acute medical disorder superimposed upon frailty, co-morbidities and polyphar-
macy. Comprehensive Geriatric Assessment was the basis for treatment planning. Assess-
ment by geriatrician, nurse, physiotherapist and occupational therapists was expected
during their ﬁrst day on the ward and this team had daily meetings to plan discharge.
Checklists and clinical routines based on published literature and previous experience.
These included medication reviews, optimal pain control, correction of physiological
disturbances preoperatively and postoperatively (hypoxaemia, anaemia, electrolyte dis-
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Watne 2014 (Continued)
turbances, acid-base disturbances, dehydration, hypotension, blood sugar etc), early and
intensive mobilisation, optimising pre and postoperative nutrition and early discharge
planning. Outpatient orthopaedic clinic at 4 months
Control: Usual care in orthopaedic ward setting. Stafﬁng levels were similar but there
was no multidisciplinary meetings and no geriatric assessments. Early mobilisation was
emphasised and patients were seen by a physiotherapist soon after surgery. Outpatient
orthopaedic clinic at 4 months
Outcomes 1. Incident delirium using CAM
2. Delirium duration (days)
3. Delirium severity using MDAS
4. Length of stay
5. In-hospital mortality
6. New care home residence at four and 12 months
7. Cognitive function at four months using composite outcome
8. Incident dementia at 12 months
9. ADL function using Barthel Index at four months
10. Falls
11. Pressure ulcers
13. Postoperative complications
Notes Funding source: Research Council of Norway through the program ‘Improving mental
health of older people through multidisciplinary efforts’ (Grant No: 187980/H10) plus
Oslo University Hospital, The Sophies Minde Foundation, The Norweigan Association
for Public Health and Civitan’s Research Foundation
Declaration of interest: The authors declare ‘they have no competing interests’
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Allocation by sealed opaque numbered en-
velopes
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
(blocks of variable and unknown size) car-
ried-out by statistician not involved in clin-
ical service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible due to nature of in-
tervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Delirium assessments; performed by study
nurse/geriatrician aware of allocation
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Watne 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 moribund patients erroneously ran-
domised were excluded from the analysis (2
from intervention and 1 from control arm)
Selective reporting (reporting bias) Low risk Study reported in accordance with pub-
lished protocol
Other bias High risk Where a bed was not available in the spe-
cialist geriatric unit, care was received in
the corridor. As a result there are concerns
about the ﬁdelity of the intervention as a
delirium prevention intervention as not all
participants had the entire length of stay in
either unit
Whitlock 2015
Methods Design: Randomised double-blind controlled trial of methylprednisolone in patients
at high risk of morbidity and mortality undergoing cardiac surgery with the use of
cardiopulmonary bypass
Date of study: June 2007 - December 2013
Power calculation: Yes but based on primary outcome of 30-day mortality
Frequency of outcomes assessment: Once on postoperative day 3
Inclusion criteria: Patients aged 18 years or older with European System for Cardiac
Operative Risk Evaluation (EuroSCORE) of at least 6 (or from 2011, at least 4 if from
India or China) and providing written informed consent
Exclusion criteria: Taking or expected to receive systemic steroids in immediate post-
operative period; history of bacterial or fungal infection in preceding 30 days; allergy
or intolerance to steroids; expected to receive aprotinin; previously participated in this
study
Participants Number in study: 7507
Country: Multinational, 18 countries
Setting: Hospital-based cardiac surgery practices
Age: Mean age 67.5 years (SD 13.6) in intervention group; 67.3 years (SD 13.8) for
controls
Sex: Male sex 2257 (60%) in intervention group; 2280 (61%) in controls
Co-morbidity: Data reported on extensive list of coexisting medical conditions, no im-
balances between groups
Dementia:Not speciﬁcally assessed; participants had toprovidewritten informed consent
Interventions Intervention: Intravenous methylprednisolone (250 mg at anaesthetic induction and
250 mg at initiation of cardiopulmonary bypass)
Control: Matched placebo
Outcomes 1. Incident delirium on postoperative day 3 using CAM
2. Length of hospital stay
3. Mortality at 30 days
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Whitlock 2015 (Continued)
4. Physical morbidity (myocardial injury; stroke; respiratory failure; infection)
Notes Funding source: Canadian Institutes of Health Research
Declaration of interest: Authors report ‘no conﬂicts to declare’
Delirium not excluded at enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Centralised computerised systemwith drug
prepared by local pharmacy
Random sequence generation (selection
bias)
Low risk Block randomisation with random block
sizes of 2, 4 or 6 stratiﬁed by centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants received intraoperative
medication; healthcare providers blinded
to medication administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data collection and outcome assessment
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis presented
Selective reporting (reporting bias) Low risk Outcomes reported as per published pro-
tocol
Other bias Low risk No evidence of other bias
ADL: activities of daily living; BIS: Bispectral index; BMI: bodymass index;CAM:ConfusionAssessmentMethod;CNS: central nervous
system; COPD: chronic obstructive pulmonary disease; DRS-R-98: Delirium Rating Scale Revised 98; DSI: Delirium Symptom
Interview; DSM: Diagnostic and Statistical Manual; FICB: fascia iliaca compartment block; Hb: haemoglobin; IM: intramuscular;
INR: International Normalised Ratio; IQR: interquartile range; IV: intravascular; mcg: micrograms; MDAS: Memorial Delirium
Assessment Scale; MMSE: Mini Mental State Examination; OBS: organic brain syndrome; PCA: patient controlled analgesia; SD:
standard deviation; RCT: randomised controlled trial; TIA: transient ischaemic attack
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al Tamimi 2015a ICU study.
Astaneh 2007 Not a randomised controlled trial.
Baldwin 2004 The intervention was not designed to prevent delirium. Cognitive impairment rather than delirium was used
as an outcome measure
Benedict 2009 Not a randomised controlled trial.
Bolotin 2014 A validated method for diagnosis of delirium was not used.
Brueckmann 2015 A validated method for diagnosis of delirium was not used.
Budd 1974 A validated method for diagnosis of delirium was not used.
Caplan 2006 Study not in hospitalised patients - active intervention in community setting
Cerchietti 2000 Not a delirium prevention study.
Colak 2015 A validated method for diagnosis of delirium was not used.
Cole 2002 Not a delirium prevention study.
Culp 2003 Randomisation not used and participants were long-term care residents
De Jonghe 2007 Not a randomised controlled trial.
Del Rosario 2008 Not a randomised controlled trial.
Ding 2015 PACU study.
Ding 2015a PACU study.
Ely 2004a ICU study.
Ely 2004b ICU study.
Finotto 2006 ICU study.
Gamberini 2009 ICU study.
Hsieh 2015 ICU study.
Hu 2006 Treatment study.
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(Continued)
Hudetz 2009 ICU study.
Hudetz 2015 ICU study.
Hwang 2015 ICU study.
Inouye 1993a Not original research- review article.
Inouye 1999 Randomisation not used.
Kaneko 1999 A validated method for delirium diagnosis was not used. Although DSM-IIIR diagnostic criteria used, data
obtained from retrospective chart review
Kat 2008 Not a randomised controlled trial.
Lackner 2008 Nursing home setting.
Landefeld 1995 Outcomes examined did not include delirium.
Lili 2013 Not delirium prevention.
Lundstrom 2005 Randomisation not used.
Maneeton 2007 Not a randomised controlled trial.
Marcantonio 2010 Post-acute care, not hospital setting.
Mardani 2013 ICU study.
Marino 2009 A validated method for diagnosis of delirium was not used.
Mentes 2003 Randomisation not used.
Meybohm 2015 ICU study.
Milisen 2001 Not a randomised controlled trial. Before and after study.
Mudge 2008 Not a randomised controlled trial.
Myint 2013 Delirium not used as an outcome measure.
Naughton 2005 Randomisation not used.
Neri 2010 Not in hospitalised patients.
Oldenbeuving 2008 Treatment study.
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Overshott 2010 Treatment study.
Pandharipande 2010 ICU study.
Parker 2015 A validated method for diagnosis of delirium was not used.
Parra Sanchez 2009 ICU study.
Perkisas 2015 Commentary.
Pitkala 2006 Treatment study.
Prakanrattana 2007 ICU study.
Pretto 2014 A validated method for diagnosis of delirium was not used.
Ritchie 2008 No recruitment, trial stopped.
Saager 2015 ICU study.
Sauer 2014 ICU study.
Short 2015 Not a delirium prevention study.
Shu 2010 ICU study and method of delirium diagnosis not validated.
Tabatabaie 2015 Not a randomised controlled trial. Retrospective observational study
Tabet 2005 Randomisation not used.
Takeuchi 2007 Treatment study and not randomised controlled trial.
Tokita 2001 A validated method for diagnosis of delirium was not used. Delirium diagnosis relied on retrospective records
review
Torres 2015 A validated method for diagnosis of delirium was not used.
van de Steeg 2014 Primary outcome is screening for incidence of delirium; unable to report incidence of delirium as ﬁrst date
of delirium diagnosis is not recorded
Wang 2012 ICU study.
Wanich 1992 Not a delirium prevention study.
Wong 2005 Not a randomised controlled study. Before and after study.
Yamaguchi 2014 ICU study.
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Yang 2015 ICU study.
DSM-IIR: Diagnostic and Statistical Manual
ICU: Intensive Care Unit
PACU: post-anaesthesia care unit
Characteristics of ongoing studies [ordered by study ID]
Al Tmimi 2015
Trial name or title Xenon for the prevention of post-operative delirium in cardiac surgery: study protocol for a randomised
controlled clinical trial
Methods Randomised controlled trial
Participants 190 patients, older than 65 years, and scheduled for elective cardiac surgery with use of cardiopulmonary
bypass
Interventions Group 1: General anaesthesia with xenon
Group 2: General anaesthesia with sevoﬂurane
Outcomes Primary outcome: Incidence of postoperative delirium during the ﬁrst 5 postoperative days measured using
3D-CAM or CAM-ICU
Secondary outcomes: Duration of postoperative delirium (total number of days and percentage of patients
with duration of longer than 2 days; delirium severity; use of physical restraints; postoperative cognitive
function; ADL; use of anti delirium medication; duration of sedation; duration of ICU and hospital stay;
adverse events
Starting date May 2013
Contact information layth.altmimi@uzleuven.be
1 Department of Anesthesiology, KU Leuven - University of Leuven, University
Hospitals of Leuven, Herestraat 49, B-3000 Leuven, Belgium
Notes EudraCT Identiﬁer: 2014-005370-11. Will need to differentiate between ICU and non-ICU delirium in
results
Avidan 2009
Trial name or title BAG-RECALL Study: BIS or anesthesia gas to reduce explicit recall
Methods Phase IV double-blind multi-centre randomised controlled trial
Participants Patients aged over 18 undergoing surgery assessed as high risk for awareness requiring general anaesthesia
121Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Avidan 2009 (Continued)
Interventions Group 1: Bispectral index-guided anaesthesia (target range 40-60)
Group 2: End-tidal anaesthetic gas-guided anaesthesia (target range 0.7-1.3 age-adjusted minimum alveolar
concentration)
Outcomes Primary outcome: Awareness with explicit recall during surgical and anaesthetic periods
Secondary outcomes: postoperative delirium, postoperative mortality, psychological symptoms, postoperative
pain
Starting date March 2008
Contact information Michael Avidan
avidanm@wustl.edu
Notes ClinicalTrials.gov identiﬁer: NCT00682825
Completed December 2010. Published N Engl J Med 2011 Aug 18;365(7):591-601 but delirium outcome
not reported yet
Avidan 2015
Trial name or title The prevention of delirium and complications associated with surgical treatments multi-centre clinical
trial (PODCAST)
Methods Phase 3 double-blind randomised controlled trial
Participants Patients 60 and over undergoing major surgery and able to provide informed consent
Interventions Intervention: Drug: Low-dose (sub-anaesthetic) ketamine (0.5 mg/kg) following induction of anaesthesia or
administration of sedative medications
Placebo Comparator: Intravenous normal saline
Outcomes Primary outcomes: Incidence of postoperative delirium within three days of surgery (assessed by the CAM or
CAM-ICU)
Secondary outcomes: Postoperative acute pain within three postoperative days (assessed by visual analogue
pain scale)
Starting date November 2013
Contact information Michael Avidan
avidanm@anest.wustl.edu
Notes ClinicalTrials.gov identiﬁer: NCT01690988
Estimated primary completion date June 2015
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Beilin 2010
Trial name or title The effect of physostigmine on cognitive functioning in the immediate period after sedation for colonoscopy
Methods Double-blind randomised controlled trial
Participants Patients over18 years old, ASA I-III, ﬂuency in Hebrew, Russian, or Arabic, without serious hearing or visual
impairment
Interventions Intervention: Physostigmine Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of
colonoscopy
Comparator: no physostigmine
Outcomes Primary outcome: Cognitive functioning at time of hospital discharge
Starting date July 2010
Contact information beilinb@clalit.org.il
Bezion Beilin, Hasharon Hospital, Rabin Medical Center
Notes ClinicalTrials.gov identiﬁer: NCT01121497
Estimated Primary Completion Date: July 2011
Bekker 2008
Trial name or title Rivastigmine prophylaxis in elderly patients at risk for delirium: a randomised, double-blind placebo-con-
trolled pilot study
Methods Phase IV double-blind randomised controlled trial
Participants 65 years and older undergoing major elective surgery greater than 2 hours duration with any of preoperative
cognitive impairment, age >70, use of psychotropic medications, previous history of delirium, severe illness/
comorbidity
Interventions Intervention: Rivastigmine patch delivering 4.6 mg/24hrs applied to upper back preoperatively for 24 hrs
Control: A gauze and Tegaderm dressing applied to upper back within 3 hrs of surgery for 24 hrs
Outcomes Primary outcome: postoperative delirium within 72 hours of surgery (CAM-ICU)
Secondary outcomes: delirium episodes, delirium severity (MDAS), length of hospital stay, cognitive function
at 1 and 3 months postoperatively
Starting date December 2008
Contact information Alex Bekker, NYU School of Medicine, New York
Notes ClinicalTrials.gov identiﬁer: NCT00835159
Data not available to us; manuscript in preparation. New York study, sponsored by Novartis. Study closed
prematurely because of emerging safety concerns with this group of drugs, encouraged by Novartis
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Brzezinski 2012
Trial name or title Effect of prophylactic, perioperative propranolol on peri- and postoperative complications in patients With
Post Traumatic Stress Disorder
Methods Randomised double-blind placebo-controlled trial
Participants Patients over 40 with full or subthreshold PTSD of threemonths duration admitted for any surgical procedure
(except open-heart or intracranial surgery) requiring general or combined general-regional anaesthesia and an
overnight hospital stay
Interventions Experimental: Drug: Propranolol hydrochloride will be taken for a total of 14 days commencing on the
morning of surgery
Comparator: Placebo pill will be taken for a total of 14 days commencing on the morning of surgery
Outcomes Primary outcomes: Postoperative delirium (assessed using CAM, CAM-ICU), ICU length of stay, hospital
length of stay, postoperative renal dysfunction
Secondary outcomes: peri- and postoperative complications, pain intensity, PTSD symptoms, use of anal-
gesics, length of mechanical ventilation, quality of life, functional status, sleep quality, depression symptoms,
postoperative neurocognitive dysfunction score, mortality
Starting date May 2012
Contact information brzezinm@anesthesia.ucsf.edu
curt.johanson@va.gov
Notes ClinicalTrials.gov identiﬁer: NCT01555554
Estimated primary completion date December 2013
Chan 2010
Trial name or title The effect of periarticular multi-drug regimen on pain after partial hip replacement
Methods Double-blind randomised controlled trial
Participants Patients admitted with femoral neck fracture, or for partial hip replacement
Interventions Intervention: oral administration of oxycodone SR 10 mg and celecoxib 200 mg with 10 mL of water 1 hour
before surgery and intraoperative periarticular injection of 50 mL solution containing ropivacaine 15 mg,
epinephrine 0.3 mg, cefmetazole 1000 mg, ketorolac 30 mg and morphine HCL 10 mg before wound closure
Control: no medication preoperatively or intraoperatively
Outcomes Primary outcome: pain visual analogue scale (VAS) on postoperative days 1, 4 and 7
Secondary outcomes: opioid consumption on postoperative days 1, 4 and 7, frequency of use of patient
controlled analgesia (PCA) on post operative days 1, 4 and 7, delirium (delirium rating scale) on postoperative
days 1, 4 and 7
Starting date May 2010
Contact information Yong Chan Ha ksdeok@cau.ac.kr
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Chan 2010 (Continued)
Notes ClinicalTrials.gov identiﬁer: NCT01112436
Correspondence with author suggests patients are assessed on surgical wards
Estimated ﬁnal data collection for primary outcome April 2012
Chaput 2009
Trial name or title A randomised, double-blind, placebo-controlled trial to assess the safety and efﬁcacy of the perioperative
administration of pregabalin in reducing the incidence of postoperative delirium and improving acute post-
operative pain management
Methods Randomised double-blind placebo-controlled trial
Participants Patients aged 60 years and older, admitted for major orthopaedic or vascular surgery with expected length of
stay > 2 days
Interventions Intervention: Pregabalin 75 mg given preoperatively, then either 50 mg or 25 mg every 8 hours for 3 days
postoperatively (based on renal function)
Control: Placebo
Outcomes Primary outcome: Delirium (CAM-ICU positive)
Secondary outcomes: Interference with daily activities (BPI), pain at rest and onmovement of the operative site
(NRS), Narcotic analgesic requirements, Sedation (RSS),Narcotic-related adverse effects (ORSDS), Recovery
using the QoR, length of stay, Medical Outcome Study (MOS) sleep score
Starting date May 2009
Contact information Dr. A. Chaput, Ottawa Hospital Research Institute
Notes ClinicalTrials.gov identiﬁer: NCT00819988
Correspondence with author suggests delirium assessed on wards
This study has been completed.
Coburn 2012
Trial name or title An international, multi-centre randomised controlled trial evaluating the effect of xenon on post-operative
delirium in elderly patients undergoing hip fracture surgery
Methods Multi-centre double-blind randomised controlled trial
Participants Patients aged 75 and over with hip fracture and surgery planned within 48 hours and able to provide informed
consent
Interventions Intervention: Xenon 60% (1 MAC) in oxygen (FiO2 0.35-0.45)
Control: Sevoﬂurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
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Coburn 2012 (Continued)
Outcomes Primary outcome: Postoperative delirium (CAM) within four days post-surgery
Secondary outcomes: Postoperative delirium (CAM) from day 5 postoperatively until discharge, sequential
organ failure assessment from day 1 to day 4 post-surgery, recovery parameters, safety and health economic
parameters
Starting date September 2010
Contact information Steffen Rex
steffen.rex@uzleuven.be
Notes ClinicalTrials.gov identiﬁer NCT01199276
Estimated completion date December 2013
Diehl 2006
Trial name or title Prevention of post-operative delirium with donepezil
Methods Double-blind randomised controlled trial
Participants Patients 70 Years and older, cognitively healthy, elective hip or knee replacement
Interventions Intervention: Donepezil before (over 5-7 days), during and after (over 7 days) surgery
Control: Placebo
Outcomes Primary outcome: Incidence of delirium
Secondary outcome: Cognitive performance
Starting date January 2006
Contact information Janine Diehl, M. D. Dept. of Psychiatry, Technische Universitaet Muenchen
Notes ClinicalTrials.gov identiﬁer NCT00220896
This study has now been completed
Fernandez-Robles 2012
Trial name or title Usefulness of bright light therapy in the prevention of delirium in patients undergoing Hematopoietic Stem
Cell Transplant (HSCT)
Methods Pilot double-blind randomised placebo-controlled study
Participants Patients aged 18 and over undergoing HSCT
Interventions Intervention: Bright light therapy (2500 Lux gaze directed every morning from 8 am until 8:30 am)
Control: Placebo sham light (<1000 Lux gaze directed every morning from 8 am until 8:30 am)
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Fernandez-Robles 2012 (Continued)
Outcomes Primary outcome: Delirium incidence and time to development of delirium (Delirium Rating Scale-Revised-
98 and/or Memorial Delirium Assessment Scale)
Secondary outcomes: Length and severity of delirium episodes, dose of antipsychotic medications required
to manage delirium, hospital length of stay, adverse events (falls, aspiration, infections, nutritional deﬁcits)
Starting date October 2012
Contact information Carlos Fernandez-Robles
cfernandez-robles@partners.org
Justin Eusebio
jeusebio@partners.org
Notes ClinicalTrials.gov identiﬁer: NCT01700816
Estimated primary completion date April 2014
Fischer 2009
Trial name or title Tailored patient management guided with absolute cerebral oximetry to prevent neurocognitive injury in
elderly patients undergoing cardiac surgery
Methods Double-blind randomised controlled trial
Participants Patients 65 and older admitted for elective cardiac or thoracic aortic surgery, able to provide informed consent
Interventions Intervention: Optimisation of cerebral oxygenation within 5 minutes once cerebral desaturation (SctO2 < 60
%) has been established
Control: No intervention in this arm if the Sct02 falls below 60%
Outcomes Primary outcome: Postoperative delirium and postoperative cognitive dysfunction within 5 days of surgery
Secondary outcome: Postoperative morbidity and mortality
Starting date September 2009
Contact information Gregory Fischer
gregory.ﬁscher@mountsinai.org
Notes ClinicalTrials.gov identiﬁer: NCT00991328
Estimated Primary Completion Date: June 2010
Foss 2006
Trial name or title Incidence of delirium in hip fracture patients randomized to regular hypnotics vs placebo
Methods Randomised controlled trial
Participants 70 years and older admitted for hip fracture
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Foss 2006 (Continued)
Interventions Intervention: Zolpidem 5 mg daily in perioperative period
Control: Placebo tablet in perioperative period
Outcomes Primary outcome: Incidence and severity of postoperative delirium
Secondary outcomes: Sleep quality. mobilisation, loss of functional ability, length of stay, sedation, nocturnal
nursing events
Starting date February 2004
Contact information Nicolai B Foss, MD, Hvidovre University Hospital
Notes Clinical trials identiﬁer: NCT00286936
Hua 2010
Trial name or title Inﬂuence of multi-modal analgesia with parecoxib and morphine on post-surgical delirium in elderly patients
Methods Single-blind randomised controlled trial
Participants Patients aged 60 years and over admitted for elective non-cardiac surgery
Interventions Intervention: multi-modal analgesia with parecoxib and morphine PCA
Control: opioid PCA
Outcomes Primary outcomes: Pain at rest and on movement, delirium diagnosis with CAM-ICU from 1 to 7 days after
operation
Secondary outcomes: adverse postoperative events, 28 day survival, hepatic and renal function at 48 hours,
delirium (CAM-ICU) assessed twice daily with CAM-ICU
Starting date December 2010
Contact information Zhen Hua: hua1013@163.com
Notes ChiCTR-TRC-10001063
http://www.chictr.org/en/proj/show.aspx?proj=342
Katznelson 2010
Trial name or title Post-operative melatonin administration and delirium prevention in patients undergoing vascular and cardiac
surgery
Methods Double-blind randomised controlled trial
Participants Patients over 60 admitted for non-emergency vascular surgery with expected length of hospital stay > 48
hours, ASA category I to IV and able to provide informed consent
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Katznelson 2010 (Continued)
Interventions Intervention: Melatonin 5 mg sublingually given at 9 pm for 5 days postoperatively or until discharge
Control: placebo
Outcomes Primary outcome: incidence of postoperative delirium (assessment up to day 7 postoperatively)
Secondary outcome: pain visual analogue score
Starting date August 2010
Contact information Rita Katznelson, Toronto General Hospital, UHN, Toronto, Ontario, Canada
Notes ClinicalTrials.gov identiﬁer: NCT01198938
Study completed February 2013
Mouchoux 2011
Trial name or title CONFUCIUS Study : Impact of a multi-faceted program to prevent postoperative delirium in the elderly
Methods Stepped wedge cluster-randomised controlled trial
Participants Patients aged over 75 admitted for scheduled surgery
Interventions Intervention: Preoperative geriatric consultation performed by a mobile geriatric team, training of surgical
ward staff and implementation of HELP (Hospital Elder Life Program), morbidity and mortality conferences
related to delirium cases
Control: Usual care
Outcomes Primary outcome: Postoperative delirium rate within 7 days after surgery (assessed using the CAM)
Secondary outcomes: Mean delirium intensity, length of hospital stay, postoperative complications 30 days
after surgery incidence, mortality 6 months after surgery, feasibility of the multi-disciplinary prevention
program
Starting date March 2011
Contact information christelle.mouchoux@chu-lyon.fr
Notes ClinicalTrials.gov identiﬁer: NCT01316965
Estimated primary completion date March 2013
Sponsors: Hospices Civils de Lyon
Nadler 2014
Trial name or title Does positive airway pressure therapy reduce the incidence of post-operative delirium in patients at risk for
obstructive sleep apnoea?
Methods Randomised controlled trial of continuous positive airways pressure
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Nadler 2014 (Continued)
Participants Patients at risk of obstructive sleep apnoea (OSA) (STOP-BANG score>2, untreated for OSA undergoing
elective joint replacement
Interventions Continuous Positive Airway Pressure (CPAP) prior to surgery and on postoperative days 0, 1 and 2 vs. routine
perioperative care
Outcomes Incidence of delirium assessed using CAM and DRS-R-98
Starting date Not reported
Contact information Not reported
Notes
Nanayakkara 2011
Trial name or title Early pharmacological intervention to prevent delirium: Haloperidol prophylaxis in older emergency depart-
ment patients
Methods Multi-centre double-blind randomised placebo-controlled trial
Participants Patients aged 70 or over, admitted to a medical or surgical specialty and at risk of delirium according to one
or more positive answers on the VMS delirium-risk questions
Interventions Intervention: Haloperidol 1 mg twice daily at 12 am and 8 pm, orally
Control: Placebo 1 mg twice-daily at 12 am and 8 pm, orally
Outcomes Primary outcome: Incident delirium and delirium duration (measured with Delirium Observation Screening
(DOS) score)
Secondary outcome Measures: Time to develop delirium, length of stay, ; The (mean) number of days
participants are admitted to the hospital; change from baseline function at 3 and 6 months (ADL scale),
change from baseline instrumental activities at 3 and 6 months (Instrumental ADL scale); mortality
Starting date November 2012
Contact information p.nanayakkara@vumc.nl
Notes ClinicalTrials.gov identiﬁer: NCT01530308
Estimated primary completion date April 2014
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Privitera 2006
Trial name or title Namenda to prevent post-operative delirium
Methods Double-blind randomised placebo-controlled trial
Participants Patients over 50, medically stable admitted for elective joint replacement under general anaesthetic
Interventions Intervention: Memantine 10 mg once daily orally 8 days prior to procedure and 4 days postoperatively
Control: Placebo orally once daily 8 days prior to procedure and 4 days postoperatively
Outcomes Incidence and severity of delirium measured with the Delirium Rating Scale Revised-98, MMSE, CAM,
Clock Drawing Test, DSM-IV-TR criteria for delirium
Starting date March 2006
Contact information M Privitera, University of Rochester, USA
Notes ClinicalTrials.gov identiﬁer: NCT00303433
Terminated early December 2009 (under-recruitment)
Schrijver 2014
Trial name or title Efﬁcacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk
patients acutely admitted to hospital through the emergency department: study protocol of a multicenter,
randomised, double-blind, placebo-controlled clinical trial (HARPOON study)
Methods Randomised controlled trial
Participants 390 patients aged 70 years and older admitted through the emergency department for general medicine and
surgical specialties
Interventions Prophylactic haloperidol 1 mg or placebo twice daily for seven days
Outcomes Incidence of delirium, severity of delirium, duration of delirium, adverse events, length of stay, all cause
mortality, institutionalisation, instrumental ADL, cognitive function
Starting date TBC
Contact information Edmee Schrijver. ej.schrijver@vumc.nl
Notes ClinicalTrials.gov identiﬁer NCT01530308
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Silverstein 2008
Trial name or title Perioperative cognitive function - dexmedetomidine and cognitive reserve
Methods Multi-centre double-blind randomised placebo-controlled trial
Participants 68 years and older, undergoing elective major surgery under general anaesthesia, ASA grade I-III, MMSE >20
Interventions Intervention: Precedex (dexmedetomidine). 0.5/ug/kg/hr. Dexmedetomidine infusions will begin prior to
the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated
postoperatively for 2 hrs postoperatively
Control: Placebo infusion.
Outcomes Primary outcome: Delirium Battery post-surgery and then daily for 5 days then at 3 and 6 months
Secondary outcomes: Neuropsychological testing at 3 and 6 months
Starting date February 2008
Contact information Jeff Silverstein, Mount Sinai School of Medicine
jeff.silverstein@mountsinai.org
Notes ClinicalTrials.gov identiﬁer: NCT00561678
Estimated Primary Completion Date: June 2013
Spies 2009
Trial name or title Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative
cognitive dysfunction: a prospective, randomised, controlled, double-blinded, two-armed single-centre trial
Methods Phase IV double-blind randomised placebo-controlled trial
Participants Patients over 18 undergoing elective liver resection with or without additional elective surgery in the same
session, able to provide informed consent, negative pregnancy testing (beta-human chorionic gonadotrophin
[B-HCG])
Interventions During liver resection:
1. 24-hour perioperative intravenous administration of physostigmine (0.02 mg/kg BW as bolus and 0.01
mg/kg BW/hr (for 24 hours) from the beginning of the operation
2. 24-hour perioperative intravenous administration of placebo over 24 hrs
Outcomes Primary outcomes: Incident delirium (DSM-IV criteria), measured preoperatively and up to hospital dis-
charge, Cambridge Neurophysiological Test Automated Battery (CANTAB), measured preoperatively, on the
7th, 90th and 365th postoperative day
Secondary outcomes: Delirium; Evaluation of intensive care unit performance, Length of postoperative hos-
pital stay, Length of postoperative ICU stay, pain, postoperative complications and organ dysfunction, rate
of systemic inﬂammatory response syndrome (SIRS) and infection, quality of life questionnaires, mortality,
postoperative survival at 90 days, 6 months and one year, immune parameters, perioperative assessment of
sleep stage, parameters of haematology, parameters of renal function
Starting date August 2009
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Spies 2009 (Continued)
Contact information gerrit.ﬂeige@charite.de
Notes ISRCTN18978802
Anticipated end date: April 2016
Strijbos 2013
Trial name or title Design and methods of the Hospital Elder Life Program (HELP), a multi component targeted intervention
to prevent delirium in hospitalised older patients: efﬁcacy and cost-effectiveness in Dutch health care
Methods Cluster-randomised controlled trial (stepped wedge)
Participants Patients aged 70 years and over at risk for delirium and admitted to cardiology, internal medicine, geriatrics,
orthopedics and surgery
Interventions Multi-component targeted delirium prevention intervention (Hospital Elder Life Program)
Outcomes Incidence of delirium, duration of delirium, severity of delirium, quality of life, length of stay, use of care
services
Starting date TBC
Contact information m.strijbos@umcutrecht.nl
Notes Netherlands trial register NTR3842
Thomas 2012
Trial name or title Does femoral nerve catheterization reduce the incidence of post-operative delirium in patients presenting for
hip fracture repair?
Methods Randomised controlled trial
Participants Patients aged 50 and over presenting with a hip fracture
Interventions Intervention: Preoperative femoral nerve catheterisation
Control: Intravenous opioids given postoperatively
Outcomes Primary outcome: Rate of postoperative delirium up to 3 days
Secondary outcomes: length of stay, pain score (VAS) and consumption of analgesic medication
Starting date March 2012
Contact information lesthomas@ochsner.org
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Thomas 2012 (Continued)
Notes ClinicalTrials.gov identiﬁer: NCT01547468
Estimated date of primary completion March 2015
van der Burg 2005
Trial name or title Randomised double-blind placebo-controlled study of post-operative haloperidol versus placebo for preven-
tion of post-operative delirium after acute hip surgery
Methods Double-blind randomised placebo-controlled study
Participants Patients aged 75 and over undergoing surgery for hip fracture
Interventions Intervention: Haloperidol 1 mg twice daily for 72 hours
Control: Placebo 1 mg twice daily for 72 hours
Outcomes Primary outcomes: Incidence of postoperative delirium in 72 hours postoperative period
Secondary outcomes: Length of stay; mortality; ADL dependence at 3 months; adverse outcomes
Starting date November 2005
Contact information Boke Linso Sjirk Borger van der Burg, Department of Surgery, Bronovo Hospital
Notes ClinicalTrials.gov identiﬁer: NCT00250237
Study completed October 2008. Results not published.
Wang 2012a
Trial name or title Effects of two different anaesthesia-analgesia methods on the incidence of post-operative delirium: a multi-
centre, randomized controlled trial
Methods Multi-centre randomised controlled trial
Participants Patients aged 60-90 years undergoing elective major (more than two hours) open abdominal or thoracic (non-
cardiovascular) surgery, able to provide informed consent
Interventions Intervention: Combined epidural and general anaesthesia (Epi-GA) with postoperative patient controlled
epidural analgesia (PGEA)
Control: General anaesthesia and patient controlled intravenous analgesia (PCIA)
Outcomes Primary outcome: Incidence of postoperative delirium.
Secondary outcomes: Incidence of postoperative complications, 30-day mortality, VAS pain score, duration
of postoperative hospital stay, daily prevalence of postoperative delirium (7 days)
Starting date November 2011
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Wang 2012a (Continued)
Contact information Yuan Zeng
yuan˙zeng@sina.com
Notes ClinicalTrials.gov identiﬁer: NCT01661907
Estimated primary completion date October 2014
Young 2015
Trial name or title Prevention of Delirium (POD) for older people in hospital: protocol for a randomised controlled feasibility
study
Methods Cluster-randomised controlled trial
Participants Patients, aged 65 years and over, admitted to a participating orthopaedic trauma or geriatric medicine
Interventions Intervention: A manualised, multi-component intervention and systematic implementation process
Control: Usual care
Outcomes Primary outcome: New onset delirium
Secondary outcomes: Number, severity and length of delirium episodes (including persistent delirium); length
of stay in hospital; in-hospital mortality; destination at discharge; health-related quality of life and health
resource use; physical and social independence; anxiety and depression; patient experience
Starting date 13/03/2014
Contact information s.hartley@leeds.ac.uk
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
University of Leeds, Leeds LS2 9JT, UK
Notes Trial registration: ISRCTN01187372
ADL: activities of daily living; CAM:ConfusionAssessmentMethod;DSM-IIR:Diagnostic and StatisticalManual; ICU: Intensive Care
Unit; MDAS:Memorial Delirium Assessment Scale; MMSE: Mini Mental State Examination; PCA: patient controlled analgesia;
PTSD: post-traumatic stress disorder
135Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Multi-component delirium prevention intervention (MCI) versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 7 1950 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.59, 0.81]
1.1 Medical patients 4 1365 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.43, 0.92]
1.2 Surgical patients 3 585 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.59, 0.85]
2 Incidence of delirium in patients
with dementia
1 50 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.59, 1.36]
2.1 Surgical patients 1 50 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.59, 1.36]
3 Duration of delirium 4 244 Mean Difference (IV, Random, 95% CI) -1.16 [-2.96, 0.64]
3.1 Medical patients 2 63 Mean Difference (IV, Random, 95% CI) -0.65 [-2.43, 1.13]
3.2 Surgical patients 2 181 Mean Difference (IV, Random, 95% CI) -2.40 [-7.27, 2.46]
4 Severity of delirium 2 67 Std. Mean Difference (IV, Random, 95% CI) -1.04 [-1.65, -0.43]
4.1 Medical patients 1 36 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.46, -0.08]
4.2 Surgical patients 1 31 Std. Mean Difference (IV, Random, 95% CI) -1.39 [-2.20, -0.58]
5 Length of admission 6 1920 Mean Difference (IV, Random, 95% CI) 0.01 [-0.48, 0.51]
5.1 Medical patients 3 1335 Mean Difference (IV, Random, 95% CI) 0.04 [-0.44, 0.52]
5.2 Surgical patients 3 585 Mean Difference (IV, Random, 95% CI) -1.24 [-4.74, 2.25]
6 Cognition 1 60 Mean Difference (IV, Random, 95% CI) 9.10 [7.20, 11.00]
6.1 Medical patients 1 60 Mean Difference (IV, Random, 95% CI) 9.10 [7.20, 11.00]
7 Improvement in Activities of
Daily Living
1 341 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.91, 1.47]
7.1 Medical patients 1 341 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.91, 1.47]
8 Return to independent living 4 1116 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.85, 1.06]
8.1 Medical patients 1 648 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.06]
8.2 Surgical patients 3 468 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.75, 1.19]
9 Depression 1 149 Mean Difference (IV, Random, 95% CI) 0.70 [-0.44, 1.84]
9.1 Surgical patients 1 149 Mean Difference (IV, Random, 95% CI) 0.70 [-0.44, 1.84]
10 Withdrawal from protocol 1 126 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Surgical patients 1 126 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Falls 3 746 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.16, 2.01]
11.1 Medical patients 1 287 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.03]
11.2 Surgical patients 2 459 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.18, 3.46]
12 Pressure ulcers 2 457 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.26, 0.89]
12.1 Surgical patients 2 457 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.26, 0.89]
13 Inpatient mortality 3 859 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.56, 1.43]
13.1 Medical patients 1 400 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.34, 1.18]
13.2 Surgical patients 2 459 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.69, 3.05]
14 12 month mortality 1 199 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.46, 1.56]
14.1 Surgical patients 1 199 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.46, 1.56]
15 Cardiovascular complication 1 260 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.78, 1.65]
16 Urinary tract infection 1 260 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.45, 3.20]
17 Mental health worsened 1 246 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.64, 1.20]
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Comparison 2. Prophylactic cholinesterase inhibitor versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 2 113 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.17, 2.62]
1.1 Donepezil 2 113 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.17, 2.62]
2 Duration of delirium 1 15 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Donepezil 1 15 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Severity of delirium 1 16 Mean Difference (IV, Random, 95% CI) -0.30 [-4.17, 3.57]
3.1 Donepezil 1 16 Mean Difference (IV, Random, 95% CI) -0.30 [-4.17, 3.57]
4 Length of admission 3 128 Mean Difference (IV, Random, 95% CI) -0.34 [-1.54, 0.86]
4.1 Donepezil 3 128 Mean Difference (IV, Random, 95% CI) -0.34 [-1.54, 0.86]
5 Cognition 1 15 Mean Difference (IV, Random, 95% CI) -1.40 [-4.45, 1.65]
5.1 Donepezil 1 15 Mean Difference (IV, Random, 95% CI) -1.40 [-4.45, 1.65]
6 Withdrawal from protocol 2 96 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.49, 1.87]
6.1 Donepezil 2 96 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.49, 1.87]
7 Adverse events (continuous) 1 33 Mean Difference (IV, Random, 95% CI) 0.13 [-0.26, 0.52]
7.1 Donepezil 1 33 Mean Difference (IV, Random, 95% CI) 0.13 [-0.26, 0.52]
8 Adverse events (binary) 1 16 Risk Ratio (M-H, Random, 95% CI) 6.25 [0.35, 112.52]
Comparison 3. Prophylactic antipsychotic versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 3 916 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.33, 1.59]
1.1 Haloperidol 2 516 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.69, 1.60]
1.2 Olanzapine 1 400 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.24, 0.52]
2 Duration of delirium 2 178 Mean Difference (IV, Random, 95% CI) -2.74 [-9.59, 4.11]
2.1 Haloperidol 1 68 Mean Difference (IV, Random, 95% CI) -6.4 [-9.38, -3.42]
2.2 Olanzapine 1 110 Mean Difference (IV, Random, 95% CI) 0.60 [0.10, 1.10]
3 Severity of delirium 2 178 Mean Difference (IV, Random, 95% CI) -1.02 [-6.80, 4.76]
3.1 Haloperidol 1 68 Mean Difference (IV, Random, 95% CI) -2.00 [-5.86, -2.14]
3.2 Olanzapine 1 110 Mean Difference (IV, Random, 95% CI) 1.90 [0.41, 3.39]
4 Length of admission 1 68 Mean Difference (IV, Random, 95% CI) -5.5 [-12.17, 1.17]
4.1 Haloperidol 1 68 Mean Difference (IV, Random, 95% CI) -5.5 [-12.17, 1.17]
5 Cognition 1 110 Mean Difference (IV, Random, 95% CI) -4.90 [-7.42, -2.38]
6 Withdrawal from protocol 2 925 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.68, 1.24]
6.1 Haloperidol 1 430 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.43, 1.26]
6.2 Olanzapine 1 495 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.71, 1.46]
7 Adverse events 1 430 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.10, 1.43]
7.1 Haloperidol 1 430 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.10, 1.43]
8 Pneumonia 1 400 Risk Ratio (M-H, Random, 95% CI) 7.28 [0.38, 140.11]
9 Urinary tract infection 1 400 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.03, 2.31]
10 Congestive heart failure 1 400 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.07, 16.52]
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Comparison 4. Prophylactic melatonin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 3 529 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.09, 1.89]
2 Duration of delirium 1 104 Mean Difference (IV, Random, 95% CI) 0.0 [-0.57, 0.57]
3 Severity of delirium (binary
severe vs. not severe)
1 104 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.58, 1.27]
4 Severity of delirium (DRS-R-98) 1 6 Mean Difference (IV, Random, 95% CI) -4.10 [-19.47, 11.
27]
5 Length of admission 2 500 Mean Difference (IV, Random, 95% CI) 0.09 [-1.20, 1.39]
6 Cognitive impairment 1 378 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.70, 1.04]
7 Activities of daily living 1 369 Mean Difference (IV, Random, 95% CI) 0.0 [-1.20, 1.20]
8 Use of psychotropic medication
(binary)
1 122 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.18]
9 Antipsychotic medication use
(cumulative)
1 378 Mean Difference (IV, Random, 95% CI) -1.0 [-1.79, -0.21]
10 Benzodiazepine use
(cumulative)
1 378 Mean Difference (IV, Random, 95% CI) -11.60 [-24.34, 1.
14]
11 Withdrawal from study 2 165 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.15, 6.87]
12 In-hospital mortality 3 543 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.37, 1.88]
13 Mortality by 3 months 1 378 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.67, 1.45]
14 Adverse events 1 43 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Prophylactic citicoline versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Incident delirium day 1
post surgery
1 80 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.22, 2.06]
2 Cognitive status 1 81 Mean Difference (IV, Random, 95% CI) -1.47 [-3.85, 0.91]
Comparison 6. Oral premedication with diazepam and diphenhydramine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 49 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 7. Intravenous methylprednisolone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 7507 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.87, 1.19]
2 Length of admission 1 7507 Mean Difference (IV, Random, 95% CI) 0.0 [-0.20, 0.20]
3 Mortality at 30 days 1 7507 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.07]
4 Myocardial injury 1 7507 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.07, 1.38]
5 Respiratory failure 1 7507 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.05]
6 Infection 1 7507 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.84, 1.06]
Comparison 8. Gabapentinoids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 21 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.01, 1.90]
2 Length of admission 1 60 Mean Difference (IV, Random, 95% CI) -0.60 [-2.12, 0.92]
3 Cognition 1 60 Mean Difference (IV, Random, 95% CI) 1.0 [-2.76, 4.76]
4 Psychotropic Medication Use 1 60 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.21, 1.38]
5 Withdrawal from protocol 1 70 Risk Ratio (M-H, Random, 95% CI) 9.00 [0.50, 161.13]
Comparison 9. Ketamine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 24 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.21, 19.23]
2 Withdrawal from protocol 1 26 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.34]
Comparison 10. Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 80 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.26, 0.98]
2 Length of admission 1 80 Mean Difference (IV, Random, 95% CI) -0.90 [-1.58, -0.22]
3 Postoperative cognitive
dysfunction at 3 days
1 80 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.21, 1.02]
4 Postoperative cognitive
dysfunction at 1 week
1 80 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.15, 0.98]
5 Postoperative cognitive
dysfunction at 3 months
1 80 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.09, 1.01]
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6 Postoperative cognitive
dysfunction at 6 months
1 80 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.02, 1.11]
Comparison 11. Intrathecal morphine and PCA morphine versus PCA morphine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 52 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.44, 1.85]
2 Length of admission 1 52 Mean Difference (IV, Random, 95% CI) -0.5 [-1.51, 0.51]
3 Cognition - days for MMSE to
return to preoperative level
1 52 Mean Difference (IV, Random, 95% CI) 0.20 [-1.03, 1.43]
4 Withdrawal from protocol 1 59 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.19, 3.17]
5 Mortality 1 59 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.13]
Comparison 12. Fascia iliaca compartment block (FICB) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 207 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.24, 0.87]
2 Severity of delirium 1 36 Mean Difference (IV, Random, 95% CI) -4.30 [-6.81, -1.79]
3 Duration of delirium 1 36 Mean Difference (IV, Random, 95% CI) -5.7 [-9.50, -1.90]
4 Mortality 1 219 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.05, 5.58]
Comparison 13. Light versus deep propofol sedation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 114 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.26, 0.89]
2 Duration of delirium 1 34 Mean Difference (IV, Random, 95% CI) -0.60 [-3.30, 2.10]
3 Length of admission 1 114 Mean Difference (IV, Random, 95% CI) 0.20 [-0.80, 1.20]
4 Cognition on day 2 1 114 Mean Difference (IV, Random, 95% CI) 3.10 [0.30, 5.90]
5 In-hospital mortality 1 114 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.36]
6 Postoperative complications
(>=1)
1 114 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.60, 1.26]
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Comparison 14. Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 2 2057 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.60, 0.85]
2 Length of admission 2 2057 Mean Difference (IV, Random, 95% CI) -0.94 [-1.45, -0.43]
3 Cognition at 7 days 2 1938 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.71, 1.05]
4 Cognition at 3 months 2 1990 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.53, 0.97]
5 SF-36 mental summary score 1 902 Mean Difference (IV, Random, 95% CI) -1.90 [-3.40, -0.40]
6 Mortality at 7 days 1 921 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.42, 5.25]
7 Mortality at 3 months 2 1938 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.77, 1.59]
8 Cardiac complications 1 902 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.52, 1.39]
9 Respiratory complications 1 902 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.59, 1.07]
10 Infective complications 1 902 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.95]
Comparison 15. Sevoflurane versus propofol anaesthesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 385 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.47, 1.34]
2 Mortality at 12 months 1 385 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.70, 2.02]
Comparison 16. Xenon versus sevoflurane anaesthesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 30 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.20, 2.79]
2 Length of admission 1 30 Mean Difference (IV, Random, 95% CI) 4.0 [-1.72, 9.72]
3 In-hospital mortality 1 30 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events 1 30 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.34, 1.64]
5 Sepsis 1 30 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.29, 7.73]
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Comparison 17. Epidural anaesthesia versus general anaesthesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 2 104 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.69, 2.03]
2 Length of admission > 10 days 1 47 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.28, 1.24]
3 Cognitive decline 1 47 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.02, 1.06]
4 Urinary tract infection 1 57 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.57, 3.09]
5 Psychological morbidity 1 57 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.23, 4.71]
5.1 Depression 1 57 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.23, 4.71]
6 Postoperative complications 1 47 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.35, 2.39]
7 Pressure ulcer 1 57 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.16, 2.36]
Comparison 18. Liberal versus restrictive blood transfusion thresholds
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 108 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.45, 1.27]
2 Delirium severity 1 38 Mean Difference (IV, Random, 95% CI) -0.10 [-2.99, 2.79]
3 Length of admission 1 138 Mean Difference (IV, Random, 95% CI) -0.10 [-1.36, 1.16]
4 Psychoactive medication use 1 138 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
5 Infection 1 138 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.23, 5.22]
6 Congestive heart failure 1 138 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.05, 5.88]
Comparison 19. Fast-track surgery versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 233 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.09, 0.77]
2 Length of admission 1 233 Mean Difference (IV, Random, 95% CI) -4.20 [-4.60, -3.80]
3 Urinary tract infection 1 233 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.14, 1.04]
4 Heart failure 1 233 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.10, 0.91]
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Comparison 20. Postoperative delirium-free protocol (DFP) versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 40 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.02, 1.06]
2 Length of admission 1 40 Mean Difference (IV, Fixed, 95% CI) -4.30 [-12.51, 3.91]
3 Behavioural disturbance 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.03, 1.56]
Comparison 21. Computerised clinical decision support system (CCDS) versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 424 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.82, 1.43]
2 Length of admission 1 424 Mean Difference (IV, Random, 95% CI) 0.90 [-0.35, 2.15]
3 Mortality within 30 days of
discharge
1 424 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.49, 2.23]
4 Falls 1 424 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.39, 2.19]
5 Pressure ulcers 1 424 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.64, 1.84]
Comparison 22. Geriatric unit care versus orthopaedic unit care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident delirium 1 329 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.79, 1.22]
2 Duration of delirium 1 163 Mean Difference (IV, Random, 95% CI) -1.0 [-2.04, 0.04]
3 Severity of delirium 1 163 Mean Difference (IV, Random, 95% CI) 1.5 [1.00, 4.00]
4 Length of admission 1 329 Mean Difference (IV, Random, 95% CI) 3.0 [1.94, 4.06]
5 Cognitive function (composite
score) at 4 months
1 228 Mean Difference (IV, Random, 95% CI) 1.80 [-5.92, 9.52]
6 Incident dementia at 12 months 1 193 Risk Ratio (M-H, Random, 95% CI) 2.26 [0.60, 8.49]
7 ADL function at 4 months 1 239 Mean Difference (IV, Random, 95% CI) 1.0 [-0.70, 2.70]
8 Institutionalisation at 4 months 1 242 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.58, 1.91]
9 Institutionalisation at 12 months 1 193 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.47, 1.59]
10 Inpatient mortality 1 329 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.21, 1.47]
11 Falls 1 329 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.61, 2.77]
12 Pressure ulcers 1 329 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.10, 1.41]
13 Other medical adverse events 1 329 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.76, 1.23]
14 Postoperative complications 1 329 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.20, 2.36]
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Analysis 1.1. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 1 Incident delirium
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical patients
Abizanda 2011 27/186 39/184 12.8 % 0.68 [ 0.44, 1.07 ]
Bonaventura 2007 0/30 5/30 0.3 % 0.09 [ 0.01, 1.57 ]
Jeffs 2013 15/305 21/343 6.1 % 0.80 [ 0.42, 1.53 ]
Martinez 2012 8/144 19/143 4.0 % 0.42 [ 0.19, 0.92 ]
Subtotal (95% CI) 665 700 23.3 % 0.63 [ 0.43, 0.92 ]
Total events: 50 (MCI), 84 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.53, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.40 (P = 0.016)
2 Surgical patients
Hempenius 2013 12/127 19/133 5.5 % 0.66 [ 0.33, 1.31 ]
Lundstrom 2007 56/102 73/97 57.9 % 0.73 [ 0.59, 0.90 ]
Marcantonio 2001 20/62 32/64 13.4 % 0.65 [ 0.42, 1.00 ]
Subtotal (95% CI) 291 294 76.7 % 0.71 [ 0.59, 0.85 ]
Total events: 88 (MCI), 124 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.70 (P = 0.00021)
Total (95% CI) 956 994 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 138 (MCI), 208 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.32, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 4.53 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.56), I2 =0.0%
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Analysis 1.2. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 2 Incidence of delirium in patients with dementia.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 2 Incidence of delirium in patients with dementia
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Surgical patients
Marcantonio 2001 13/21 20/29 100.0 % 0.90 [ 0.59, 1.36 ]
Total (95% CI) 21 29 100.0 % 0.90 [ 0.59, 1.36 ]
Total events: 13 (MCI), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 3 Duration of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 3 Duration of delirium
Study or subgroup MCI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medical patients
Jeffs 2013 15 2.4 (5.93) 21 2.1 (3.85) 17.2 % 0.30 [ -3.12, 3.72 ]
Martinez 2012 19 2 (0.74) 8 3 (2.96) 28.4 % -1.00 [ -3.08, 1.08 ]
Subtotal (95% CI) 34 29 45.6 % -0.65 [ -2.43, 1.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Surgical patients
Lundstrom 2007 56 5 (7.1) 73 10.2 (13.3) 16.3 % -5.20 [ -8.77, -1.63 ]
Marcantonio 2001 20 2.9 (2) 32 3.1 (2.3) 38.1 % -0.20 [ -1.38, 0.98 ]
Subtotal (95% CI) 76 105 54.4 % -2.40 [ -7.27, 2.46 ]
Heterogeneity: Tau2 = 10.66; Chi2 = 6.78, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 110 134 100.0 % -1.16 [ -2.96, 0.64 ]
Heterogeneity: Tau2 = 1.85; Chi2 = 7.18, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.4. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 4 Severity of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 4 Severity of delirium
Study or subgroup MCI Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medical patients
Jeffs 2013 15 3 (1.48) 21 4 (1.11) 56.2 % -0.77 [ -1.46, -0.08 ]
Subtotal (95% CI) 15 21 56.2 % -0.77 [ -1.46, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 Surgical patients
Hempenius 2013 12 9 (4.5) 19 15 (4) 43.8 % -1.39 [ -2.20, -0.58 ]
Subtotal (95% CI) 12 19 43.8 % -1.39 [ -2.20, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00078)
Total (95% CI) 27 40 100.0 % -1.04 [ -1.65, -0.43 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 3.35 (P = 0.00080)
Test for subgroup differences: Chi2 = 1.33, df = 1 (P = 0.25), I2 =25%
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Analysis 1.5. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 5 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 5 Length of admission
Study or subgroup MCI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medical patients
Abizanda 2011 198 9.1 (5.1) 202 8.7 (4.8) 21.7 % 0.40 [ -0.57, 1.37 ]
Jeffs 2013 305 5.5 (3.93) 343 5.6 (4.22) 41.9 % -0.10 [ -0.73, 0.53 ]
Martinez 2012 144 9 (5.2) 143 9 (5.2) 15.1 % 0.0 [ -1.20, 1.20 ]
Subtotal (95% CI) 647 688 78.6 % 0.04 [ -0.44, 0.52 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Surgical patients
Hempenius 2013 127 8 (22.3) 133 8 (7.2) 1.5 % 0.0 [ -4.07, 4.07 ]
Lundstrom 2007 102 28 (17.9) 97 38 (40.6) 0.3 % -10.00 [ -18.79, -1.21 ]
Marcantonio 2001 62 5 (2.96) 64 5 (2.96) 19.6 % 0.0 [ -1.03, 1.03 ]
Subtotal (95% CI) 291 294 21.4 % -1.24 [ -4.74, 2.25 ]
Heterogeneity: Tau2 = 5.49; Chi2 = 4.90, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.70 (P = 0.49)
Total (95% CI) 938 982 100.0 % 0.01 [ -0.48, 0.51 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.71, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.48), I2 =0.0%
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Analysis 1.6. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 6 Cognition.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 6 Cognition
Study or subgroup MCI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medical patients
Bonaventura 2007 30 27.4 (1.5) 30 18.3 (5.1) 100.0 % 9.10 [ 7.20, 11.00 ]
Total (95% CI) 30 30 100.0 % 9.10 [ 7.20, 11.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 7 Improvement in Activities of Daily Living.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 7 Improvement in Activities of Daily Living
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical patients
Abizanda 2011 82/173 69/168 100.0 % 1.15 [ 0.91, 1.47 ]
Total (95% CI) 173 168 100.0 % 1.15 [ 0.91, 1.47 ]
Total events: 82 (MCI), 69 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
MCI Control
149Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 8 Return to independent living.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 8 Return to independent living
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical patients
Jeffs 2013 221/305 258/343 51.9 % 0.96 [ 0.88, 1.06 ]
Subtotal (95% CI) 305 343 51.9 % 0.96 [ 0.88, 1.06 ]
Total events: 221 (MCI), 258 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
2 Surgical patients
Hempenius 2013 76/113 87/110 29.6 % 0.85 [ 0.72, 1.00 ]
Lundstrom 2007 48/64 37/55 17.4 % 1.11 [ 0.88, 1.41 ]
Marcantonio 2001 5/62 8/64 1.0 % 0.65 [ 0.22, 1.86 ]
Subtotal (95% CI) 239 229 48.1 % 0.94 [ 0.75, 1.19 ]
Total events: 129 (MCI), 132 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.99, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 544 572 100.0 % 0.95 [ 0.85, 1.06 ]
Total events: 350 (MCI), 390 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.26, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
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Analysis 1.9. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 9 Depression.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 9 Depression
Study or subgroup MCI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Surgical patients
Lundstrom 2007 81 5.2 (3.6) 68 4.5 (3.5) 100.0 % 0.70 [ -0.44, 1.84 ]
Total (95% CI) 81 68 100.0 % 0.70 [ -0.44, 1.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 10 Withdrawal from protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 10 Withdrawal from protocol
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Surgical patients
Marcantonio 2001 0/62 0/64 Not estimable
Total (95% CI) 62 64 Not estimable
Total events: 0 (MCI), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.11. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 11 Falls.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 11 Falls
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical patients
Martinez 2012 0/144 4/143 14.4 % 0.11 [ 0.01, 2.03 ]
Subtotal (95% CI) 144 143 14.4 % 0.11 [ 0.01, 2.03 ]
Total events: 0 (MCI), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Surgical patients
Hempenius 2013 4/127 2/133 29.9 % 2.09 [ 0.39, 11.24 ]
Lundstrom 2007 12/102 26/97 55.7 % 0.44 [ 0.23, 0.82 ]
Subtotal (95% CI) 229 230 85.6 % 0.78 [ 0.18, 3.46 ]
Total events: 16 (MCI), 28 (Control)
Heterogeneity: Tau2 = 0.81; Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 373 373 100.0 % 0.57 [ 0.16, 2.01 ]
Total events: 16 (MCI), 32 (Control)
Heterogeneity: Tau2 = 0.63; Chi2 = 4.00, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 1.38, df = 1 (P = 0.24), I2 =28%
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Analysis 1.12. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 12 Pressure ulcers.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 12 Pressure ulcers
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Surgical patients
Hempenius 2013 5/127 7/133 29.7 % 0.75 [ 0.24, 2.30 ]
Lundstrom 2007 9/102 21/95 70.3 % 0.40 [ 0.19, 0.83 ]
Total (95% CI) 229 228 100.0 % 0.48 [ 0.26, 0.89 ]
Total events: 14 (MCI), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 13 Inpatient mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 13 Inpatient mortality
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Medical patients
Abizanda 2011 15/198 24/202 68.2 % 0.64 [ 0.34, 1.18 ]
Subtotal (95% CI) 198 202 68.2 % 0.64 [ 0.34, 1.18 ]
Total events: 15 (MCI), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
2 Surgical patients
Hempenius 2013 10/127 4/133 11.2 % 2.62 [ 0.84, 8.14 ]
Lundstrom 2007 6/102 7/97 20.6 % 0.82 [ 0.28, 2.34 ]
Subtotal (95% CI) 229 230 31.8 % 1.45 [ 0.69, 3.05 ]
Total events: 16 (MCI), 11 (Control)
Heterogeneity: Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 427 432 100.0 % 0.90 [ 0.56, 1.43 ]
Total events: 31 (MCI), 35 (Control)
Heterogeneity: Chi2 = 4.64, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 2.80, df = 1 (P = 0.09), I2 =64%
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Analysis 1.14. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 14 12 month mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 14 12 month mortality
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Surgical patients
Lundstrom 2007 16/102 18/97 100.0 % 0.85 [ 0.46, 1.56 ]
Total (95% CI) 102 97 100.0 % 0.85 [ 0.46, 1.56 ]
Total events: 16 (MCI), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 15 Cardiovascular complication.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 15 Cardiovascular complication
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hempenius 2013 40/127 37/133 100.0 % 1.13 [ 0.78, 1.65 ]
Total (95% CI) 127 133 100.0 % 1.13 [ 0.78, 1.65 ]
Total events: 40 (MCI), 37 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 16 Urinary tract infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 16 Urinary tract infection
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hempenius 2013 8/127 7/133 100.0 % 1.20 [ 0.45, 3.20 ]
Total (95% CI) 127 133 100.0 % 1.20 [ 0.45, 3.20 ]
Total events: 8 (MCI), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Multi-component delirium prevention intervention (MCI) versus usual care,
Outcome 17 Mental health worsened.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 1 Multi-component delirium prevention intervention (MCI) versus usual care
Outcome: 17 Mental health worsened
Study or subgroup MCI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hempenius 2013 43/117 54/129 100.0 % 0.88 [ 0.64, 1.20 ]
Total (95% CI) 117 129 100.0 % 0.88 [ 0.64, 1.20 ]
Total events: 43 (MCI), 54 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 1 Incident delirium
Study or subgroup
Cholinesterase
inhibitor Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Donepezil
Liptzin 2005 8/39 7/41 59.0 % 1.20 [ 0.48, 3.00 ]
Sampson 2007 2/19 5/14 41.0 % 0.29 [ 0.07, 1.30 ]
Total (95% CI) 58 55 100.0 % 0.68 [ 0.17, 2.62 ]
Total events: 10 (Cholinesterase inhibitor), 12 (Control)
Heterogeneity: Tau2 = 0.59; Chi2 = 2.50, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 2 Duration of
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 2 Duration of delirium
Study or subgroup
Cholinesterase
inhibitor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Donepezil
Liptzin 2005 8 1 (0) 7 1.3 (0.5) Not estimable
Total (95% CI) 8 7 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.3. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 3 Severity of
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 3 Severity of delirium
Study or subgroup
Cholinesterase
inhibitor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Donepezil
Marcantonio 2011 7 1.3 (2.5) 9 1.6 (5.2) 100.0 % -0.30 [ -4.17, 3.57 ]
Total (95% CI) 7 9 100.0 % -0.30 [ -4.17, 3.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 4 Length of
admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 4 Length of admission
Study or subgroup
Cholinesterase
inhibitor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Donepezil
Liptzin 2005 39 4.4 (0.81) 41 4.2 (0.51) 61.9 % 0.20 [ -0.10, 0.50 ]
Munger 2008 6 3.5 (2) 9 4 (2) 22.0 % -0.50 [ -2.57, 1.57 ]
Sampson 2007 19 9.9 (3.2) 14 12.1 (4.1) 16.1 % -2.20 [ -4.79, 0.39 ]
Total (95% CI) 64 64 100.0 % -0.34 [ -1.54, 0.86 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 3.66, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 5 Cognition.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 5 Cognition
Study or subgroup
Cholinesterase
inhibitor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Donepezil
Munger 2008 6 25.3 (2.7) 9 26.7 (3.3) 100.0 % -1.40 [ -4.45, 1.65 ]
Total (95% CI) 6 9 100.0 % -1.40 [ -4.45, 1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 6 Withdrawal
from protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 6 Withdrawal from protocol
Study or subgroup
Cholinesterase
inhibitor Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Donepezil
Liptzin 2005 11/39 11/41 89.1 % 1.05 [ 0.52, 2.14 ]
Marcantonio 2011 1/7 3/9 10.9 % 0.43 [ 0.06, 3.28 ]
Total (95% CI) 46 50 100.0 % 0.95 [ 0.49, 1.87 ]
Total events: 12 (Cholinesterase inhibitor), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 7 Adverse
events (continuous).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 7 Adverse events (continuous)
Study or subgroup
Cholinesterase
inhibitor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Donepezil
Sampson 2007 19 1.84 (0.5) 14 1.71 (0.61) 100.0 % 0.13 [ -0.26, 0.52 ]
Total (95% CI) 19 14 100.0 % 0.13 [ -0.26, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Prophylactic cholinesterase inhibitor versus placebo, Outcome 8 Adverse
events (binary).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 2 Prophylactic cholinesterase inhibitor versus placebo
Outcome: 8 Adverse events (binary)
Study or subgroup
Cholinesterase
inhibitor Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Marcantonio 2011 2/7 0/9 100.0 % 6.25 [ 0.35, 112.52 ]
Total (95% CI) 7 9 100.0 % 6.25 [ 0.35, 112.52 ]
Total events: 2 (Cholinesterase inhibitor), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Prophylactic antipsychotic versus control, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 1 Incident delirium
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Haloperidol
Fukata 2014 25/59 20/62 32.7 % 1.31 [ 0.82, 2.10 ]
Kalisvaart 2005 32/201 36/194 33.3 % 0.86 [ 0.56, 1.32 ]
Subtotal (95% CI) 260 256 66.0 % 1.05 [ 0.69, 1.60 ]
Total events: 57 (Antipsychotic), 56 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Olanzapine
Larsen 2010 28/196 82/204 34.0 % 0.36 [ 0.24, 0.52 ]
Subtotal (95% CI) 196 204 34.0 % 0.36 [ 0.24, 0.52 ]
Total events: 28 (Antipsychotic), 82 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.31 (P < 0.00001)
Total (95% CI) 456 460 100.0 % 0.73 [ 0.33, 1.59 ]
Total events: 85 (Antipsychotic), 138 (Control)
Heterogeneity: Tau2 = 0.43; Chi2 = 20.12, df = 2 (P = 0.00004); I2 =90%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 14.02, df = 1 (P = 0.00), I2 =93%
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Analysis 3.2. Comparison 3 Prophylactic antipsychotic versus control, Outcome 2 Duration of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 2 Duration of delirium
Study or subgroup Antipsychotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Haloperidol
Kalisvaart 2005 32 5.4 (4.9) 36 11.8 (7.5) 47.7 % -6.40 [ -9.38, -3.42 ]
Subtotal (95% CI) 32 36 47.7 % -6.40 [ -9.38, -3.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000026)
2 Olanzapine
Larsen 2010 28 2.2 (1.3) 82 1.6 (0.7) 52.3 % 0.60 [ 0.10, 1.10 ]
Subtotal (95% CI) 28 82 52.3 % 0.60 [ 0.10, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
Total (95% CI) 60 118 100.0 % -2.74 [ -9.59, 4.11 ]
Heterogeneity: Tau2 = 23.31; Chi2 = 20.60, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 20.60, df = 1 (P = 0.00), I2 =95%
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Analysis 3.3. Comparison 3 Prophylactic antipsychotic versus control, Outcome 3 Severity of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 3 Severity of delirium
Study or subgroup Antipsychotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Haloperidol
Kalisvaart 2005 32 14.4 (3.5) 36 18.4 (4.3) 49.5 % -4.00 [ -5.86, -2.14 ]
Subtotal (95% CI) 32 36 49.5 % -4.00 [ -5.86, -2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P = 0.000024)
2 Olanzapine
Larsen 2010 28 16.4 (3.7) 82 14.5 (2.7) 50.5 % 1.90 [ 0.41, 3.39 ]
Subtotal (95% CI) 28 82 50.5 % 1.90 [ 0.41, 3.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Total (95% CI) 60 118 100.0 % -1.02 [ -6.80, 4.76 ]
Heterogeneity: Tau2 = 16.67; Chi2 = 23.61, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 23.61, df = 1 (P = 0.00), I2 =96%
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Analysis 3.4. Comparison 3 Prophylactic antipsychotic versus control, Outcome 4 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 4 Length of admission
Study or subgroup Antipsychotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Haloperidol
Kalisvaart 2005 32 17.1 (11.1) 36 22.6 (16.7) 100.0 % -5.50 [ -12.17, 1.17 ]
Total (95% CI) 32 36 100.0 % -5.50 [ -12.17, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Prophylactic antipsychotic versus control, Outcome 5 Cognition.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 5 Cognition
Study or subgroup Antipsychotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Larsen 2010 28 19.6 (6.5) 82 24.5 (3.5) 100.0 % -4.90 [ -7.42, -2.38 ]
Total (95% CI) 28 82 100.0 % -4.90 [ -7.42, -2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Prophylactic antipsychotic versus control, Outcome 6 Withdrawal from
protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 6 Withdrawal from protocol
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Haloperidol
Kalisvaart 2005 20/212 28/218 30.8 % 0.73 [ 0.43, 1.26 ]
Subtotal (95% CI) 212 218 30.8 % 0.73 [ 0.43, 1.26 ]
Total events: 20 (Antipsychotic), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 Olanzapine
Larsen 2010 47/243 48/252 69.2 % 1.02 [ 0.71, 1.46 ]
Subtotal (95% CI) 243 252 69.2 % 1.02 [ 0.71, 1.46 ]
Total events: 47 (Antipsychotic), 48 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Total (95% CI) 455 470 100.0 % 0.92 [ 0.68, 1.24 ]
Total events: 67 (Antipsychotic), 76 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.95, df = 1 (P = 0.33), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours antipsychotic Favours control
167Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.7. Comparison 3 Prophylactic antipsychotic versus control, Outcome 7 Adverse events.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 7 Adverse events
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Haloperidol
Kalisvaart 2005 3/212 8/218 100.0 % 0.39 [ 0.10, 1.43 ]
Total (95% CI) 212 218 100.0 % 0.39 [ 0.10, 1.43 ]
Total events: 3 (Antipsychotic), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Prophylactic antipsychotic versus control, Outcome 8 Pneumonia.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 8 Pneumonia
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Larsen 2010 3/196 0/204 100.0 % 7.28 [ 0.38, 140.11 ]
Total (95% CI) 196 204 100.0 % 7.28 [ 0.38, 140.11 ]
Total events: 3 (Antipsychotic), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antipsychotic Favours control
168Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.9. Comparison 3 Prophylactic antipsychotic versus control, Outcome 9 Urinary tract infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 9 Urinary tract infection
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Larsen 2010 1/196 4/204 100.0 % 0.26 [ 0.03, 2.31 ]
Total (95% CI) 196 204 100.0 % 0.26 [ 0.03, 2.31 ]
Total events: 1 (Antipsychotic), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Prophylactic antipsychotic versus control, Outcome 10 Congestive heart
failure.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 3 Prophylactic antipsychotic versus control
Outcome: 10 Congestive heart failure
Study or subgroup Antipsychotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Larsen 2010 1/196 1/204 100.0 % 1.04 [ 0.07, 16.52 ]
Total (95% CI) 196 204 100.0 % 1.04 [ 0.07, 16.52 ]
Total events: 1 (Antipsychotic), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Prophylactic melatonin versus placebo, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 1 Incident delirium
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al-Aama 2011 2/56 10/52 31.6 % 0.19 [ 0.04, 0.81 ]
de Jonghe 2014 55/186 49/192 43.7 % 1.16 [ 0.83, 1.61 ]
Hatta 2014 1/23 5/20 24.7 % 0.17 [ 0.02, 1.37 ]
Total (95% CI) 265 264 100.0 % 0.41 [ 0.09, 1.89 ]
Total events: 58 (Melatonin), 64 (Control)
Heterogeneity: Tau2 = 1.37; Chi2 = 8.97, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Prophylactic melatonin versus placebo, Outcome 2 Duration of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 2 Duration of delirium
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jonghe 2014 55 2 (1.48) 49 2 (1.48) 100.0 % 0.0 [ -0.57, 0.57 ]
Total (95% CI) 55 49 100.0 % 0.0 [ -0.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Prophylactic melatonin versus placebo, Outcome 3 Severity of delirium (binary
severe vs. not severe).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 3 Severity of delirium (binary severe vs. not severe)
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
de Jonghe 2014 25/55 26/49 100.0 % 0.86 [ 0.58, 1.27 ]
Total (95% CI) 55 49 100.0 % 0.86 [ 0.58, 1.27 ]
Total events: 25 (Melatonin), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Prophylactic melatonin versus placebo, Outcome 4 Severity of delirium (DRS-
R-98).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 4 Severity of delirium (DRS-R-98)
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hatta 2014 1 6.3 (6.5) 5 10.4 (9.8) 100.0 % -4.10 [ -19.47, 11.27 ]
Total (95% CI) 1 5 100.0 % -4.10 [ -19.47, 11.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Prophylactic melatonin versus placebo, Outcome 5 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 5 Length of admission
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Al-Aama 2011 61 18.5 (26.4) 61 14.5 (21.6) 2.3 % 4.00 [ -4.56, 12.56 ]
de Jonghe 2014 186 11 (6.3) 192 11 (6.7) 97.7 % 0.0 [ -1.31, 1.31 ]
Total (95% CI) 247 253 100.0 % 0.09 [ -1.20, 1.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Prophylactic melatonin versus placebo, Outcome 6 Cognitive impairment.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 6 Cognitive impairment
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
de Jonghe 2014 87/186 105/192 100.0 % 0.86 [ 0.70, 1.04 ]
Total (95% CI) 186 192 100.0 % 0.86 [ 0.70, 1.04 ]
Total events: 87 (Melatonin), 105 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Prophylactic melatonin versus placebo, Outcome 7 Activities of daily living.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 7 Activities of daily living
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jonghe 2014 183 9 (5.9) 186 9 (5.9) 100.0 % 0.0 [ -1.20, 1.20 ]
Total (95% CI) 183 186 100.0 % 0.0 [ -1.20, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Prophylactic melatonin versus placebo, Outcome 8 Use of psychotropic
medication (binary).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 8 Use of psychotropic medication (binary)
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al-Aama 2011 33/61 38/61 100.0 % 0.87 [ 0.64, 1.18 ]
Total (95% CI) 61 61 100.0 % 0.87 [ 0.64, 1.18 ]
Total events: 33 (Melatonin), 38 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Prophylactic melatonin versus placebo, Outcome 9 Antipsychotic medication
use (cumulative).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 9 Antipsychotic medication use (cumulative)
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jonghe 2014 186 4 (4.4) 192 5 (3.3) 100.0 % -1.00 [ -1.79, -0.21 ]
Total (95% CI) 186 192 100.0 % -1.00 [ -1.79, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Prophylactic melatonin versus placebo, Outcome 10 Benzodiazepine use
(cumulative).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 10 Benzodiazepine use (cumulative)
Study or subgroup Melatonin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jonghe 2014 186 63.4 (52.5) 192 75 (72.6) 100.0 % -11.60 [ -24.34, 1.14 ]
Total (95% CI) 186 192 100.0 % -11.60 [ -24.34, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.074)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Prophylactic melatonin versus placebo, Outcome 11 Withdrawal from study.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 11 Withdrawal from study
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al-Aama 2011 2/61 2/61 100.0 % 1.00 [ 0.15, 6.87 ]
Hatta 2014 0/23 0/20 Not estimable
Total (95% CI) 84 81 100.0 % 1.00 [ 0.15, 6.87 ]
Total events: 2 (Melatonin), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.12. Comparison 4 Prophylactic melatonin versus placebo, Outcome 12 In-hospital mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 12 In-hospital mortality
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al-Aama 2011 6/61 8/61 65.4 % 0.75 [ 0.28, 2.03 ]
de Jonghe 2014 4/186 4/192 34.6 % 1.03 [ 0.26, 4.07 ]
Hatta 2014 0/23 0/20 Not estimable
Total (95% CI) 270 273 100.0 % 0.84 [ 0.37, 1.88 ]
Total events: 10 (Melatonin), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Prophylactic melatonin versus placebo, Outcome 13 Mortality by 3 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 13 Mortality by 3 months
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
de Jonghe 2014 39/186 41/192 100.0 % 0.98 [ 0.67, 1.45 ]
Total (95% CI) 186 192 100.0 % 0.98 [ 0.67, 1.45 ]
Total events: 39 (Melatonin), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 4.14. Comparison 4 Prophylactic melatonin versus placebo, Outcome 14 Adverse events.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 4 Prophylactic melatonin versus placebo
Outcome: 14 Adverse events
Study or subgroup Melatonin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hatta 2014 0/23 0/20 Not estimable
Total (95% CI) 23 20 Not estimable
Total events: 0 (Melatonin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Prophylactic citicoline versus placebo, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 5 Prophylactic citicoline versus placebo
Outcome: 1 Incident delirium
Study or subgroup Citicoline Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Incident delirium day 1 post surgery
Diaz 2001 4/34 8/46 100.0 % 0.68 [ 0.22, 2.06 ]
Subtotal (95% CI) 34 46 100.0 % 0.68 [ 0.22, 2.06 ]
Total events: 4 (Citicoline), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 5.2. Comparison 5 Prophylactic citicoline versus placebo, Outcome 2 Cognitive status.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 5 Prophylactic citicoline versus placebo
Outcome: 2 Cognitive status
Study or subgroup Citicoline Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diaz 2001 46 23.48 (6) 35 24.95 (4.9) 100.0 % -1.47 [ -3.85, 0.91 ]
Total (95% CI) 46 35 100.0 % -1.47 [ -3.85, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Oral premedication with diazepam and diphenhydramine, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 6 Oral premedication with diazepam and diphenhydramine
Outcome: 1 Incident delirium
Study or subgroup Premedication No premedication Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ashraf 2015 0/26 0/23 Not estimable
Total (95% CI) 26 23 Not estimable
Total events: 0 (Premedication), 0 (No premedication)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 1 Incident delirium
Study or subgroup Methylprednisolone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Whitlock 2015 295/3755 289/3752 100.0 % 1.02 [ 0.87, 1.19 ]
Total (95% CI) 3755 3752 100.0 % 1.02 [ 0.87, 1.19 ]
Total events: 295 (Methylprednisolone), 289 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 2 Length of
admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 2 Length of admission
Study or subgroup Methylprednisolone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Whitlock 2015 3755 9 (4.44) 3752 9 (4.44) 100.0 % 0.0 [ -0.20, 0.20 ]
Total (95% CI) 3755 3752 100.0 % 0.0 [ -0.20, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 3 Mortality at 30
days.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 3 Mortality at 30 days
Study or subgroup Methylprednisolone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Whitlock 2015 154/3755 177/3752 100.0 % 0.87 [ 0.70, 1.07 ]
Total (95% CI) 3755 3752 100.0 % 0.87 [ 0.70, 1.07 ]
Total events: 154 (Methylprednisolone), 177 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 4 Myocardial injury.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 4 Myocardial injury
Study or subgroup Methylprednisolone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Whitlock 2015 486/3755 399/3752 100.0 % 1.22 [ 1.07, 1.38 ]
Total (95% CI) 3755 3752 100.0 % 1.22 [ 1.07, 1.38 ]
Total events: 486 (Methylprednisolone), 399 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 5 Respiratory failure.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 5 Respiratory failure
Study or subgroup Methylprednisolone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Whitlock 2015 343/3755 375/3752 100.0 % 0.91 [ 0.80, 1.05 ]
Total (95% CI) 3755 3752 100.0 % 0.91 [ 0.80, 1.05 ]
Total events: 343 (Methylprednisolone), 375 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Intravenous methylprednisolone versus placebo, Outcome 6 Infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 7 Intravenous methylprednisolone versus placebo
Outcome: 6 Infection
Study or subgroup Methylprednisolone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Whitlock 2015 465/3755 493/3752 100.0 % 0.94 [ 0.84, 1.06 ]
Total (95% CI) 3755 3752 100.0 % 0.94 [ 0.84, 1.06 ]
Total events: 465 (Methylprednisolone), 493 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Gabapentinoids versus placebo, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 8 Gabapentinoids versus placebo
Outcome: 1 Incident delirium
Study or subgroup Gabapentinoids Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Leung 2006 0/9 5/12 100.0 % 0.12 [ 0.01, 1.90 ]
Total (95% CI) 9 12 100.0 % 0.12 [ 0.01, 1.90 ]
Total events: 0 (Gabapentinoids), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Gabapentinoids versus placebo, Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 8 Gabapentinoids versus placebo
Outcome: 2 Length of admission
Study or subgroup Gabapentinoids Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pesonen 2011 29 7.5 (3.1) 31 8.1 (2.9) 100.0 % -0.60 [ -2.12, 0.92 ]
Total (95% CI) 29 31 100.0 % -0.60 [ -2.12, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Gabapentinoids versus placebo, Outcome 3 Cognition.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 8 Gabapentinoids versus placebo
Outcome: 3 Cognition
Study or subgroup Gabapentinoids Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pesonen 2011 29 28 (6.67) 31 27 (8.15) 100.0 % 1.00 [ -2.76, 4.76 ]
Total (95% CI) 29 31 100.0 % 1.00 [ -2.76, 4.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Gabapentinoids versus placebo, Outcome 4 Psychotropic Medication Use.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 8 Gabapentinoids versus placebo
Outcome: 4 Psychotropic Medication Use
Study or subgroup Gabapentinoids Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pesonen 2011 5/29 10/31 100.0 % 0.53 [ 0.21, 1.38 ]
Total (95% CI) 29 31 100.0 % 0.53 [ 0.21, 1.38 ]
Total events: 5 (Gabapentinoids), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Gabapentinoids versus placebo, Outcome 5 Withdrawal from protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 8 Gabapentinoids versus placebo
Outcome: 5 Withdrawal from protocol
Study or subgroup Gabapentinoids Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pesonen 2011 4/35 0/35 100.0 % 9.00 [ 0.50, 161.13 ]
Total (95% CI) 35 35 100.0 % 9.00 [ 0.50, 161.13 ]
Total events: 4 (Gabapentinoids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Ketamine versus placebo, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 9 Ketamine versus placebo
Outcome: 1 Incident delirium
Study or subgroup Ketamine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Urban 2008 2/12 1/12 100.0 % 2.00 [ 0.21, 19.23 ]
Total (95% CI) 12 12 100.0 % 2.00 [ 0.21, 19.23 ]
Total events: 2 (Ketamine), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Ketamine versus placebo, Outcome 2 Withdrawal from protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 9 Ketamine versus placebo
Outcome: 2 Withdrawal from protocol
Study or subgroup Ketamine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Urban 2008 1/13 1/13 100.0 % 1.00 [ 0.07, 14.34 ]
Total (95% CI) 13 13 100.0 % 1.00 [ 0.07, 14.34 ]
Total events: 1 (Ketamine), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 1 Incident delirium
Study or subgroup Parecoxib Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2013 9/40 18/40 100.0 % 0.50 [ 0.26, 0.98 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.26, 0.98 ]
Total events: 9 (Parecoxib), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 2 Length of admission
Study or subgroup Parecoxib Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Li 2013 40 11.4 (1.5) 40 12.3 (1.6) 100.0 % -0.90 [ -1.58, -0.22 ]
Total (95% CI) 40 40 100.0 % -0.90 [ -1.58, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 3 Postoperative cognitive dysfunction at 3 days.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 3 Postoperative cognitive dysfunction at 3 days
Study or subgroup Parecoxib Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2013 7/40 15/40 100.0 % 0.47 [ 0.21, 1.02 ]
Total (95% CI) 40 40 100.0 % 0.47 [ 0.21, 1.02 ]
Total events: 7 (Parecoxib), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 4 Postoperative cognitive dysfunction at 1 week.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 4 Postoperative cognitive dysfunction at 1 week
Study or subgroup Parecoxib Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2013 5/40 13/40 100.0 % 0.38 [ 0.15, 0.98 ]
Total (95% CI) 40 40 100.0 % 0.38 [ 0.15, 0.98 ]
Total events: 5 (Parecoxib), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 5 Postoperative cognitive dysfunction at 3 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 5 Postoperative cognitive dysfunction at 3 months
Study or subgroup Parecoxib Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2013 3/40 10/40 100.0 % 0.30 [ 0.09, 1.01 ]
Total (95% CI) 40 40 100.0 % 0.30 [ 0.09, 1.01 ]
Total events: 3 (Parecoxib), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline,
Outcome 6 Postoperative cognitive dysfunction at 6 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 10 Intravenous parecoxib sodium analgesia versus Morphine and Saline
Outcome: 6 Postoperative cognitive dysfunction at 6 months
Study or subgroup Parecoxib Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2013 1/40 7/40 100.0 % 0.14 [ 0.02, 1.11 ]
Total (95% CI) 40 40 100.0 % 0.14 [ 0.02, 1.11 ]
Total events: 1 (Parecoxib), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Intrathecal morphine and PCA morphine versus PCA morphine, Outcome 1
Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 11 Intrathecal morphine and PCA morphine versus PCA morphine
Outcome: 1 Incident delirium
Study or subgroup Intrathecal morphine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beaussier 2006 9/26 10/26 100.0 % 0.90 [ 0.44, 1.85 ]
Total (95% CI) 26 26 100.0 % 0.90 [ 0.44, 1.85 ]
Total events: 9 (Intrathecal morphine), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intrathecal + PCA Favours control
Analysis 11.2. Comparison 11 Intrathecal morphine and PCA morphine versus PCA morphine, Outcome 2
Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 11 Intrathecal morphine and PCA morphine versus PCA morphine
Outcome: 2 Length of admission
Study or subgroup Intrathecal morphine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Beaussier 2006 26 7.9 (2) 26 8.4 (1.7) 100.0 % -0.50 [ -1.51, 0.51 ]
Total (95% CI) 26 26 100.0 % -0.50 [ -1.51, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Intrathecal morphine and PCA morphine versus PCA morphine, Outcome 3
Cognition - days for MMSE to return to preoperative level.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 11 Intrathecal morphine and PCA morphine versus PCA morphine
Outcome: 3 Cognition - days for MMSE to return to preoperative level
Study or subgroup Intrathecal morphine Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Beaussier 2006 26 3 (2.4) 26 2.8 (2.1) 100.0 % 0.20 [ -1.03, 1.43 ]
Total (95% CI) 26 26 100.0 % 0.20 [ -1.03, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Intrathecal morphine and PCA morphine versus PCA morphine, Outcome 4
Withdrawal from protocol.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 11 Intrathecal morphine and PCA morphine versus PCA morphine
Outcome: 4 Withdrawal from protocol
Study or subgroup Intrathecal morphine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beaussier 2006 3/29 4/30 100.0 % 0.78 [ 0.19, 3.17 ]
Total (95% CI) 29 30 100.0 % 0.78 [ 0.19, 3.17 ]
Total events: 3 (Intrathecal morphine), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Intrathecal morphine and PCA morphine versus PCA morphine, Outcome 5
Mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 11 Intrathecal morphine and PCA morphine versus PCA morphine
Outcome: 5 Mortality
Study or subgroup Intrathecal morphine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beaussier 2006 0/29 1/30 100.0 % 0.34 [ 0.01, 8.13 ]
Total (95% CI) 29 30 100.0 % 0.34 [ 0.01, 8.13 ]
Total events: 0 (Intrathecal morphine), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Fascia iliaca compartment block (FICB) versus placebo, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 12 Fascia iliaca compartment block (FICB) versus placebo
Outcome: 1 Incident delirium
Study or subgroup FICB block Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mouzopoulos 2009 11/102 25/105 100.0 % 0.45 [ 0.24, 0.87 ]
Total (95% CI) 102 105 100.0 % 0.45 [ 0.24, 0.87 ]
Total events: 11 (FICB block), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Fascia iliaca compartment block (FICB) versus placebo, Outcome 2 Severity
of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 12 Fascia iliaca compartment block (FICB) versus placebo
Outcome: 2 Severity of delirium
Study or subgroup FICB block Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mouzopoulos 2009 11 14.3 (3.6) 25 18.6 (3.4) 100.0 % -4.30 [ -6.81, -1.79 ]
Total (95% CI) 11 25 100.0 % -4.30 [ -6.81, -1.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00079)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Fascia iliaca compartment block (FICB) versus placebo, Outcome 3 Duration
of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 12 Fascia iliaca compartment block (FICB) versus placebo
Outcome: 3 Duration of delirium
Study or subgroup FICB block Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mouzopoulos 2009 11 5.2 (4.3) 25 10.9 (7.2) 100.0 % -5.70 [ -9.50, -1.90 ]
Total (95% CI) 11 25 100.0 % -5.70 [ -9.50, -1.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 Fascia iliaca compartment block (FICB) versus placebo, Outcome 4 Mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 12 Fascia iliaca compartment block (FICB) versus placebo
Outcome: 4 Mortality
Study or subgroup FICB block Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mouzopoulos 2009 1/108 2/111 100.0 % 0.51 [ 0.05, 5.58 ]
Total (95% CI) 108 111 100.0 % 0.51 [ 0.05, 5.58 ]
Total events: 1 (FICB block), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 Light versus deep propofol sedation, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 1 Incident delirium
Study or subgroup Light sedation Deep sedation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sieber 2010 11/57 23/57 100.0 % 0.48 [ 0.26, 0.89 ]
Total (95% CI) 57 57 100.0 % 0.48 [ 0.26, 0.89 ]
Total events: 11 (Light sedation), 23 (Deep sedation)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Light versus deep propofol sedation, Outcome 2 Duration of delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 2 Duration of delirium
Study or subgroup Light sedation Deep sedation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sieber 2010 11 2.8 (2.3) 23 3.4 (5.7) 100.0 % -0.60 [ -3.30, 2.10 ]
Total (95% CI) 11 23 100.0 % -0.60 [ -3.30, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours light sedation Favours deep sedation
Analysis 13.3. Comparison 13 Light versus deep propofol sedation, Outcome 3 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 3 Length of admission
Study or subgroup Light sedation Deep sedation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sieber 2010 57 4.7 (3.1) 57 4.5 (2.3) 100.0 % 0.20 [ -0.80, 1.20 ]
Total (95% CI) 57 57 100.0 % 0.20 [ -0.80, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Light versus deep propofol sedation, Outcome 4 Cognition on day 2.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 4 Cognition on day 2
Study or subgroup Light sedation Deep sedation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sieber 2010 57 23.1 (5.5) 57 20 (9.3) 100.0 % 3.10 [ 0.30, 5.90 ]
Total (95% CI) 57 57 100.0 % 3.10 [ 0.30, 5.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours light sedation Favours deep sedation
Analysis 13.5. Comparison 13 Light versus deep propofol sedation, Outcome 5 In-hospital mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 5 In-hospital mortality
Study or subgroup Light sedation Deep sedation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sieber 2010 1/57 2/57 100.0 % 0.50 [ 0.05, 5.36 ]
Total (95% CI) 57 57 100.0 % 0.50 [ 0.05, 5.36 ]
Total events: 1 (Light sedation), 2 (Deep sedation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 13.6. Comparison 13 Light versus deep propofol sedation, Outcome 6 Postoperative complications
(>=1).
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 13 Light versus deep propofol sedation
Outcome: 6 Postoperative complications (>=1)
Study or subgroup Light sedation Deep sedation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sieber 2010 26/57 30/57 100.0 % 0.87 [ 0.60, 1.26 ]
Total (95% CI) 57 57 100.0 % 0.87 [ 0.60, 1.26 ]
Total events: 26 (Light sedation), 30 (Deep sedation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours light sedation Favours deep sedation
196Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.1. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 1 Incident delirium
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 70/450 109/452 44.3 % 0.65 [ 0.49, 0.85 ]
Radtke 2013 95/575 124/580 55.7 % 0.77 [ 0.61, 0.98 ]
Total (95% CI) 1025 1032 100.0 % 0.71 [ 0.60, 0.85 ]
Total events: 165 (BIS-guided), 233 (BIS-blinded/clin judge)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BIS-guided Favours BIS-blinded
197Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.2. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 2 Length of admission
Study or subgroup BIS-guided
BIS-
blinded/clin
judge
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chan 2013 450 7 (3.7) 452 8 (4.4) 92.2 % -1.00 [ -1.53, -0.47 ]
Radtke 2013 575 15.7 (16.9) 580 15.9 (14.6) 7.8 % -0.20 [ -2.02, 1.62 ]
Total (95% CI) 1025 1032 100.0 % -0.94 [ -1.45, -0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 3.61 (P = 0.00031)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 3 Cognition at 7 days.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 3 Cognition at 7 days
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 83/382 93/401 55.4 % 0.94 [ 0.72, 1.22 ]
Radtke 2013 70/575 90/580 44.6 % 0.78 [ 0.59, 1.05 ]
Total (95% CI) 957 981 100.0 % 0.87 [ 0.71, 1.05 ]
Total events: 153 (BIS-guided), 183 (BIS-blinded/clin judge)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BIS-guided Favours BIS-blinded
199Interventions for preventing delirium in hospitalised non-ICU patients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.4. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 4 Cognition at 3 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 4 Cognition at 3 months
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 42/412 62/423 69.4 % 0.70 [ 0.48, 1.00 ]
Radtke 2013 21/575 28/580 30.6 % 0.76 [ 0.43, 1.32 ]
Total (95% CI) 987 1003 100.0 % 0.71 [ 0.53, 0.97 ]
Total events: 63 (BIS-guided), 90 (BIS-blinded/clin judge)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 5 SF-36 mental summary score.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 5 SF-36 mental summary score
Study or subgroup BIS-guided
BIS-
blinded/clin
judge
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chan 2013 450 50.2 (12.1) 452 52.1 (10.9) 100.0 % -1.90 [ -3.40, -0.40 ]
Total (95% CI) 450 452 100.0 % -1.90 [ -3.40, -0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 14.6. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 6 Mortality at 7 days.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 6 Mortality at 7 days
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 6/462 4/459 100.0 % 1.49 [ 0.42, 5.25 ]
Total (95% CI) 462 459 100.0 % 1.49 [ 0.42, 5.25 ]
Total events: 6 (BIS-guided), 4 (BIS-blinded/clin judge)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 14.7. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 7 Mortality at 3 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 7 Mortality at 3 months
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 26/382 22/401 43.7 % 1.24 [ 0.72, 2.15 ]
Radtke 2013 31/575 31/580 56.3 % 1.01 [ 0.62, 1.64 ]
Total (95% CI) 957 981 100.0 % 1.10 [ 0.77, 1.59 ]
Total events: 57 (BIS-guided), 53 (BIS-blinded/clin judge)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 14.8. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 8 Cardiac complications.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 8 Cardiac complications
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 28/450 33/452 100.0 % 0.85 [ 0.52, 1.39 ]
Total (95% CI) 450 452 100.0 % 0.85 [ 0.52, 1.39 ]
Total events: 28 (BIS-guided), 33 (BIS-blinded/clin judge)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 14.9. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 9 Respiratory complications.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 9 Respiratory complications
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 64/450 81/452 100.0 % 0.79 [ 0.59, 1.07 ]
Total (95% CI) 450 452 100.0 % 0.79 [ 0.59, 1.07 ]
Total events: 64 (BIS-guided), 81 (BIS-blinded/clin judge)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 14.10. Comparison 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded
anaesthesia/clinical judgement, Outcome 10 Infective complications.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 14 Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement
Outcome: 10 Infective complications
Study or subgroup BIS-guided
BIS-
blinded/clin
judge Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2013 75/450 104/452 100.0 % 0.72 [ 0.55, 0.95 ]
Total (95% CI) 450 452 100.0 % 0.72 [ 0.55, 0.95 ]
Total events: 75 (BIS-guided), 104 (BIS-blinded/clin judge)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 Sevoﬂurane versus propofol anaesthesia, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 15 Sevoﬂurane versus propofol anaesthesia
Outcome: 1 Incident delirium
Study or subgroup Sevoﬂurane Propofol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lurati 2012 21/184 29/201 100.0 % 0.79 [ 0.47, 1.34 ]
Total (95% CI) 184 201 100.0 % 0.79 [ 0.47, 1.34 ]
Total events: 21 (Sevoﬂurane), 29 (Propofol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Sevoﬂurane versus propofol anaesthesia, Outcome 2 Mortality at 12 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 15 Sevoﬂurane versus propofol anaesthesia
Outcome: 2 Mortality at 12 months
Study or subgroup Sevoﬂurane Propofol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lurati 2012 25/184 23/201 100.0 % 1.19 [ 0.70, 2.02 ]
Total (95% CI) 184 201 100.0 % 1.19 [ 0.70, 2.02 ]
Total events: 25 (Sevoﬂurane), 23 (Propofol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 Xenon versus sevoﬂurane anaesthesia, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 16 Xenon versus sevoﬂurane anaesthesia
Outcome: 1 Incident delirium
Study or subgroup Xenon Sevoﬂurane Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stoppe 2013 3/15 4/15 100.0 % 0.75 [ 0.20, 2.79 ]
Total (95% CI) 15 15 100.0 % 0.75 [ 0.20, 2.79 ]
Total events: 3 (Xenon), 4 (Sevoﬂurane)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 Xenon versus sevoﬂurane anaesthesia, Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 16 Xenon versus sevoﬂurane anaesthesia
Outcome: 2 Length of admission
Study or subgroup Xenon Sevoﬂurane
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Stoppe 2013 15 18 (9.7) 15 14 (5.8) 100.0 % 4.00 [ -1.72, 9.72 ]
Total (95% CI) 15 15 100.0 % 4.00 [ -1.72, 9.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 Xenon versus sevoﬂurane anaesthesia, Outcome 3 In-hospital mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 16 Xenon versus sevoﬂurane anaesthesia
Outcome: 3 In-hospital mortality
Study or subgroup Xenon Sevoﬂurane Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stoppe 2013 0/15 0/15 Not estimable
Total (95% CI) 15 15 Not estimable
Total events: 0 (Xenon), 0 (Sevoﬂurane)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 16.4. Comparison 16 Xenon versus sevoﬂurane anaesthesia, Outcome 4 Adverse events.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 16 Xenon versus sevoﬂurane anaesthesia
Outcome: 4 Adverse events
Study or subgroup Xenon Sevoﬂurane Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stoppe 2013 6/15 8/15 100.0 % 0.75 [ 0.34, 1.64 ]
Total (95% CI) 15 15 100.0 % 0.75 [ 0.34, 1.64 ]
Total events: 6 (Xenon), 8 (Sevoﬂurane)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 16.5. Comparison 16 Xenon versus sevoﬂurane anaesthesia, Outcome 5 Sepsis.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 16 Xenon versus sevoﬂurane anaesthesia
Outcome: 5 Sepsis
Study or subgroup Xenon Sevoﬂurane Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stoppe 2013 3/15 2/15 100.0 % 1.50 [ 0.29, 7.73 ]
Total (95% CI) 15 15 100.0 % 1.50 [ 0.29, 7.73 ]
Total events: 3 (Xenon), 2 (Sevoﬂurane)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 1 Incident delirium
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berggren 1987 14/28 11/29 81.7 % 1.32 [ 0.73, 2.39 ]
Papaioannou 2005 3/19 6/28 18.3 % 0.74 [ 0.21, 2.59 ]
Total (95% CI) 47 57 100.0 % 1.19 [ 0.69, 2.03 ]
Total events: 17 (Regional anaesthesia), 17 (General anaesthesia)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 2 Length of
admission > 10 days.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 2 Length of admission > 10 days
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papaioannou 2005 6/19 15/28 100.0 % 0.59 [ 0.28, 1.24 ]
Total (95% CI) 19 28 100.0 % 0.59 [ 0.28, 1.24 ]
Total events: 6 (Regional anaesthesia), 15 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 17.3. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 3 Cognitive
decline.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 3 Cognitive decline
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papaioannou 2005 1/19 10/28 100.0 % 0.15 [ 0.02, 1.06 ]
Total (95% CI) 19 28 100.0 % 0.15 [ 0.02, 1.06 ]
Total events: 1 (Regional anaesthesia), 10 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 4 Urinary tract
infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 4 Urinary tract infection
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berggren 1987 9/28 7/29 100.0 % 1.33 [ 0.57, 3.09 ]
Total (95% CI) 28 29 100.0 % 1.33 [ 0.57, 3.09 ]
Total events: 9 (Regional anaesthesia), 7 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 5 Psychological
morbidity.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 5 Psychological morbidity
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Depression
Berggren 1987 3/28 3/29 100.0 % 1.04 [ 0.23, 4.71 ]
Total (95% CI) 28 29 100.0 % 1.04 [ 0.23, 4.71 ]
Total events: 3 (Regional anaesthesia), 3 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 6 Postoperative
complications.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 6 Postoperative complications
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papaioannou 2005 5/19 8/28 100.0 % 0.92 [ 0.35, 2.39 ]
Total (95% CI) 19 28 100.0 % 0.92 [ 0.35, 2.39 ]
Total events: 5 (Regional anaesthesia), 8 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 Epidural anaesthesia versus general anaesthesia, Outcome 7 Pressure ulcer.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 17 Epidural anaesthesia versus general anaesthesia
Outcome: 7 Pressure ulcer
Study or subgroup Regional anaesthesia General anaesthesia Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berggren 1987 3/28 5/29 100.0 % 0.62 [ 0.16, 2.36 ]
Total (95% CI) 28 29 100.0 % 0.62 [ 0.16, 2.36 ]
Total events: 3 (Regional anaesthesia), 5 (General anaesthesia)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 1 Incident delirium
Study or subgroup Liberal Restrictive Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gruber-Baldini 2013 16/53 22/55 100.0 % 0.75 [ 0.45, 1.27 ]
Total (95% CI) 53 55 100.0 % 0.75 [ 0.45, 1.27 ]
Total events: 16 (Liberal), 22 (Restrictive)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 18.2. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 2 Delirium
severity.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 2 Delirium severity
Study or subgroup Liberal Restrictive
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gruber-Baldini 2013 16 6.8 (4.4) 22 6.9 (4.6) 100.0 % -0.10 [ -2.99, 2.79 ]
Total (95% CI) 16 22 100.0 % -0.10 [ -2.99, 2.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 18.3. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 3 Length of
admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 3 Length of admission
Study or subgroup Liberal Restrictive
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gruber-Baldini 2013 66 6.6 (3.9) 72 6.7 (3.6) 100.0 % -0.10 [ -1.36, 1.16 ]
Total (95% CI) 66 72 100.0 % -0.10 [ -1.36, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 18.4. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 4
Psychoactive medication use.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 4 Psychoactive medication use
Study or subgroup Liberal Restrictive Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gruber-Baldini 2013 57/66 63/72 100.0 % 0.99 [ 0.87, 1.12 ]
Total (95% CI) 66 72 100.0 % 0.99 [ 0.87, 1.12 ]
Total events: 57 (Liberal), 63 (Restrictive)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 18.5. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 5 Infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 5 Infection
Study or subgroup Liberal Restrictive Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gruber-Baldini 2013 3/66 3/72 100.0 % 1.09 [ 0.23, 5.22 ]
Total (95% CI) 66 72 100.0 % 1.09 [ 0.23, 5.22 ]
Total events: 3 (Liberal), 3 (Restrictive)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 18.6. Comparison 18 Liberal versus restrictive blood transfusion thresholds, Outcome 6
Congestive heart failure.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 18 Liberal versus restrictive blood transfusion thresholds
Outcome: 6 Congestive heart failure
Study or subgroup Liberal Restrictive Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gruber-Baldini 2013 1/66 2/72 100.0 % 0.55 [ 0.05, 5.88 ]
Total (95% CI) 66 72 100.0 % 0.55 [ 0.05, 5.88 ]
Total events: 1 (Liberal), 2 (Restrictive)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 Fast-track surgery versus usual care, Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 19 Fast-track surgery versus usual care
Outcome: 1 Incident delirium
Study or subgroup Fast-track surgery Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jia 2014 4/117 15/116 100.0 % 0.26 [ 0.09, 0.77 ]
Total (95% CI) 117 116 100.0 % 0.26 [ 0.09, 0.77 ]
Total events: 4 (Fast-track surgery), 15 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 Fast-track surgery versus usual care, Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 19 Fast-track surgery versus usual care
Outcome: 2 Length of admission
Study or subgroup Fast-track surgery Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jia 2014 117 9.01 (1.75) 116 13.21 (1.32) 100.0 % -4.20 [ -4.60, -3.80 ]
Total (95% CI) 117 116 100.0 % -4.20 [ -4.60, -3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 20.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 Fast-track surgery versus usual care, Outcome 3 Urinary tract infection.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 19 Fast-track surgery versus usual care
Outcome: 3 Urinary tract infection
Study or subgroup Fast-track surgery Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jia 2014 5/117 13/116 100.0 % 0.38 [ 0.14, 1.04 ]
Total (95% CI) 117 116 100.0 % 0.38 [ 0.14, 1.04 ]
Total events: 5 (Fast-track surgery), 13 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fast-track Favours usual care
Analysis 19.4. Comparison 19 Fast-track surgery versus usual care, Outcome 4 Heart failure.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 19 Fast-track surgery versus usual care
Outcome: 4 Heart failure
Study or subgroup Fast-track surgery Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jia 2014 4/117 13/116 100.0 % 0.31 [ 0.10, 0.91 ]
Total (95% CI) 117 116 100.0 % 0.31 [ 0.10, 0.91 ]
Total events: 4 (Fast-track surgery), 13 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 Postoperative delirium-free protocol (DFP) versus usual care, Outcome 1
Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 20 Postoperative delirium-free protocol (DFP) versus usual care
Outcome: 1 Incident delirium
Study or subgroup DFP Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aizawa 2002 1/20 7/20 100.0 % 0.14 [ 0.02, 1.06 ]
Total (95% CI) 20 20 100.0 % 0.14 [ 0.02, 1.06 ]
Total events: 1 (DFP), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 Postoperative delirium-free protocol (DFP) versus usual care, Outcome 2
Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 20 Postoperative delirium-free protocol (DFP) versus usual care
Outcome: 2 Length of admission
Study or subgroup DFP Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aizawa 2002 20 25.6 (9.4) 20 29.9 (16.2) 100.0 % -4.30 [ -12.51, 3.91 ]
Total (95% CI) 20 20 100.0 % -4.30 [ -12.51, 3.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 Postoperative delirium-free protocol (DFP) versus usual care, Outcome 3
Behavioural disturbance.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 20 Postoperative delirium-free protocol (DFP) versus usual care
Outcome: 3 Behavioural disturbance
Study or subgroup DFP Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aizawa 2002 1/20 5/20 100.0 % 0.20 [ 0.03, 1.56 ]
Total (95% CI) 20 20 100.0 % 0.20 [ 0.03, 1.56 ]
Total events: 1 (DFP), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 Computerised clinical decision support system (CCDS) versus usual care,
Outcome 1 Incident delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 21 Computerised clinical decision support system (CCDS) versus usual care
Outcome: 1 Incident delirium
Study or subgroup CCDS Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boustani 2012 67/199 70/225 100.0 % 1.08 [ 0.82, 1.43 ]
Total (95% CI) 199 225 100.0 % 1.08 [ 0.82, 1.43 ]
Total events: 67 (CCDS), 70 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 Computerised clinical decision support system (CCDS) versus usual care,
Outcome 2 Length of admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 21 Computerised clinical decision support system (CCDS) versus usual care
Outcome: 2 Length of admission
Study or subgroup CCDS Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boustani 2012 199 7.7 (7.4) 225 6.8 (5.4) 100.0 % 0.90 [ -0.35, 2.15 ]
Total (95% CI) 199 225 100.0 % 0.90 [ -0.35, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 Computerised clinical decision support system (CCDS) versus usual care,
Outcome 3 Mortality within 30 days of discharge.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 21 Computerised clinical decision support system (CCDS) versus usual care
Outcome: 3 Mortality within 30 days of discharge
Study or subgroup CCDS Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boustani 2012 12/199 13/225 100.0 % 1.04 [ 0.49, 2.23 ]
Total (95% CI) 199 225 100.0 % 1.04 [ 0.49, 2.23 ]
Total events: 12 (CCDS), 13 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 21.4. Comparison 21 Computerised clinical decision support system (CCDS) versus usual care,
Outcome 4 Falls.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 21 Computerised clinical decision support system (CCDS) versus usual care
Outcome: 4 Falls
Study or subgroup CCDS Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boustani 2012 9/199 11/225 100.0 % 0.93 [ 0.39, 2.19 ]
Total (95% CI) 199 225 100.0 % 0.93 [ 0.39, 2.19 ]
Total events: 9 (CCDS), 11 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 21.5. Comparison 21 Computerised clinical decision support system (CCDS) versus usual care,
Outcome 5 Pressure ulcers.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 21 Computerised clinical decision support system (CCDS) versus usual care
Outcome: 5 Pressure ulcers
Study or subgroup CCDS Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boustani 2012 24/199 25/225 100.0 % 1.09 [ 0.64, 1.84 ]
Total (95% CI) 199 225 100.0 % 1.09 [ 0.64, 1.84 ]
Total events: 24 (CCDS), 25 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 1 Incident
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 1 Incident delirium
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 80/163 83/166 100.0 % 0.98 [ 0.79, 1.22 ]
Total (95% CI) 163 166 100.0 % 0.98 [ 0.79, 1.22 ]
Total events: 80 (Geriatric unit), 83 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 22.2. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 2 Duration of
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 2 Duration of delirium
Study or subgroup Geriatric unit Orthopaedic unit
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Watne 2014 80 3 (3.7) 83 4 (3) 100.0 % -1.00 [ -2.04, 0.04 ]
Total (95% CI) 80 83 100.0 % -1.00 [ -2.04, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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Analysis 22.3. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 3 Severity of
delirium.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 3 Severity of delirium
Study or subgroup Geriatric unit Orthopaedic unit
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Watne 2014 80 21.5 (7.2) 83 20 (9) 100.0 % 1.50 [ -1.00, 4.00 ]
Total (95% CI) 80 83 100.0 % 1.50 [ -1.00, 4.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 22.4. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 4 Length of
admission.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 4 Length of admission
Study or subgroup Geriatric unit Orthopaedic unit
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Watne 2014 163 11 (5.2) 166 8 (4.6) 100.0 % 3.00 [ 1.94, 4.06 ]
Total (95% CI) 163 166 100.0 % 3.00 [ 1.94, 4.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 22.5. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 5 Cognitive
function (composite score) at 4 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 5 Cognitive function (composite score) at 4 months
Study or subgroup Geriatric unit Orthopaedic unit
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Watne 2014 112 54.7 (30.3) 116 52.9 (29.1) 100.0 % 1.80 [ -5.92, 9.52 ]
Total (95% CI) 112 116 100.0 % 1.80 [ -5.92, 9.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 22.6. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 6 Incident
dementia at 12 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 6 Incident dementia at 12 months
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 7/98 3/95 100.0 % 2.26 [ 0.60, 8.49 ]
Total (95% CI) 98 95 100.0 % 2.26 [ 0.60, 8.49 ]
Total events: 7 (Geriatric unit), 3 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 22.7. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 7 ADL function at
4 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 7 ADL function at 4 months
Study or subgroup Geriatric unit Orthopaedic unit
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Watne 2014 119 17 (7.4) 120 16 (5.9) 100.0 % 1.00 [ -0.70, 2.70 ]
Total (95% CI) 119 120 100.0 % 1.00 [ -0.70, 2.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 22.8. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 8
Institutionalisation at 4 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 8 Institutionalisation at 4 months
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 19/121 18/121 100.0 % 1.06 [ 0.58, 1.91 ]
Total (95% CI) 121 121 100.0 % 1.06 [ 0.58, 1.91 ]
Total events: 19 (Geriatric unit), 18 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 22.9. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 9
Institutionalisation at 12 months.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 9 Institutionalisation at 12 months
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 16/98 18/95 100.0 % 0.86 [ 0.47, 1.59 ]
Total (95% CI) 98 95 100.0 % 0.86 [ 0.47, 1.59 ]
Total events: 16 (Geriatric unit), 18 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 22.10. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 10 Inpatient
mortality.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 10 Inpatient mortality
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 6/163 11/166 100.0 % 0.56 [ 0.21, 1.47 ]
Total (95% CI) 163 166 100.0 % 0.56 [ 0.21, 1.47 ]
Total events: 6 (Geriatric unit), 11 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 22.11. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 11 Falls.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 11 Falls
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 14/163 11/166 100.0 % 1.30 [ 0.61, 2.77 ]
Total (95% CI) 163 166 100.0 % 1.30 [ 0.61, 2.77 ]
Total events: 14 (Geriatric unit), 11 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Geriatric unit Orthopaedic unit
Analysis 22.12. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 12 Pressure
ulcers.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 12 Pressure ulcers
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 3/163 8/166 100.0 % 0.38 [ 0.10, 1.41 ]
Total (95% CI) 163 166 100.0 % 0.38 [ 0.10, 1.41 ]
Total events: 3 (Geriatric unit), 8 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Geriatric unit Orthopaedic unit
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Analysis 22.13. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 13 Other
medical adverse events.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 13 Other medical adverse events
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 72/163 76/166 100.0 % 0.96 [ 0.76, 1.23 ]
Total (95% CI) 163 166 100.0 % 0.96 [ 0.76, 1.23 ]
Total events: 72 (Geriatric unit), 76 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Geriatric Unit Favours Orthopaedic Unit
Analysis 22.14. Comparison 22 Geriatric unit care versus orthopaedic unit care, Outcome 14 Postoperative
complications.
Review: Interventions for preventing delirium in hospitalised non-ICU patients
Comparison: 22 Geriatric unit care versus orthopaedic unit care
Outcome: 14 Postoperative complications
Study or subgroup Geriatric unit Orthopaedic unit Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Watne 2014 4/163 6/166 100.0 % 0.68 [ 0.20, 2.36 ]
Total (95% CI) 163 166 100.0 % 0.68 [ 0.20, 2.36 ]
Total events: 4 (Geriatric unit), 6 (Orthopaedic unit)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Geriatric unit Orthopaedic unit
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A D D I T I O N A L T A B L E S
Table 1. Individual components of multi-component interventions
Study
Intervention Components
In-
di-
vid-
u-
alised
care
Check-
lists/
pro-
to-
cols
Ed-
u-
ca-
tion/
train-
ing
1
Re-
ori-
en-
ta-
tion
At-
ten-
tion
to
sen-
sory
de-
pri-
va-
tion
Fa-
mil-
iar
ob-
jects
Cog-
ni-
tive
stim-
u-
la-
tion
Nu-
tri-
tion/
hy-
dra-
tion
Iden-
tifi-
ca-
tion
of
in-
fec-
tion
Mo-
bil-
isa-
tion
Sleep
hy-
giene
MDT-
care
2
CGA
3
Oxy-
gena-
tion
Elec-
trolytes
Pain
con-
trol
Med-
ica-
tion
re-
view
Mood
4
Bowel/
blad-
der
care
Post-
op-
era-
tive
com-
pli-
ca-
tions
Abizanda
2011
Bonaven-
tura
2007
Jeffs
2013
Mar-
tinez
2012
Hempe-
nius
2013
Lund-
strom
2006
Mar-
can-
to-
nio
2001
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1Education/training: structured education/training of staff or carers; 2MDTMultidisciplinary Team; 3CGA Comprehensive Geriatric
Assessment; 4Mood: assessment for depression/anxiety
A P P E N D I C E S
Appendix 1. Search Strategy
Source Strategy
ALOIS
www.medicine.ox.ac.uk/alois
[last searched: 4 Dec 2015]
delirium OR DEL
MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R) 1946 to Present (Ovid SP)
[last search: 4 Dec 2015]
1. Delirium/
2. deliri*.mp.
3. “acute confusion*”.ti,ab.
4. “acute organic psychosyndrome”.ti,ab.
5. “acute brain syndrome”.ti,ab.
6. “metabolic encephalopathy”.ti,ab.
7. “acute psycho-organic syndrome”.ti,ab.
8. “clouded state”.ti,ab.
9. “clouding of consciousness”.ti,ab.
10. “exogenous psychosis”.ti,ab.
11. “toxic psychosis”.ti,ab.
12. “toxic confusion”.ti,ab.
13. Delirium, Dementia, Amnestic, Cognitive Disorders/su
[Surgery]
14. obnubilat*.ti,ab.
15. or/1-14
16. Primary Prevention/
17. prevent*.mp.
18. reduc*.ti,ab.
19. stop*.ti,ab.
20. taper*.ti,ab.
21. avoid*.ti,ab.
22. “cut* down”.ti,ab.
23. or/16-22
24. 15 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomi?ed.ab.
28. placebo.ab.
29. drug therapy.fs.
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(Continued)
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. or/25-32
34. (animals not (humans and animals)).sh.
35. 33 not 34
36. 35 and 34
EMBASE 1974 to 2015 Week 01 (Ovid SP)
[last search: 4 Dec 2015]
1. Delirium/
2. deliri*.mp.
3. “acute confusion*”.ti,ab.
4. “acute organic psychosyndrome”.ti,ab.
5. “acute brain syndrome”.ti,ab.
6. “metabolic encephalopathy”.ti,ab.
7. “acute psycho-organic syndrome”.ti,ab.
8. “clouded state”.ti,ab.
9. “clouding of consciousness”.ti,ab.
10. “exogenous psychosis”.ti,ab.
11. “toxic psychosis”.ti,ab.
12. “toxic confusion”.ti,ab.
13. Delirium, Dementia, Amnestic, Cognitive Disorders/su
[Surgery]
14. obnubilat*.ti,ab.
15. or/1-14
16. primary prevention/
17. prevent*.mp.
18. reduc*.ti,ab.
19. stop*.ti,ab.
20. taper*.ti,ab.
21. avoid*.ti,ab.
22. “cut* down”.ti,ab.
23. or/16-22
24. 15 and 23
25. randomized controlled trial/
26. random*.ti,ab.
27. placebo.ti,ab.
28. trial.mp.
29. controlled clinical trial/
30. or/25-29
31. 24 and 30
PsycINFO 1806 to December Week 1 2015 (Ovid SP)
[last search: 4 Dec 2015]
1. Delirium/
2. deliri*.mp.
3. “acute confusion*”.ti,ab.
4. “acute organic psychosyndrome”.ti,ab.
5. “acute brain syndrome”.ti,ab.
6. “metabolic encephalopathy”.ti,ab.
7. “acute psycho-organic syndrome”.ti,ab.
8. “clouded state”.ti,ab.
9. “clouding of consciousness”.ti,ab.
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(Continued)
10. “exogenous psychosis”.ti,ab.
11. “toxic psychosis”.ti,ab.
12. “toxic confusion”.ti,ab.
13. obnubilat*.ti,ab.
14. or/1-13
15. Prevention/
16. prevent*.mp.
17. reduc*.ti,ab.
18. stop*.ti,ab.
19. taper*.ti,ab.
20. avoid*.ti,ab.
21. “cut* down”.ti,ab.
22. or/15-21
23. 14 and 22
24. random*.mp.
25. trial.mp.
26. placebo*.mp.
27. group.ab.
28. or/24-27
29. 23 and 28
CINAHL (EBSCOhost)
[last search: 4 Dec 2015]
1 deliri*
2 “acute psycho-organic syndrome” or “clouded state” or “cloud-
ing of consciousness” or “exogenous psychosis” or “toxic psychosis”
or “toxic confusion”
3 “acute brain confusion” or “acute brain failure” or “acute or-
ganic psychosyndrome” or “acute brain syndrome” or “metabolic
encephalopathy”
4 “Delirium”/ without-subheadings
5 #1 or #2 or #3 or #4
6 “Preventive-Trials”/ without-subheadings
7 prevent* or avoid*
8 #6 or #7
9 #5 and #8
10 random* or placebo* or control* or “normal care” or “standard
care” or “normal treatment” or “standard treatment”
11 #9 and #10
12 “Alcohol-Withdrawal-Delirium”/ without-subheadings
13 “delirium tremens” in TI
14 #12 or #13
15 #11 not #14
16 (animal in DE) not ((human in DE) and (animal in DE))
17 #15 not #16
LILACS (BIREME)
[last search: 4 Dec 2015]
deliri$ OR delirio OR loucura [Words] and randomly OR ran-
domised OR randomized OR trial OR ensaio clínico [Words]
ISI Web of Science - all databases (ISI Web of Science)
[last search: 4 Dec 2015]
Topic=(deliri* OR “acute confusion*” OR “acute organic psy-
chosyndrome” OR “acute brain syndrome” OR “metabolic
encephalopathy” OR “acute psycho-organic syndrome” OR
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(Continued)
“clouded state” OR “clouding of consciousness” OR “exogenous
psychosis” OR “toxic psychosis” OR “toxic confusion” OR ob-
nubilat*) AND Topic=(prevent* OR reduc* OR stop* OR taper*
OR avoid* OR “cut* down”) AND Topic=(randomised OR ran-
domized OR randomly or placebo or “double-blind” or trial OR
groups OR “controlled study” OR RCT OR “single-blind*”)
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&
HCI, CPCI-S, CPCI-SSH
Lemmatization=On
CENTRAL (The Cochrane Library, Wiley)
[last search: 4 Dec 2015]
#1 MeSH descriptor Delirium, this term only
#2 deliri*
#3 “acute confusion*”
#4 “acute organic psychosyndrome”
#5 “acute brain syndrome”
#6 “metabolic encephalopathy”
#7 “acute psycho-organic syndrome”
#8 “clouded state”
#9 “clouding of consciousness”
#10 “exogenous psychosis”
#11 “toxic psychosis”
#12 “toxic confusion”
#13 obnubilat*
#14 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13)
#15 MeSH descriptor Primary Prevention, this term only
#16 prevent*
#17 reduc*
#18 stop*
#19 taper*
#20 avoid*
#21 “cut* down”
#22 (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#14 AND #22)
ClinicalTrials.gov
[last search: 4 Dec 2015]
Search 1: randomized AND delirium AND hospital AND pre-
vention | Interventional Studies | Adult, Senior |received
Search 2: preventionAND(deliriumOR toxic psychosisOR toxic
confusion) | Interventional Studies | Adult, Senior |
ICTRP
[last search: 4 Dec 2015]
#1 Advanced search: Condition: delirium AND date rec: 01/10/
2008-23/01/2015
#2 Basic search: Prevention AND delirium
#3 Basic search: prevent AND delirium
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Appendix 2. Summary of update searches and returned hits
Source December
2015
Hits
January
2015
Hits
February
2014
Hits
January
2013
Hits
November
2010
Hits
ALOIS 2 0 29 99 31
MEDLINE (Ovid
SP)
91 95 92 191 139
EMBASE (Ovid
SP)
197 178 183 329 257
PSYCINFO (Ovid
SP)
24 27 18 64 35
CINAHL (EBSCO
Host)
25 13 21 - 45
LILACS (BIREME) 0 0 15 1 54
ISI Web of Knowl-
edge
(all databases)
94 n/a 148 260 166
CENTRAL
(The Cochrane Li-
brary)
39 27 22 41 33
Clinicaltrials.gov 2 0 6 Search 1: 30
Search 2: 56
80
ICTRP
(WHO Portal)
2 4 44 - 74
WH A T ’ S N E W
Last assessed as up-to-date: 4 December 2015.
Date Event Description
8 February 2016 New search has been performed Conclusions changed; authors changed
31 January 2016 New citation required and conclusions have changed Review updated with results of searches in January 2013,
February 2014, January 2015 and December 2015.
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(Continued)
Changes to authors as described in section ’Differences
between protocol and review’
H I S T O R Y
Protocol ﬁrst published: Issue 4, 2005
Review ﬁrst published: Issue 2, 2007
Date Event Description
23 January 2015 New search has been performed An update search was performed for this review on 23 January 2015
25 February 2014 New search has been performed An update search was performed for this review on 25 February 2014
20 January 2013 New search has been performed An update search was performed for this review on 20 January 2013
24 November 2010 New search has been performed An update search was performed for this review on 18 November 2010.
The search retrieved new studies for consideration by the authors
18 March 2008 New search has been performed The update searches of March and October 2008 retrieved some studies for
consideration by the authors
C O N T R I B U T I O N S O F A U T H O R S
NS, AC, ET, JH and SS reviewed search results and extracted data for included studies.
AC, ET and JH completed ’Summary of ﬁndings’ tables and generated GRADE Evidence Proﬁles.
JT reviewed and interpreted results for studies testing approaches to anaesthesia and pain management.
All authors contributed to write up of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• Health Sciences, University of York, Hull York Medical School, UK.
• Bradford District Care NHS FoundationTrust, UK.
• University of Leeds, UK.
• The Alzheimer Scotland Dementia Research Centre and Centre for Cognitive Ageing and Cognitive Epidemiology, The
University of Edinburgh, UK.
JKH is supported by a Clinical Research Fellowship funded by Alzheimer Scotland and The University of Edinburgh Centre for
Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/L501530/1).
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Medical Research Council (MRC) is
gratefully acknowledged.
External sources
• NIHR, UK.
This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do
not necessarily reﬂect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was published in 2005 and stated the analysis would be performed using an intention-to-treat approach and this
was adopted in the original version of the review (Siddiqi 2007). However, for this update an available case analysis was performed
consistently, including re-analysing the six studies included in the original review.
We added adverse events (falls, pressure ulcers, mortality) as outcomes although this was not speciﬁed in the original published protocol.
We also removed physical morbidity from secondary outcomes, and instead included infections (speciﬁcally wound infections, urinary
tract infections, pneumonia) and cardiac adverse events (speciﬁcally myocardial infarction and cardiac failure) as adverse events.
’Summary of ﬁndings’ tables were added in accordance with current Cochrane Collaboration Guidance utilising GRADE assessments.
We also speciﬁed studies conducted in ICU settings would be excluded in this update.
Authorship for this update has changed with the addition of AC, ET, JH, JY, SS, and JT. AB, JH and RS are no longer authors on this
update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Hospitalization; Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline [administration & dosage]; Delirium
[∗prevention & control]; Halothane; Indans [administration & dosage]; Nootropic Agents [administration & dosage]; Piperidines
[administration & dosage]
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MeSH check words
Humans
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